var title_f15_1_15376="Conjunctivitis in Kawasaki";
var content_f15_1_15376=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78898&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78898&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Conjunctivitis in Kawasaki disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 185px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Sundel, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_1_15376=[""].join("\n");
var outline_f15_1_15376=null;
var title_f15_1_15377="Nevus patchy reticular";
var content_f15_1_15377=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F62442&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F62442&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Dermoscopic image of a nevus with a patchy reticular pattern",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_1_15377=[""].join("\n");
var outline_f15_1_15377=null;
var title_f15_1_15378="Rotator cuff muscles";
var content_f15_1_15378=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F72027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F72027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The rotator cuff muscles",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 415px; height: 531px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Subscapularis inserts on the lesser tuberosity. The remaining muscles insert at the greater tuberosity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_1_15378=[""].join("\n");
var outline_f15_1_15378=null;
var title_f15_1_15379="Focal photocoag for Tx ME";
var content_f15_1_15379=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F51401&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F51401&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Focal photocoagulation for the treatment of macular edema: Appearance on fundus photograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Color fundus photograph displaying the laser photocoagulation burns used in grid treatment of diabetic macular edema; note: photograph modified to accentuate the burns, which typically are much less visible on color photographs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_1_15379=[""].join("\n");
var outline_f15_1_15379=null;
var title_f15_1_15380="Linear salpingostomy";
var content_f15_1_15380=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F72097&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F72097&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Linear salpingostomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 344px; height: 627px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) The tube is stabilized and injected with a dilute solution of vasopressin; (B) An incision is made on the antimesenteric border overlying the ectopic; (C) The products of conception are removed using atraumatic forceps; (D) The implantation site is irrigated and hemostasis obtained.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_1_15380=[""].join("\n");
var outline_f15_1_15380=null;
var title_f15_1_15381="Trichostrongylosis life cycle";
var content_f15_1_15381=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F71043&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F71043&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 615px\">",
"   <div class=\"ttl\">",
"    Trichostrongylosis life cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 595px; height: 451px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHDAlMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAAnHJriPFPxP8ACnh6RoLnUhd3i8G1sl8+Qexxwv8AwIitL4i6XqGs+Ebyy0d0F27RsEdyiyorqzxkgggMoZfx54rx/QfgdqzNKL++sLG0k58qJGkfr1O0qA3upx6g0AaOofHSRp5odM8PGIRNteW9uVBT2ZF4z7bvSm2nxm1LzAZ7LTpIsAsrB4CM/wAIIMnP4dxnGa6mx+DmiW6p5t9qMkgUBmiMUAb/AL9oD6ckk8dTSan8I7KWBhY6ncCU8j7bDHOpP1CrIPThxQBu+D/H2k+Irn7F+8sdVXObO5wGbA5KMCVcdehz6gV2AOelfKOsaM/h3xJLZarEmn6gmyZJIJNkMoyFSaNsDaVxjgDbgnGOD798OPEU+tWFxaamQdVsCqTMF2+ch+5JjsTghgOAysBwKAOxooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiuA8N2Ot+ILS9v5fGOt2n/Ezv7dILaCx8uOOG7miQDfbsx+WNeSxJOa1f+EX1f/oe/En/AH407/5FoA6qiuV/4RfV/wDoe/En/fjTv/kWj/hF9X/6HvxJ/wB+NO/+RaAOqorlf+EX1f8A6HvxJ/3407/5Fo/4RfV/+h78Sf8AfjTv/kWgDqqK5X/hF9X/AOh78Sf9+NO/+RaP+EX1f/oe/En/AH407/5FoA6qiuV/4RfV/wDoe/En/fjTv/kWj/hF9X/6HvxJ/wB+NO/+RaAOqorlf+EX1f8A6HvxJ/3407/5Fo/4RfV/+h78Sf8AfjTv/kWgDqqK5X/hF9X/AOh78Sf9+NO/+RaP+EX1f/oe/En/AH407/5FoA6qiua+Hl3e3nht21O8lvrmHUL+0+0SoivIkN5NEhYIqrnai5worpaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAIyKQDFLRQAUUUUAeV/HizA0rRdZji33FhqEabVAzJFKdrxnIIIbgYII5rnvgpeSjxHBnZ5MsV5aDYchljaF0Y+p/eS8+r1v/tEXIXwVaWIZRJeX8SrnsFyxPbpgen1Fc78CllvPFU0rxstvbW808a5Y+V5zRKqc9cCFxnvnPPWgD3cHPtS0AUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHh/jmNJfgJ4gjkVXjfxFcKysMgg662QRXk2h+DNN1WPUXj0q2Is7V7lvLtYjwv97cy4HuNx9jXsPiq0ur74H69BYWlzd3H/CQ3TiG2haWRgutuzEIoJOFBPA6A15/4au9Y0SHV0/4RTxJP/aFlJZ5/si7Xy92Pm/1RzjHTj60Hz2b0qs68OVS5bO9r/oX/ANnqxtLL4pt9jtYLffo11u8qMJuxPa4zj6mva9Z8Xvo3iq4sNQtLaLR7bSpdWn1D7Q7OkcZAceSIznrnhumeM8V5N8CtN1OH4ktdXej6vZ2y6TcxmW8sJrdN7TW5CgyKASQrHA9DXrXiPwPa6/qd/eXmp6miXulzaRJbxGERiGUYYgmMtuzggliMjpjIoPQyqNSOEgqqaeu++7MLxR8ULGPToB4ckne/mvYLRvtGkXkhhWQM4k8kKryAqjbdpAY9Dwa3IfiF4aAmW41TabeKWSS4e0mhglERAlMTsu2TBOMIzEdOafL4F0yTW49Uae8+0JJaShQ67c26SqnG3OCJmzz2GMc5wYPg14Zgm1ExCVIb1ZVKLb2qvEZG3ZScQifIPI3SMOxBHFB6Jot8R9PbxNomlQafrDR6nHOwml0u7iMbRmID5GhBKnzeX4VdvJ5qxo/xC0G+0WK+mvoI3MNrLJHCszj/AEk7Ydm6NWcM3A+UHIOQKkHg121DSdQufEmt3Goaa0ojuJFtQzxSeXvhcLCFKHylOQA/XDelXT/hpodjP4Xljkvnbw/bi2tw8oxOqj5DMAoDFCSy4xgkmgDW0XxjoetambDTruWS42PIhe2ljjmVGCu0UjKEkAJAJQnGRVHX/H2k6UmtJCl9e3mlwySTJBY3DxK6Reb5bTLG0asVK9TkbhxVXwb8M9C8I6zJqGkDaWV0SJrS1BjDNk4lWETN6fNI3HXOBh+r/DrTNX8TT61f3l4800MluYo47eIeW8RjKmRIhK64YkK7sAcHHAwASwfEPRf7M0+9vk1SyjvEjIefSrtYo2dgoDSmIKvzEAFiAcg9CKlHxC8M/wBoy2Z1CRXiM6tM1pMtvmFS0oE5TyyUCtnDcYNc5qnwa0jVpLR9V1nWLyS2higR50tGYJGxZNp8jMZ6AmPaWAG7dVRPhjd3XiN4tRmUeEozf+VYfbfNJ+1BlcKogRox+8c8ySY4C4oA7/w54n0rxE1ymlzTtJbBGljuLWW3dVcEo22VVJVsHDAYODg8VtVyfgPwLpngpLtdLbf9oCBibO1gICZwMwQxlvvdX3H0xk56ygDlfhp/yLl5/wBhrVv/AE43FdVXK/DT/kXLz/sNat/6cbiuqoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAo4pCQOtef/ABa8cR+FNJ+y2LCXXr1GFrCo3GNQPmmYf3VHPuePXAB5l8ZvEjaj4ySGyeMxaZvtot65BlwfNkXpyh2gEd439Oe+/Z/0VbDwnNqZi8ptTlMkak5Kwp8sYz3/AIjnvnPevHPCOgXXifXYPDwgnjfCve3DqQYrfdvZskZ8x8qATg9MjIJr6ss7aK0tore2jWKCFBHGijAVQMAD2AFAE9FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBwPhrXtN8M+AtT1bW7g29hBrWpiSQRPIQX1OdFG1AWOWZRwO9VP8Ahd/gD/oMXX/gqvP/AI1XK+P/APk37xJ/2MNz/wCnxq8/+HfhO2uTo2uaxcAWU2sQ2MNqLcTfaHyCQ+WAVMcE89+DWsIKSbbNqdNSi22fQnhL4keFvFuqvpugajLcXqQtcGOSznh/dqyqSDIig4LrxnPNdfXz38LLeG1/aM8RwWsUcMEdlfKkcahVUC5t8AAcAV3niK91e48ba9aweKZtDsNM0m1vU/cW7w73kuAxlMkZYriJRhWXv3qJrldkROPK7I9IoryTTvibenTftd1ZKuoT2unPHYTySBTLPC8jJEkNvLMSNhOCH4H8ODmGT4y3EvhqXVtP8PQubTS21S9iutQa32KJpYdkf7kl23Qv1VMZXOCcVJB7DRXnF78Sbmw1W4F3oaf2PDqkmlG6ivN05kSBptwh8sDaQpH3857Gq8PxK1Z7MOPC8c13NZW+pW8NnfPcj7PK+3dJshLqV6kIkmeducGgD0+ivGbj4h6/PdeILy2SwbR7TwydTK2t6fMhkVrpWaMyWuWfdCEKyKFXbnDEla7bwp4o1DxDql1HaabarpNlN9lnupr4i4MgjVjthWLaVywGS65GTjoCAdhRXBeKvGmp6T4hm0qLSIYoHjxbX93PNGk8pRmCIVgePORjDupPOAe/Ir8WtX0LwDoep61pljqN7LpMOpXK211O0rQsi/vmWO1McZY78hmVARgMewB7XRXml18TprfUgx0aJtFOpz6X9o+2n7SZIoXldxB5eNv7sgZkBOQcYIrQ+G/ju88YSSfaPD93p1s1tHdQXLJP5UisT8haWGMbwNp+QupB4Y4oA0fhp/yLl5/2GtW/9ONxXVVyvw0/5Fy8/wCw1q3/AKcbiuqoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiis3WNc0vRfJ/ta/t7JZiQjTvsViMZGTxnmk2krsuFOVSXLBXfZGlRWXaeIdFvMC01fTp89PKuUbP5GtNWV1DKQynkEHINCknsE6c6btNNeotFFFMgKRjjFDHArhfih40PhrTxa6cVfWriNnjBXesEY6ysO+OgH8R9gSABvxL+IVp4StxbWiJe69MuYbTPCD/AJ6Skcqg5PqccdyPnxYtQ8S67NvRtT128m2pcDndMDggAgAQqnK5Hyg7j2DS6bp154l8QwW9jbz6jq8n+kSSzSBsN082SQdB36cYwFJ+UfRfgHwTZ+FLUyFhdapMgSa7YHO0dI0ySVQemcnqSTQMd8N/B1t4N0MWyMs2oXBEt5c45lk9BnnaOgH49Sa66k289TS0CCivKvij8QPEnhLxDFBpXh83+lG2WR52glwJNzZAdflwAF4xnn6Vg6V+0PpzuE1jQry2I4Y28qy8/RguK9ilkOOr0VXow5ovs1f7r3OaWMpRlyydme50Vw+g/FTwdrRVINZht5m48u7BhOfTLfKfwJrtopEljWSJ1eNhlWU5BHsa86vha2HfLWg4vzVjaFSM1eLuOooorAs4/wAUHUrzxpoekWGt32k20+n3t3K1nFA7yPFJaqgJmjkAAEz9AO3pXIT+IYY/iVZ+CI/HXi6fV7hHYyRWummGFljMhR2NtndtAOAD95c4zXaal/yVPw92/wCJLqf/AKPsK4W0+D19pXxF8Ka1pniG7n0zS3uprk3phNzI8wO7BWAB95OGZzuA+6QQMAHd+BZtQ+1+J7DUtUudT/s7U1t4J7mOJJPLa0tpcHykRThpX525xXVVyvg3/kY/Hf8A2Go//TdZ11VAHhXxm8YeJtH8fLpuia5Pp1kumQXBjit4H3SPLOpJMkbHpGvAOOK5e88W+PrTT7G8k8YXxjuw5Qf2fbLjacH5mtgrdf4S2O+Ku/Hr/kqZ/wCwLa/+j7qsXX9bttQ8L+HNNhSZZ9NSdZWcAK29wRt5yenOQKD5LMsdWpYmrCNRpJKy/wDAf+Cz3X4N6xqOvfDzT9Q1m6a8v3muo3nZEQuI7mWNchAF+6qjgDpXa153+z//AMkq03/r6v8A/wBLJ69EoPqaLcqcW+yCiiig0CiiigAooooAKKKKACiiigAooooAKKKKAPJr/wAN33i34P65oulPbJez67fPG1y7JH+71iWQglVYjIQjoecVyGh/DT4o6HafZdN1DwwluJ1ulSSd5Qkq9HXfbHa3uMV6xb+DLqza5XTPF/iCxtprqe7+zxR2TJG80rSuFL27Njc7Yyxqb/hF9X/6HvxJ/wB+NO/+RapTcVZFxnKKsjhfhb8PfFehfES+8S+KrnSJjc2c8Lmznd3aWSWJ9xBiRQP3Z6eo4r0zVPC3h/VtRiv9V0LSr2+iCrHc3NpHJIgU5ADMCRgkke5rN/4RfV/+h78Sf9+NO/8AkWj/AIRfV/8Aoe/En/fjTv8A5FpNtu7JlJyd2auq+HNE1dZl1XR9NvlmZGlFzapKHKAhC24HJAZsZ6ZOOtc14q+F3hzxHDY209tFaafaKyLaWlnaqhVm3MAzRM8eTnPlsmcnvzWh/wAIvq//AEPfiT/vxp3/AMi0f8Ivq/8A0PfiT/vxp3/yLSEbv9k6dvD/AGC03i4+1hvJXPnbdvm9Pv443dccVmL4K8KrZ3FovhrRBaXLiSeEWEWyVh0Zl24YjJwT61V/4RfV/wDoe/En/fjTv/kWj/hF9X/6HvxJ/wB+NO/+RaAL8vhLw3Ktssvh/SHW2ga2gDWUZEUTAq0a/L8qkMwKjggn1qZfDmiLrKauujaaNWRdi3otU89V27cCTG4Dbx16cVlf8Ivq/wD0PfiT/vxp3/yLR/wi+r/9D34k/wC/Gnf/ACLQBrP4d0STWhrEmj6a2rgYF81qhnxjH+sxu6cdelZz+AfBzxqj+E/D7IpZgp02EgFsbj93qcDPriov+EX1f/oe/En/AH407/5Fo/4RfV/+h78Sf9+NO/8AkWgCu3w80h/HEXiiZne+hfzIoxb20ao3lmPJdIhK+FJwHdhz04GNzR/Deh6JcTz6No2m6fPP/rpLS1SJpOc/MVAJ59ay/wDhF9X/AOh78Sf9+NO/+RaP+EX1f/oe/En/AH407/5FoAPhp/yLl5/2GtW/9ONxXVVleGNFj8P6QthFdXN3++nuHnudnmSSTSvK5OxVUfNI3AUADFatABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSEhQSSABySa858cfFrQ/DjSW1kRqmorkGKFv3aH/afp+AyfXFcBHp3xC+KDB9QmbS9EkOQrAxRlf8AZT70n1bj3rkqYuKfJBc0vI9/CcPVqlP6xipKjS7y3fot3+Hkej+Kvix4Z0AvEl0dRu1yPKtMMAfd/uj8CT7V5b4m8X+K/iTps9npnh9E0gHez7N+3bzkythVP0wetemeFPhF4a0NUku4Dqt4Osl0Mpn2j6fnk+9d/LbQy2b2rRgW7oYyi/KNpGMDHTj0rOVGvWVqkrLsv8zsp5jlWWTUsHSdSafxz29VFfhezPk34b/D3UfGd2HG610qNsS3TDr/ALKDu36Dv2B+o/Degad4b0qPT9It1ht05PdnbuzHuT/nir1jaW9haRWtlDHBbQqEjjjXCqPQCp60wuEjh13fc5M94hr5vOz92mto/q+7/LoFFFFdZ8+MmdY42eQgIo3EnsB1r5P1jU7rXdd/tmUy/a7tpbxIjEGVY42CQqD7MdvpuJJyGIr6wlRZI2RwCjAhge4NfJOkWU+jeI9Y0rUWWLUY0urW1Yni4kjlSWFfbcFUZ4HzLQB9H/Drwha+ENAS1jCyX8x869uf4ppT1Of7o6AdhXU4FUdC1W11vRrHVLCTfaXkKzxN0yrDIq/QAUUUUAFZmraBpGsKRqul2V5kYzPArkfiRxWnRVQnKD5oOzE0nozy3X/gd4R1Pc1nFc6ZMec20pK591fPHsMVxE3wq8eeDpWuPBWvG5iX5vJSTyWb6xsSjfifwr6Jor2KHEGOpLknLnj2kuZfjr+JzTwdKTulZ+Wh8+aX8avEPh27Ww8e6DLvHBlSMwSkeu0/K34FRXrvhHxz4e8WIP7G1GOSfGWtpPklX/gJ5P1GRW1qul2Or2jWuqWdvd27dY5ow4+vPf3rx7xh8B7GdzeeD7x9Nu1O9YJXZos9trfeX/x78K6VVyrH6VIuhPutY/Nbr5GfLiKOz51+J6xrvhzQ/EHkf29o2m6n5G7yvttqk3l7sbtu4HGcDOOuBWV/wrjwP/0Jvhv/AMFcH/xNeOab8RfG3w6vYtO8d6fPfWJO1JpCDIQO6Sjh/XB59xXtnhDxhoni6y+0aJeJMVAMkDfLLF/vL1H16Hsa4cdk+IwcfaO0qb2lHVf8D5m1LEwqvl2fZ7mjomiaVoNo1roemWOm2zuZGis7dIUZyACxCgAnAAz7CtCiivKOgxdb8J+HNeu0utc0DSNSuUQRrLeWUczhASQoZlJxkk49zWf/AMK48D/9Cb4b/wDBXB/8TXVUUAVNK02x0iwisdKsraxsos+Xb20SxRpkknCqABkkn6k1borN1/W9P0GwN3qt0lvEWCJwWaRz0RFHLMewAJoA0qK8s8SeNtTjKCZl8PQzLugt2iF1qdwvqsIO2Ie7k47gVw+oNqesAiYXMaEk+bql9JdSn/tlGyQp+ANJyS3MqtenS+N2PouivmeHQbu3cSQ30LOOm6F4/wBY5FYfnWvZeKPEfh8F5bu8+zR/M8kkhvoNv+0j/v19SVd8ehpKaZlDG0ZuykfQNFct4Q8UprTm1voEs9VSIT+UkoljnhP3ZoZBw8Z/MHggcZ6kVR1BRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVwfxK+I+n+DYDBHtu9Xdcx2wPCejOew9up/WoqVI04803ZHThMHWxtVUaEeaT/r7jpPE/iPS/DGmte6xdLBF0ReryH+6q9z/k14jqXinxf8Ur6XTfDFtJYaODtkcNt+X/AKayf+yL/wCPVL4V8B658QdSXxD44uZ47J8NFCfleROoCj+BP1PXvmvdtK02z0mwistNtora1iGEjjXAH+J9+9cdqmK1fuw/Fn0jngsh92CVbELr9iD8u7X9W2OF8CfCjRPDQjubxF1PU1586ZfkjP8AsJ0/E5P0r0WiiuunShSXLBWPnMZjsRjqntcRNyfn+nb5BRRRWhyhRRRQAUUUUAIwyK+e/wBoPw7I2vyXtrHHi+05mdmIBjkhZV3jIP3o5NpA5O1O2a+hCcV4f+0HqsR1PSLFHBaCKV7gBuQJAFUdRk/KWx/s0Adb8H7mCLTLrSrEn+z7cRXViG5KW86bgn/AXEi/hXog6CvKvghZ3ca6xc3zo0gEFmSiFVDIhZgAewMmPqDXpGsajHpWlXl/PHJJFawtM6xAFmCjJABIGeO5FAF2isfwlr9v4m0G21W0ilhjn3Dypcb0Kkgg4JHUdjWxQAUUUUAFFFFABRRRQBV1PT7PVLKS01K1hurWQYeKVAyn8DXhnjP4NX2iXn9t/Dm7nhniO8WfmkOv/XN+4/2W6+p6V77RXoYDNMRgJXpPR7p6p+q/pmNbDwrL3lr36nifw8+NCzXQ0bx1F/Z2pI3l/amTy0LdMSKfuH36f7te1qwdQykFSMgg5zXEfEf4b6P43tWe4QWuqKuIr2NRu9g4/iX26jsRXkfhzxb4k+EetJoHi6GW60Mn91ICW2L/AHom7r6oensevrTwOGzaLq4BclRaun384v8AT8uvOqtTDvlrax7/AOZ9KUVS0nVLLWNNh1DTbmO4s5l3JKh4I9/QjuDyKuAggEHIPevmpRcW4yVmjtTT1Q2aVIonklcJGgLMzHAAHJJryafWEsNKXxtqMSXWv6riHQ7Kdjtt4XI2BVGcEriSRhzjjOABXY/E65kt/AmsCEhXnjFpuPRBKwjLH6ByfwrhfibbDTvF/h8y4TTzp72Np2RZQwJUdgWQLgf7BqW7IzrzdOm5JbGFaWjpPcXd7MbrU7pvMubtlw0h7Af3VHQKOAKtj3pBw3TmlBzXOfMSk5vmluLRRRQQZdmZ9Lu1tNPO14zJqGkHnEFyi7pbf/rnNGH+XoGH0x79o99FqemWl/bHMF1CkyZ/usAR/OvCZWJ1jQYIDm9fUbdoE7/K4ZzgdgoYk+lesfC4k/D/AEHrs+yr5ef7n8H/AI7itoO6Po8BUlOiubpodVRRRVnYFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUV5b8YfiN/wjsJ0bRH365OACyjP2dT0Pu57D8fTOdWrGlHnkdmAwFbMK6w9BXb+5Lu/JCfFj4nJ4eD6PoJE+uvhSwAZbfPqO7+i/n6HO+GPwtZLgeIPGgN1qUrealtMd2wnnfJnq3seB9elz4RfDVdIRNd8RxmfW5v3iRy/N9nzzk56yHqT2+ua9Yrlp0ZVpe1rfJdv+Ce7jcxo5bSeAyx7/AB1Osn2XaP5/iyiiiu4+WCiiigAooooAKKKKACiiqWtana6NpN3qOoS+VaWsZlkf0A9Pf2oA5n4neOrPwPoH2uby5dQuCYrK1Z9vnSY7nso6k+nuRXz74atNQ8Q63Hqlw8uqane3LfZPOTZHNNgbnZOyJgEjsiKp5cLReXsnjvxjPq/iTzoNPt0EssancYrfgrFGR1Y5QEDlnkGRjOPoTwD4dayRtW1O2jg1O4iWKO2TlLC2HKW6e46sf4mz2AoA2/DGiwaBodtp1s7yCIEvM/3ppGJZ5G/2mYkn61Y1qNG0e/V+VNvIDnnjaavVzfxAvnsfCOpmHLXM8f2S3QdWllIjQD/gTCgDnPgCWHw1sVck7Lm5QZOeBM4HP0r0euJ+ENsLXwTaouNjXFwyFRgMvmthh9Rz+NdtQAUUUUAFFFFABRRRQAUUUUAFY3ivw7pfijR5dO1q3WW3bkN0aJv7yt2I9fwPBrZpCAwIIyD2q6dSVKSnB2a6oUoqSsz4+1LVNV+Gup61oGh65a6hpl5E8ZaFw6ruBXdwfklA4OPbrxj6B+BviT/hI/h9ZGVy15Yf6HNnqdoG0++V28+uaXxb8JPCniMPIbEafeNz59liPJ91+6fyz71jfC74fa18P/Et4qXcOoaFfRbXdf3bxuuSrMh7csvBPUcYr67MMwwGZYF2fLWVm7pLma0eq02PNo0a1Cr3j+RofGLxFZWVhbaLcSEPeuss4QbpBAjhiFXu7sBGo9WJ6KTXAapb6p4ksrh9e1S9Se7O9rZJQ1vBzlUWMjb8vHzDDEjORTvjJo8Hhzx7pviO41WWGPVpzC8jWJuPsqrGB1zjbkcAAN8zYPWuUvvFupC8Nto23UWHKltLeN2X+9sWdmA/3lWvznMY4ubisO7L11PosHVwdK/1jVvodD4esdOsLuK08cXepSWMnyJqMN7JFCCTgLMAdyZ/vbivriupl8C+JNNATSJtP1jT/wDlg80xhmVP4dzYZX4wNwxnGcV5hD41v4pZIdZtraJ1Xc8Els8BZTxjLOxBP+0oU9NwzXsXwKvbeXT9ZsrJv9CSeO6tYxwqRTRK2FH8I3h+O1Xg6ldv2WJjr3XX/gnNi8JgqseehtfbZo5C3vJBPLaajazWGpQIGmtp1IKjn5lPR0yDhhx/KqjeJtEBH/E407BUMP8ASF5/WvbPFfhTS/E0MQ1GN1uYCTBdQPsmhzjO1h2OOQeDVCO2074b+DBDpcFzcxRyiO3geXdJNNK+FTcegLN+Az6Yru9mjxXlkXJ2eh5Pokd3Nqt3e6RaNFca3a/2VYzzx4aVt2ZLhARlY4492WwAxKgZwK990mzh07TraxtV229tEsMY9FUYH8qxPDGgXFtqFxrOvTx3Wu3SCNmiB8q2iHIhiB5255JPLHk44A6cADoKtKysejTgqcFBdAoooplhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVj+LPEFn4Y0K51TUG/dRD5UB+aRz0Qe5/xPalKSirs0pUp1pqnTV5PRLzOc+LHjuLwbo2y3KvrFypFvGedg6GRh6DsO5/HHKfBjwDKJh4s8Th5dRuD51tHLyV3c+a3+0c8enXrjGH8NfDt58Q/FVx4u8UL5ljHLmKFh8kjDogH9xf1PXPzV9BVw0ovEz9tP4Vsv1PqMwrQybDvLcM71JfxJL/ANIXkuv/AA6RRRRXefJhRRRQAUUUUAFFFFAHC+LNE0rXviT4btdc0yx1K2TSdSkWK8t0mRXE1iAwDAjOCRn3NedeItO03QPiBoOj3PgzwLNZ6tqJtgn/AAjxgEMJyUIun/dSSkD/AFarnPA7GvSvFV8ukeP/AA/qVzaalNZLpmoW7SWWnz3eyR5bNlDCFGK5Eb4JGPlNcpdweHdQ1fTrzWL7x/qdvp17/aFpY3Wg3hhimySrZW0EjbcnaGcgdOlAHVfDvTbHSdT8bWOlWVtZWUWtJ5dvbRLFGmbCzJwqgAZJJ+pNYvx7uHPhS305RuS6mMkyBsFoolLsM/ULz9K6DwBM15f+Lr9La+gtrzV0kg+2Wktq8iLZWsZYJKqtjcjjOP4TXI/tDie20fR9RiV2gguJIJdg5AljKqfpkAfjQBzfwT0mHWdaFzctJcvYOby5kkLYedifJG09MDe56ZYqewr6BUYrxD4MajZaLKJZ7wG21tFRppHBEN5FlfIY/wAJaPYUz1wQO2fZ76/tLC0kur65htraMbnlmcIqj1JPAoAs55rynxfq8urz32o2Pz2GkObLTl7XmqSHylYeqxl8A/3ix/hpk3jxPHfix/CHhSa6tbcW5uL3VhGVIiBUFIc8hm3AbzjA5GeDWxotna6r4ltLXSoEi8NeFyYoVQfJLebSpx6iNWYZ/vue4oA6/wAO6YmjaHp+mRHKWkCQ7v721cE/iea0qKKACiiigAooooAKKKKACiiigAooooAKKKKAPOPjZpT67oOkaXDdzW9xc6rAiLGNyyDJLbgcAhVBfk9VFb/gTwjZeDtKe0tZHuJ5XMs91KoEkzH1x0AAAA7YrT8QaHaa7ZLbXwkUJIs0UsMhjkhkX7row5BH/wCusb+wfEVgQdL8UPcR7cGPVrVJwPdWj8tgfqWH0pWV7i5Vfm6lf4teGE8S+Dr1YbdJNTtUa4sm25bzFBOzPo4ypH+1XmX7NdzDHqV3Y2zsY108AxseY9lxJsB9DtlH5V6HN4uvdF0nxMNcW3u9U0ho/KW2jaFLpJgohIUsxXLlkPJ+6a8Z8DeLbfwN4/vWnT7VZ3MIh1GeIkBLnzd7uAeqqsnQe3oa5q04xqwv5v5W/wCCdmGoKpGaS952S21d729bXt/wT6lByK5LxipuPEXhCyPMbag9w49fKhdh+pB/CuqikR4leNgyMNwYcgj1rk/HTfY9R8L6o2RBa6kIpWxnasyNECfbcyj8a6jkOwopM5paACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooADxya+d/FV9dfFj4iQaJpUjDQ7JjulXptBw8v4/dX8OmTXa/HrxedD8PrpFjJjUdSUqxXrHD0Y/Vvuj8fStf4PeDh4T8MI1zHjVL0CW5J6p/dj/AHn3JrhrP29T2K2Wr/AMj6rLEspwbzOa/eTvGmvzl8tl/wTsdK0+10nTbawsIlhtbdAkaDsB/XvmrdFFdqVlZHy8pObcpO7YUUUUyQooooAKKKKACiiigAooooAKy/Eei2mv6HeaXqClrW5jKMV4ZT2YHsQcEfStSgjNAHy/qXgjUtAaey1OdLdS2E1Ca3aS3ljH3V3KrY6D5JAAM9WABGHJp0+o31vGHtYWh4V7bdchOeHRIwSG+n0OBzX13t+tIqKv3Rj6cUAePeCfB17b201vosOo6PbXhzfaxqJX+0boEkkRoM+Vkk5Zvm9BkAj1bSdNtNJ063sdOhSC0gQJHGvRR/U9ye9XNopaACiiigAooooAKKKKACiiigAooooAKKKKACiiigApG6c00tziuRufFl1qd3NZeDrCPU3hbZPfTSeXZwsOqhwCZGHcIDjuQaAOd+M2j3F22mT6Xt+33hawKE/wCtK/6TEPwkgAz2DmvBbu4k0TxPHrOmv5MOoSi8t5JV+VZgMPFIO38SMPQj3x9SaR4buzq0er+JNRGoajCpW3iij8q3tcjBKJkksRwWYk44GBXnfxd8DQWkV7qlvE76NdSebqEMajdaSHrcx+399fct6g8mJhJNVYa239PLzX/ANoKNSDoydr6p9mtjpfhZ8QLvxnqGrxXOnfZ4bfY8ToCdgPBikOfvggkEYBHOAMZ7jXtKt9b0a9029ybe6iaJivBXI4Ye4OCD6ivkXS9U1vwTrkgsZvLu4EieKdCDHe2zNja2eoBHfkZ4POT9jKxKjIwe49KvD1VUjdO/n6hVTa5pJRa91pd0lr873+/sc34J1m4u7ebStZIXXtMAiu1xgSg/cnT1VwM+x3DtXTK2c8VgeJvDz6jNbalpd0LDXLMFYLopvV0JBaKVcjfGcDjOQQCCDVCy8WXFjew2Hi6wTSrqZhHb3UcnmWlyx6KsmAUY/wB1wM9ia6DE7CikU5HNLQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVBfXcNhZXF3dyCO3gjaWRz0VQMk/kKnryH9onxG1loNtoNoxNzqLbpQvJESkYH/Amx/3yayr1VSpub6HfleBlmGLhho/aevkur+45r4e2c3xG+J174m1JCdOspA8UbdMj/VJ+AG4+/wBa+g65f4a+Gk8K+ELLTyoFyV865PrK3X8uF+gFdRWeFpOnD3t3qzrz7HxxmKtR0pwXLFeS6/PcKKKK6TxQooooAKKKKAOQ+LWrX+h/D7VdQ0eaSC/i8oRSRojMN0qKcBwVzhiORiuAj8SeJpLS3QXN3PfQeKYrKO11GaK1ufLMDEpcm3Xy9pbLAqrArtPzGvZ72ztr+2e2vreG5t3wWimQOjYIIyDxwQD+FQTaPpk1+L6bTrOS9BQi4eBTICm7Z82M8bmx6bj6mgDzPWvi9Lp3h1dRXRYJruFbxryxW5nd4hbStE7o0ds4KFkb55PKUcZI5xFovjy/07WNcuLy1a80O68QR2cMrXjGe3MlnA6pHDsIKAkscOMbmODya9Dv/CHhrUUjXUPD2j3SxtI6CeyicK0jFnIyvBYkk+pOTTB4f8OWWv29/FoOnx6vNlUvYdOBkG1MfNKq/KNowNxGeg9KAPLZ/iBrFzq9hq8sJsdPvdLtJ7a2tNRErMk9/bxh5FaEorbZCCAGONwDqfmFjTfHXin/AIR7T59Qitjd3V/qtvbyQ3a7ZPIS8ZVmU2/CqYUUFDlsBm7ofQLrQ/B2gbJJND0azN9dRQBotPQGWZpFZA21eu9VbJ6FQcjANaUfhjQIrya7i0PS0uppDLLMtpGHkcqylmbGSSruCT2Zh3NAHlfhXx1qXh7wrELzTPtps9NtNU1O5udblmlZbjIVohJH8zHYSYwURSdqkmumvfiBqqJcyWXh62miTVzosJl1ExmWbzdgbAibamOSckgjAB61e1+Xw1B4lsNPufCy6jd6bZi6SeDTop/7PgBKptH+s5KMFWJWPy9BWvokmjawdSittNiUWGpusokgQBrlQrmVcZ5ywO44bOaAOb8L/EDU9V1uystS0G2sobq7vbBZodQM7LPalg+VMSfIdjYbOeOVFVNb8WXPh/xz4o+dblRa6XHaWU804RpZGu9wjWKKVt5EY4VCTtGeld5PZaXpsX2z+zoVMEklwpt7TzJFkkJ8x1VFLFmLHcQMnJzWJANB8XajrdpdeG4ry3t5Vtbi7vLWB4bmSLJCAEl22F2wWUAEtg9aAMHwz8StQ8TpYR6P4diN5cWs9xJHc3zQrEYbgwMuTFuJJGRlVPYheSIofiyl7prXenabCSiW8TpcXEuftsm4vaKsMMrtIioScL3HHUj0DTND0nSvL/svS7Gy8tGjT7NbpHtVm3Mo2gYBb5iO55qO78N6HeWVxZ3ejaZPZ3E5uZoJbWNo5ZScmRlIwWJ/iPNAHN6T8Qobz4XXXjK406aBLWO5aazDEsGhd0Kgsqnkp1ZVIB5Awa5CX4haxoHiLXG1fTlnvLifT7S10+0vJ7uCJpIZpC25IC4yE5CRMScdRyPR9+i6JdaZ4YttMht7fUY7gx29vboluFXDSBlGB82/sDnJzT4fBvhiDTp7CHw5osdjOVM1sljEI5NpJG5QuDgk4z60AcdD8U7kJaQX3hq5stV1CNP7Os7iVomuZftBhkXDxqyhAUk3FeUfOARisbxF8T77VvD/AIvg03RdStLaGw1OODVIluFMMsEUmGZvJWNMsh2lZWYHAIB6erWegaPZR2MdnpOn28dgXNosVsiC2LZ3eWAPkzk5xjOTVaTwl4clv7q+k8P6Q97dI8dxcNZRmSZXXayu23LAjgg9RxQBx2nfEafzbZZdKjbTWvJNKW5N7/pD3EcJdiYSnCHY3zbyeh24NV7D4oavdabBMPCiyXd3pVvrFrb2l89wfIldVJk2w7lK7t2EWQsAcAkYrvH8MaGb+a/TSNPi1KWIwtex2yLPsK7cb8ZxjjFZmh/Dzwpo/hyPRIdB0yazEUUU3n2cTNdGMAK83ygO+RnJHUk0AaXhDWv+Eg8P22olbZHkLq6W8jyKjK5UrmSONwwK4IZFIORjjNbNV9OsbTTLKKz061gtLSEbY4IIxGiD0CgYFWKACiiigAoorI8U61FoOkveSRPPIXWKC3ixvnlY4SNc9yfyGT2oA0by5itLd57mWOGCMbnkkYKqj1JPAFcrJ480+4JXQLbUNdkztH2C3Jiz/wBdm2x49wxqLTvCL6lNHqfjVo9T1HO+Oz62dn/spGeHYf8APRgSe2BxXZooVAqgADgAdqAOLk0jXfE+B4klXStJP3tLspd0kw9JphjA9VTHux6V1thZ29haQ2tlBHb2sKhI4o12qqjoAPSrNZviHWLPQtGu9S1GQpbW6b2KjLN2CqO7E4AHckUAM8Ra7p3h7Tze6tdJbQ52rnJaRuyoo5ZvYc1zel/EPRdW1CHTrm3v7Nrw+VAb632JOSPudTgkZ4bGf0rzx5LzWtVbW9dXF8wK29tu3JZRH+Be248Fm6k8dAKqeJx/xJJ3HDxNHIjd1YSKQR7g14M86X1hUqavG9r/AOR7UMofsHUqOzte3+Zx/jq1OmiO3suDYajd6bbktyI92Ywc/wB3aoz7V69pfxPuTYWv/Egv71YYxHPciaJTLIow7Rrn5huBwcgHtXkPxaPy6ju5H9u3hb6eW+f0zXZeGN3/AAjmm7sZ+zp0+lZV8ZPBRbpreT323Zvh8JDFR99rZbfF8KWvl280z2vwx4i07xNYfa9KnMiKxSWKRSkkL91dDyp+v1HFX9SsbXUbGazvreK4tZ1KSxSKGV19CK8OWW+0XVI9b0RS17GAtxb5wt7D3jb/AGhyVbseOhNe16Bq1nrek2up6dJ5lpcoHQkYI9QR2IIII7EGvVwONhjKfMtGt0eVjMHLCz5Xqnszm4dM8QeF1CaDINZ0kYCafezbJ4F9IpjnePRX54+92qaLx5pkLKmuRX2hTHgjUYCkef8ArqMx/wDj1deOelRyIJAyuAyHggjINdxxjbeeO4iSa3lSWJxlXRgysPUEcGpq4jUfClxoryal4F8uyuxl5dMJ22d56gr0jc9nXHP3gRXQ+GdYg17SINQtleMSZWSGTh4ZFO142HZlYEH6UAa1FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVzmt+C9E1rXbHWL+2Z9Qs2Ro5BIQCFOVBXoRnnpXR0VMoxkrSVzWjXq0Jc9KTi9tNNGFFFFUZBRRRQAUUUUAFFFFABRRRQAVxnxE8LXviVrE2MttH5EF7E3nMwyZrZ4lxgHgMwJ9vXpXZ1ynjfxFJoOoaAqLM63U1yHRJEVWEdpNNhsoxIzGPulTnBJIypAOC1H4PlQF07TfD8lqi6ZKbGcFYZ7i3aXz2f922DIkijftYtg7hWno/w91Kz8Y2uptbaLbpFqEl61/BI5uzC0RRbIL5ajylJAB3Ywg+QHmug8D+M7zxBqC2ep6RFp0sumW+qwGG8NwGhlLABsxptcFeg3DnrXG6n4m8WzNfjZalLXxbDY2vlXzRNIm5MQyARDCENksSx5IwQASAbHj/4at4k1bxPqNtBpIu9R0FNNtJ50/eRT7pg7lghKgpIi5BJIXBGAKwvHPwu8Q67/akVs2hSW15eXdzGbhU86EypEqMryW8u3GxsqmxvukSDFaF78XryF1s7bwtPd6xGbsXFtbyTzoDBL5REbxW7sxY9C6xqOMkZrrPG3jT/AIRrQtJvo9Lubm51O4jtoLZklDI7Rs/ziOORxgIRhUY57dSADl734Y3d9pviA3h0641a9trWG0uZWZjC8cCRytkrldxU8qMkYz6VBc/CpopJLm20jw5fNJrF1fT2N0DFDdwyBxEJGETZaMuSAVYDc2CDzVi7+KmqwadLd/8ACJvF9k0uTVb6G8upLaSKNJZI2CI0O5iRHvXcEyCM7TxVu/8AiU7SatpsOmyR6pYRX010iXK7re3hiDxTgmMgmTzItoK4BL/e2EEAyLf4TXjaFr9tqT6ZeX114fj0ywlkLsttOEuVLDcCVUCdFVhltobpnBkm+EFvDdXlzpNjo1pcCbTJrGSNCjW7QSo1yykL8rSKuMjluN2K0ZPiTewWWqTJoqTW+mvZWzTTXwRpprmKBo+BFtUBpwHY4AAyAc7Q4fEXV5dTGj23h2xl1mO5ubadDqpFuhhhilysohJbKzAY2AhgQfUAGx8QPDWq65eWVzo8unJJb2V7b7b5DJGzTIiruTBDL8pyD2PQ9K4Xw18JNUtpYY9VGknTRrMOoyWMbqY/LW0mhddsdvDGSzSISuwAjduJP3tWb4tX0th/aGleG4rmyj07TtQmM2o+VIovHZERVETBipU5JYDH5GW/+Kt9ZObCTw55mtrqE9g1vbzz3EP7qGKYuHit3kOVmQAeUOd2SAM0AMuvhrqUWp6v/ZU2kpo6xXM2jWNxCXjt7q4jCSmRMbTGAJNoGf8AXuCMAZ0vhB4L1Pwd/bg1I2KQX00UsNvZuhSIqm1uI4IEGcA/LGPfJ5NV/ifqCh528MPBZ2yWDXourpobmE3ThAohMXJRjzllyPyrZ+E2ta7rvhya68Qx2e9b26hilgnLs4S5lTay+WgXaFVQQSWA3HBOKAO2ooooAKKKKACiiigBG6GuQ1pRqXxC8PWTYaOwt59TZT/f+WKM/wDj8h/Cuvboa5TQv9K+IPiW5KcWkFpYK3vteZv0mT8hQB1ajFLRRQAHpXjfj3VDr/i46fGwbTNEZWcZ4luyuefURqRj/ab2Fen+J9Yi0Hw9qOqTgFLSB5dpP3iBwv4nA/GvB47218PaRby65eJDJM7STzyZw0zku5Jxxkk4z7CvIzjESp0fZ0/ilp8up6eVUI1KvtJ7R1+fQp+KdY1Lw441GaKC70PckcyxgrNbg8b+uHGe3B5rS8SFX8O3TIQVIQgjnI3rzXOeLfFfh/UtAvtOt9ShmuLqBkhEfI3kfIdxwPvY70sesWo+HwivrmGC7tYI4rmKSQB0KMASR15Aznv2r5+lQkvZzlGz5ktumln/AME9ypWi/aRUrqz+/sUfi5nZqGM4/t27J+mx8/pmu08OH/iQ6bzz9nj/APQa888YX/8AbtveQRxPDeieXV3WT5f3UpkyuT/EiPFuz03fStrW5LnS/DOg67Y7Gk01IxNEx4mikARlz2OSpB9q68dFVWoJ2bk7fO9vv7mWEbpUlNpWS6fFpy3v5Lp58x3bfdrR+HWqHQ/Fj6Q5xp2sFpoPSO6UZdR6B1Bb6qfWsq3mW4giljB2SoHXPXBGaqa7FMdPaazOL21dbq2b0ljO9fzxg+xNcGXYl4WupPbZ+h047DrEUXFb7o9+TpTqoaFqMOsaNZalbf6i7hSZBnOAwBx+GcVfr7s+MA9DXI+GlOn+N/E+njCw3HkanEue8imOTA/3ocn3b3rrj0NcjqDLZ/ErRJsH/TtPubQ/7yNHIn6eZQB11FIDn6UtABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVWvLCzvWha9tLe4aEsYzLGrlCylGK5HGVZlOOoJHQ1ZooAq22m2NrMktrZW0MqQrbK8cSqyxLkrGCB90ZOF6DNVD4c0Q6nJqJ0fTTqErI73RtU812TG0l8ZJGBg54xWrRQBi6l4T8O6nEItS0DSbyISvOEuLOOQCRzl3wQfmY8k9T3q7qGk6bqWnHT9R0+zu7AgD7NPCskWB0G0gjirtFAGTB4a0K3sms7fRdMitGgNq0CWkaoYSSxjKgY2EsxK9Mk+tWW0nTXmupX0+zaW6iFvcOYVLTRjICOcfMoyeDxyau0UAUDoulm2u7c6bZG3uwFuYvITbMAgQBxjDYVVXnsAOgqPT/AA/o2mx28enaRp1pHb7/ACVgtkjEe/G/aAON2BnHXHNadFAGZH4f0aKBoI9J09IGjihaNbZApjiJMSkYxtQklR0GeMUzUfDWhanBNDqWi6ZdwzTfaJY7i0jkWSXaF8xgQcttAG484AFa1FAGZH4f0aK2a2i0nT0t2WJDEtsgUrEcxjGMYTA2+nbFS6fo+mabc3lzp2nWdpcXj+ZcywQLG07c/M5ABY8nk56mr1FABRRRQAUUUUAFFFFACN0rlPBPya14wjkI84arvI/2Wt4Sh/Lj8DXVt0Ncnbg2fxPnWPAj1PShNIP9uCUKD+KzAf8AARQB1tFFQ3EyQJvlkSNMhdztgZJAA59SQPqaAOD+M027QdO04dL/AFCJHGM5RMysP/HBXHuiyKVkUMp4IIyDXRfFt2OveFojnYGupf8AgQjCj9HNed6vrGux6gbXRNAN2iY33VzcCGPJGcL1Y/XFfK50pVcSoR6Lul18z6TKHGnQcn1fa5rxaXp9urCCxtYw+Q22FRuB6g4HNcb4m0yz0mW2+x3Vxb5YzGEKkixQp97ZuUlckqqgHG5hiodY8X+IdLuYoNR07TbZ5SPuXBm2KTjeQMHH8+gyay57DUdf1qWG8knt7aPy57iV1CzzNyY0CciJF+8F5OSCeTxjg8LV51KctH53/wCAdVWpGt+7pR977jd+KGmXPhmz0J7hlj1T7BNf3Mi4JSV5VLgH0VcJ7hRXPfa4p/DfkszfZmw4sVnX7K79cLNjKHPzeWxXkcHFdNr9hcasDdX17eajfQQult9qlDhSR6YwefXNQf2bN9jtru3VINXjhVW4GyXA5jkA4ZSc/TqK9avGE5XgtrW+X9b/AHCw+V4mnQl7SSerduuqV9eu2i27mZpPiSfQbq2N5cGbR3xDNkuWtG/hLK3zAe+Sp7c8H05XDKrKVZTggjkEV5r4l0S2vPDg8QeHrVUljjLT2OMxyKCRJGV6ZBDDA4OPXBHR+D9KtbWztLvQtQvBpFxEJUspGEsahhkbS3zLj0zivDxcKU4qotHqnp187dfwflYrDSqQl7N6rdf12/I9e+C8+fBz2JOf7OvZ7Qeyhyyf+Ostd5XnXweyqeJ0H3RqakfjbQE/qa9BgljniEkMiSxkkBkYEHBweR719fhZudGEn1S/I+WxEeSrOK6NkhrkfFZDeK/BsSEed9snk/4ALaQN/wChAfiK649K5KBftvxOnaQ5XS9LjWMEdHuJGLkf8BgQfia3MTq0706iigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKCQKK5j4heLIPCGhG9eCS8vZnFvZWUXMl1M33UUfqT2ANAGprus6boVi97rF7BZ2w/jlcDJ9AOpPsOa8n1H9oPw4srLotndaiEJDOWWIY9QDlv0FI/ww1/xrZNceONRis7i55ljt182VY/8AnirE7Y09Qgy2PmZq0rX4GaHb2YtRrXiEwjOI/tSbBkYOFKEDNAGHB+0NYGRhceH7kqv3jbXsMhGOuclR+tdPpnxo8K3CqdQN9pSs+xZL2HEbHOOGUkGsfUPgTZS2xitdcuwq8xrdRLMqH2XIUflXK6n8D9T0+GRtNTzJAPll066EDMf9uFwI2HtuFAH0FpOradq8HnaXf2t5F3aCVXA+uDxV7cPWvim70i88P6iIr+yk06/aQsk9xHJaEH1VosLjpwFx1+bPNdJbeMvGFmlwkOo3silFdc6rFgKxwCm8OzD15yKAPrPIziq91fWlp/x93UEH/XWQL/Ovlp9R8TX4V9UstbuEdQ0S3FxPLBKQ2DjadsgIx91RjnkisvUbPV7m4LajpvhvTLQpiOCGSC1mBwfmYFlk3DjO44OelAH1xa31peZ+yXUE+OvlSBv5VYJA618czado0km8m2gnVcqkC+aWf1VkmcKfdh+FW9N8Za34ZSBtM166dcKBAZftMTZJHKscocqflCjAOc0AfXeR60teY/DL4nw+Kb0aRqsMdnrQViqxvlJtoBbaOqnBBwcgjkE4OPTqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAEbpXK2cb3PxMv7jDeTY6XDApIIBeWR3bHY8Rx5+orqyMimquPSgB1cB8dnlj+FmuS24zPH5Dx/7wnjI/UV39cl8UYPtXg+4tRybi6s4Bnpl7qJR+poA5X4lzi9u/BmpxDEFyJlXvjzIRIv6Ia5jXZ7y30m5l0y2+03wXEMRIALE4GSew6n6Vr6uDL8HNDu3/wBdoV1FHMc/dEUhgf8ADaTWRrGq2GkW5m1K6itoz93eeWPsOp/CvlM7pv6zCSV7rbvZn0mUTX1eUW7Wf5owvDPhUWEv2/V5hf6w53vK3Ko3+yPXtk9uBgVF4hJ0zXUu0DTJeoFmgiUvKpQf60KOSoXhvTAPrVGXx5b3dz5MHm6fa5w13PAHkP8AuRFl/NiPpXeeAvHvw30aR/s17dHUZxia+vVEk0v+zlCcL6KoAFdOBy/Ezq+2raeX6W6DrY6GHSjh1drr/W5zMUsdzbrLbyq8ci5SRDuB9xVbRBeDTIRqWftYzvyQc8nHTjpiu/1Xwv4a8STSaj4K1yxsNQk+aS3BBgmJ7tFkFGPquM9wa8i0rXrm3+0pqdvcy/v3CywgOq4JG3Gd3BB5xXdVoSps9TDZ5hqlN+2koPTd2+5nWeDcCDVIOCEvpDtx0DKrYx+J/OqugaPf+HNYltLFFn8O3LNKilsPZOeSoB+8hPTHQmqXhDXYIodRu7u2vreKe7Yq7W7OgCgLyyZCng8HFdC3ibRzaS3MN/bzLEu7Yjgsx7KF6kk8YxXz2Lp16dWa5HaXl+P3mMKlColNSWl7a9P8rHbfDm9/szwr4y1lwPLhvJ5hnoRDbop/WM1tfBASD4UeG/OBExtt0mf75Zi36k1hyaXNo/wZttJugY9R1No4JU7+dczAuv4B2/Kuo+FiiLwFpcWf9V5sWR32yuuf0r7ChT9nTjDskj5CtP2lSU+7Z1p6GuVCSW3xNEgU+Rf6RtLAcb4JsgE+uLg/kfSuqNNC4PatTMdRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFQT2kE9xBPLDG80BJidlBMZIwSp7ZHFT0UAA4FFFFABSEZxS0UAV7yyt722e3vIIriB+GjlQOp/A1zTeAtIjfdps2p6YP7lleyRp+CZKj8BXW0UAcn/AMIDokrBtS+36ow/5/72Wdf++S239K29P0PS9NULp2nWdqB08mBU/kK0a4vWdT1+XxbqWnaTqOj6dY6fptteyy3unyXLMZZLhTys8YUAQA9D1NAHVXmnWd6hW9tbe4U9polcfqK5XV/hf4O1bm60O2R/79uWhb80IrD0DxTrGvap/Zun+LdBF+YBdJBc+Fr22aSEnAkQS3K71z/EuRXYeBdUvtX8Pm41VrZr2K9vLSR7aJoo38i6lhDBGZiuRGDjceT1oAyfCfwz8O+FtbfVtMiuWvmiMHmXM7TFUJBwC3PYDPpxXbUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXMeOLa5vV0S2tYpHV9VtpJmUZCRxkylj6DKKPqRXT0hUGgDz9mstD1zxTpethW0XUbWTV1WQZUrt23UePrsfH/TQ182RWdpqGp3GqraeRHKxFvC0jSGKMH5V3MST/U+2K9u/aglFr4GsrqKXyrkXogVh1ZHRt6/Qgc/SvJIECwokY+VVAAHYVwY+q6cUo7s78DTUm2xyjYoVBtUdhwKr3llaXqlby2hnB6+Ygb+dR6i0zG3trZtktw+zf3VQMsR74HH19qzWj0U6k2lI+zUkBYMC3mKcZzv7kZBwTXn0sPKUfadCcdmlPCzVJxcna7t0Rcj0qwslLxK0Ea5Y4mZVHvjOBWfpTxyl2upC6Sylbcq+CRuI6D2x1qxd2F7JPH9okjvYiuxVZdixP/z1ZRxJgZwpwN2DzzQmjC11S1lt8mAfeyckEDr+Nbc1SEV77b9XoTHMsDiadSk6nLeLa0trHW1+jdrdbq63aNGxj+warbbL6awtpyY2mjOPLkONrNjHynkHnqRW9rWoXulY/tyK3a/tMXlhqAjBPmxMGCk474A/Hn1rFugZjDZxJHLc3biCGKTkOzHHI9B1PsK6bxf4S1TSPA135Wu/a7exhF0VubcF/wB3yyq4OQpAIAOT2zya6YZtRoctLESs5bHFk9WtiaEvaK6XX+ux7TfP/bvjzS7MK32XR4f7RuVPaeQFIUPuB5jfgvrV3wHBc2em6haXcDxeTqd35W4YDxvK0isPUfP+lc98CbyTVvCl7qt42++u7+Xzjkk4jCxpkn/YRT+NejhRk8cV6Bb0HDpRRRQIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4+GSWL4keKJLaHz500LTmji3BfMYTX+FyeBk8ZrsK5/WfCOlavqralcnUob1oUt2kstUurTfGjOyhhDIobBkcgkZ+Y0Aea/DDRPF118RrvxX8RdEvoNVlha0sxDNatZ2MH3sDbMZGZiMZ2dzk88egfDT/kXLz/sNat/6cbij/hA9I/5/PEn/hR6j/8AH62tB0ey0HTE0/TElS2R5JP3szzOXkdpHZnclmJZmJJJ60AaFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAfPv7WIkvtCt7WBiPsMTXzDOPmZ1hT8cNIfwo8P8Aw+0U6ZbS6tGdUuZYFZ3mcmNSR1jUcL14PX3roPipZSamPHZXyEuLHTNPntzP9zEcs0pz7EgjHcqKl8M2jWXhXTbR98bx2iIQ7ZZDsGRn2NfMcTVp0qdP2crXb2+R6WXRUnK6OP1n4XWkmpQX+hXsthNBEyLBKXnidj3O5sjjI4/pzw3iDwvriRWcU+hXcV0+prcLf2JN0IoymJFdB0G5VYHHIyOOK9N0qDUtJ+HVj4lGv2zWs9sks8ers8pMvT91Ip3YfjCFTg9AORVaw+JNpKkZvdH1a03LyTGsmG9MKSce+KiDzjAx5FH2sPv/AOD99zKqsDVnzzfLJq2ul1+R5c6s93frqv2yNLNvL2QRzxcf89GAAYZyMBv161uaJ4X8S3rSpa2bRWh2tDcak5RgG6jaAWbGM84PIFegP8SNCihDyf2kj7wiRGyk3sScLtGMHJ6DOay7n4n2ks1wmm2wcW7bHF0zxPvxnhFVjgdycdcAdcOeOzGvBUaWF5X3d/1sccMqy+Lc5VOaPa+n4G94X8JWfh15bxriW7vHjCPc3AVQijkhQANo7nkngZPFcv47uP8AhI/C+u6hGlxLoFnZM1uhBjS5lwSZv7zJGOR2JBIzgGtLWNO0zXfh/qWtz+IH1y7sFjzAsX2aC2YuhYvEQGIIBGXJ+UnAGTWj8TrOW88EXunWMghlvGhs4guAG8yVE2ewIbHFebWwdfCYmlKvLmqTaXktV/Wlra+p69KdKdKUaStGKOg+C1u+kWz6XI2BNpthqS/7ReMxufrmJSf96un8czah9q8L2Gm6nc6Z/aOptbzz20cTyeWtpcy4Hmo6jLRJztziqyWsdh8RNHhthlRok8DjjhI5Ydh/NmH4+1WfGH/Iw+A/+wzJ/wCm68r7s8cX/hF9X/6HvxJ/3407/wCRaP8AhF9X/wCh78Sf9+NO/wDkWtXxZq//AAj/AIW1nWfI+0f2dZTXnk79nmeWhfbuwcZxjODj0rldc8Y654fEJ1628E6YJ93lfbfFEkPmYxnbutBnGRnHqKANX/hF9X/6HvxJ/wB+NO/+RaP+EX1f/oe/En/fjTv/AJFrP0rxjqt1e+HzPp/h+bSdZuZLWG+0rWnvAGWGaXIBt0Vh+4ZThuCa7qgDlf8AhF9X/wCh78Sf9+NO/wDkWj/hF9X/AOh78Sf9+NO/+Ra6qigDlf8AhF9X/wCh78Sf9+NO/wDkWj/hF9X/AOh78Sf9+NO/+Ra6qigDlf8AhF9X/wCh78Sf9+NO/wDkWj/hF9X/AOh78Sf9+NO/+Ra6rNGRQByv/CL6v/0PfiT/AL8ad/8AItH/AAi+r/8AQ9+JP+/Gnf8AyLXVZ4ozQByv/CL6v/0PfiT/AL8ad/8AItH/AAi+r/8AQ9+JP+/Gnf8AyLXVA0UAcr/wi+r/APQ9+JP+/Gnf/ItH/CL6v/0PfiT/AL8ad/8AItdVRQByv/CL6v8A9D34k/78ad/8i0f8Ivq//Q9+JP8Avxp3/wAi11VFAHK/8Ivq/wD0PfiT/vxp3/yLR/wi+r/9D34k/wC/Gnf/ACLXVUUAcB4ksdb8P2llfxeMdbu/+JnYW7wXMFj5ckc13DE4Oy3Vh8sjchgQcV39cr8S/wDkXLP/ALDWk/8Apxt66qgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApM80tYHjvUX0rwdrd9D/AK6G0kMX+/twv6kUAef+K7ptX0Lxt4lgiX+y1019Kti4z56o7ebPj0DMQnrtJ7itSzXZbQKsjOFRQHbq3HU+9X/GWhx2PwivtLtiVGnaerRlVzuaABxkdwSnP1NZ9pN59tDLlD5iB8ocjkZ4PcV8dxZf9121/Q9XLPtfI4e80rUNU+HdlZadDJe3nh7Vbg3dmqhZmRzIY5AnRjtdWwPU45GK821OOa9mb7FqAtpAApjkZo2jIznKnHXIzuHGOO9eg+OdV1rw9r5j0m5vbez1xI45pra3eWbzo8hIomUEpuViTxn5flIJNeba1pEGuW95cLBcf2xG7Is97v8AN8xTg7vMOSOoO73r6zKcQ8VhIVFbVfitz5nNoQo4m7unte11Z+pbih36lAqXUs16TiK3smeWdmxg7SCWUn1UL35HNV9KuNQuLgpp+npYadbzGOQyr8z4zuAAPXOQfcE5PSu2sfGeu6dOkelS6DpMmwOLOz09cMB/eJO9h6kYrlvD+qahp1hdG8iYXnnybYbKaaKbYzbuCUeCSPOcCUHoMgGu68ou7Rx8lKtHlU7vzVkl3S0XzOq8GW41Pw7481K1lDaWNJa2aWMhhLMpLjA7hRkEn+9x0Ndf4rkf/hC/OcxqR9mkcJyDiRCQnuegPriuGMEEtxENOkigv50Me7TwtrcvG3yujQM3lSg7sZSRDkjCZ4rvLQWOtan4c0nSCm+xvYbie0mQwS20USsfnhfD9QFBAIzznjNfN51hqlfFYdxjtK78tt/uPocqnClhpRT0tprudr4gdtE8b6frk6h9OvIF0mZx1tnaQtG/+6zHafQlPerPjH/kYvAn/YZk/wDTdeVd8aaY2seEdXsIgTNNbP5OOokAyh/BgprAvdRXWB8MdSTAF3qHn4z03aZdnH4Zr2zM0/ix/wAks8Zf9gW9/wDRD1zvxd0qxu9X8PanO/ii21LSkuZrC60XT/tipIyoCsieVJycDGQB97kcV3niHSoNd0DU9IvHkS21C1ltJWiIDqkiFSVJBGcE4yDWIPC+r/8AQ9+JP+/Gnf8AyLQBy2g3PiK80b4XXHjWBYNfk1aY3KBQpH+g320lRwrFdpI7HPToPVK5W38Iz/2vpl/qXifW9T/s6ZriCC5S0SPzGikiyfKgRjhZX43YziuqoAKKimmSGOSSVkSNAWZ3YAKB1JPYV5X41+K8dn5lt4btmu7nyWnWUoSGjUZaRU4OwDPzttU9t1AHqN7fWtjD515cRW8Wcb5WCjPpz3rktS+JGgWrOIXuLto/veUgUL65Zyq8d+a+dL8ax4o8QSanPrLapbeQVje2nliY/OQyqWxHEdy7CSFAHIB4J5m7dZLKGbTbRYpBDMWkfc4a5ZfmHnljkKFGVGFIPO75sgH0RN8a9Ma+W1s4rKWd87I/t5kdsDJwII5BnHbNB+Juqy6bPqNta6Y1hEOZQZWDHGdq7ghZuOgGeR618vX2rXniLU4BqDXrvDAbW+njt4jlhkqy7gBnJOG4IUL6V6J4ZibQIrKWAWutW8CLi2uby2tJFJXqksbBgRkg7s59aBnpLfGLVza3N1BpUNzbW0vkSzLbSpGsmM7C5bGfzrM0X9pGO4Kf2p4L1iKPLK0tkwuACuN3BC9MjPPesjUNW8GfZotMPh5YHkklAiuNXne1YOFDPuidgpbLD5gD8vvWXp2kaTolrKLC/VtNCqpSyMkgG5wpDM4AUsAu6TGFwp28ZAB7b4W+MXgjxEI1tdZjtZ5DtEV6pgbd1K5bgnkdCa7+GaOeJZIXWSNhlXRgQfoRXxP4a8ERKb/VobgX2kadq0SNpt5CG3GVlUSEEkFQr8kjBxnFel69Zal4e8Tz23w5vP8AhH2Vx5VlPIDaXBO3k78jaxLhcf3CAQSBQI+kAcjNLXh/hH47WwS2tfHNmNKvHdomnjVvKZlIBIBGSOQeC2MjtzXs2n31tqNpFdWE8NzayjcksThlYeoIoAtUUUUAFFFFAHK/Ez/kXLT/ALDOk/8Apxt66quU+Jn/ACLlp/2GdJ/9ONvXV0AFFFFABRRRQB80+HdQ1dPDU1xrl9exWup6BqSwyXGpz3iahONxC7ZPlgkREYhU+8CcE7SB1J+IGs+F9Gax1W50pZYbHTZbW5jsj5aicSjy5RJcxrx5P+sMiLlh8o4Fe20UAfOC/ErULm40/wAUSX2g6bqR0S+jEV2heO8eK72rFCqzZ3vsGMNJjnAbrW9qfjC91/xjoFjfzaZpz2uvwINGeNjfAfZ2bzmYuBsJcgYjx0+bPFe41y2q+NtL0fxeuh6xdWWnpJZpcxXN1dpEJXaRk8tVbGT8ueD+FAHidj431qLQtYv7rWLOJJvCdpf2ul3E115kziO4LmCU3IkBBUF3G5iuwEgruO/b6pqHh7xL4h1aa68P2zah4gl02TWdQsXxZQpArosknnDKHaiKuUUMS2TkLXq2oeM/DdhLf282uaYb2xhknuLRbuPz0VF3NlC2Rgc84qtp/wAQPCl5o2nan/wkGk29vfqPJE97EjF8AmP72N67gCoJwaAOJ0/4heJNStb2eCHSbeOy0H+13MlvK/nsJbpBsG9dqOsCOCckBsfNnIhbx14ztTeyXcnh6WGxt9MvJkisZkaRLuUoY1YzHaV2sd5Bzx8oruPB/jvR/EVtODe2FrqMEt0s1ibxHlijhneLzGXghSEDcjA3Dk9TeHjTwsdLbUh4l0Q6csnkm6F/F5QfGdm/djdjnGc0Ac58TdQTSfEfhbUZWKpaLqE7MIjKQFtHOdgILdOgIz6iuQ8L/FfXtdlktLYaNNKdRs7SK5EQEZjnjmYkrFczDcpi6eZznBCnke2WtxDeWsNzaTRz28yCSKWJgyOpGQykcEEHIIqWgDyy58ea7p2t6houpQ2f2rS459QvL2GylaI2Cwho5Ej8wne0pK7d5/1T+xFj4PePr3xpda7BfGxlSw+zvDcWiogkWVX4IS4nUEFD/HnnkAivS6KACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArkvignmeDrqHBPnXFpDgdTvuYlwPc5xXW1yXjljdaj4a0lSQLvUknkx/ctwZv/AENI6AOrdFdGV1DKwwQRwR7149pEX/COalN4XvNsTQFpdPYnAubZmJXb/tJnYwHoD0NexjpWdrWi6Zrdp9m1ewtryAHcEmjDbT6j0PuOa8/Msvhj6PspOz3T7M3w9d0J8yPK/GWLjT7XToiPtl/eW8Nuo5YN5qsZFHX5FDP/AMB7Vl/F/wACDQdD1/xRoupywhS129pNAskYdm+Yq3BUEnPOfwr1rRPCOgaFdNc6VpVtb3TLsMwXdJt/uhmyQPYcVynxLnvvE0OqeDtFigjLQRm9vrknZCHOVVEHLsQueoAHfPFRlmCWV0HHnvrdvbsLFuONklKN12OBstG0nUdANhouhx3zFg9zreoXTRSG4A5EDRqWwpJXjavBGDzVbwN4EuNTu7nSdf8AET2eq2+ZPKhgjYTQE/LJG7DnHRsrkHr1Fbfgqe30D4bWMl65SGwgdbhghOCjsHOBk/eDVoeKNC/4SA6W0dx5cMM2+YocGaBlIePI7N8ufUV4keI69LFyVXSndr7v1/zOmplNCrSj7qctDF0LQ9In1YXGireNo1oRN9vuf9ZqNwpYB9x58pB90AKpLE811vhXR7fxvJfahrcH2rQo9sGlxSx7ckYL3MbffUk/KrKRwpPfNUBZjxJrMHh3Tnmh0y3DDVJLQBBFF5eEgDYwrMSvC8hQemRXrdnBFa28VvbxrFBEgjjRRgKoGAB9BXoZZCri6rzCvpdWiuy7/Miu4UYLD0+m5yX9ieI9EyfDmsjUbUZI0/WmaQj0CXK5kX/gYkrkNE1BI77wBobafqFrLZ6xc7XlVZYXUWd6CEnjJQlS23aSr/KcqMHHsJ4NeU6SxNz4WiOf3Xi/Ulxnpm2v24/76r3jjPWBQKBRQAVU1TULbS7KS7v5RDbxjLMeepwAAOSScAAckmrLZ4xXz18Y/GOoaxenT9Dklt7KBJCt8kLSrCwyv2hgvIGQyqwztAZ8fdoAg8c+OdQ8T+JjoVnNb2EaRvPL9tOILSNFZ8yY/wBZMQh4+4nQ5bJHnHiz7drtpp3h1Vjt9bjIludTNyGW8hlG0FJV5lRzhmGCQ3Az0EOhaHNrukReF0gSTxalz5K3FpeJKrQOhJkZlVsxhWIIDgfMOCa+nPht8MdG8EwRvEi3epgYa7kQfLnqEH8OfXqfXGAADzzw38L9WuhH9mk/sawY5nlnj82W7PAz5bdAAoAJ2HHVW616Hofwo8LaaoMtrNfzL92W7lLbckkhVGFUEk8AAV39FAFCw0bTNOwbDTrO2I4zDCqH9BV7H1pkzrEjSSOERRksxwB9TXFaz8UfCeltKran9qkjzuW0Qy7SOxYfKPxIoA7gD61m33h/R7/JvdKsZ2PVpIFY/njNeTah+0Bpcd/HZ6b4d1y9uZW8uNNirvY5woILDPB79q0Ivip4gMyxy/DvWYi396cZx/eA28igDc1H4VeHHhC6TbjSsZOy3UGJiTn5kIweee1eVePvhPq1vYXwsbKG8+1IsBmt9zL5YkWQ7ozl0PyYBUuAGPTv10Xx90WK4FtrWha5plyzBVjmWIluCcgFwSOOw9PUV23h74i+FtfnS3sNXhW7Zdy21zmGUj1CvjI9xkUAfIet3N1omjaR/a10ZdStrho45IIll+zxosC5CPwz7Qy5OCdozjg10Xg7xJ4j8L6hfTaVqLzz/NcTWYgYQkpGGfcqggLu3LnggqxHHNfTvjDwLo/icPJc26Q35AxdRoNxxyA4PDjPr07EHmvnfWvAeofDnUkGsu194cupgr3CQjyU+VgCwIbadrup3Efe3Kw7AHuPwx+Kuk+OEFoVbTtdRA0unznDMMA7oycblwR7juBXoanIr5QuPDb3/hyzXQtUe4EF4txpd1bz7Xw7qqsrE53KCEIJzwOowa9g+Gnj+6vWs9E8WCKHWpYt1vcJxHegZB4OCr5U5UgcgjgjFAHqNFIp45paAOU+Jn/It2n/AGGdJ/8ATjb11dcp8TP+RctP+wzpP/pxt66ugAooooAKKKKACiiigArjPGPgZPElxrczXqwNqWiPo4zBvMW5mbzM7hn7w+Xj7vWuzooA8uvPhdf3/iyHVdQ8UT3FrBNPJDbPHKTGksLxeWMzGIBQ+QREGOMEnrV/RvA+uaRdaXe2uv6a97Z6cmku0ulOY5LdGDJhRcArJ1y24qePlGBXoVFAHmd98J7e+0KDTJ9TZURtTLyxQbXf7Y7t13cbNwHfdt7VUh+FN5FYSqNYsm1N5o5RqDRag0qBI3QbXN+XU4dhlXAKkgqR09XooAp6PazWOk2VpdXct9cQQpHJdSgB5mCgFyBxkkZ/GrlFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFclrx2/ETwsX+41veov+/tiP8gfyNdbXI/EYLbWWl6vkK2l6jbzM+ORG7eTJ/45KT+FAHXCigdKDwKAEbPGK5jxL4Wj1O9TUrC6l07Wo4/LS6j+ZXUHISVDw6ZJ9GGeCK1Nb1/StCW2bWb+3sluZPKiaZtoLYJ69BwOp4/OtFWWVFeNldGGVZTkEHuDTnSfInKOj+5iUtdHqfPpuY7L4QXUd4v+kW1m9ncxdzc/6t0+rSHj/eFdd4T+Ft1Z6PEuoa9qdjOwQ/Y9NmUW9vgDKL5iuTk5JIwMngAVleN/A0mr/EIaTDqKw2OrSjWriMxEspgVImVSGA5JRuRwRnnivbB0rx8FlcKHtFUSkpSur66f5nXWxLny8ulkZXhzQ7Pw/pqWOnI6wqzSM0jl3ldjlndjyWJ71q0UV6yVtEcohGTXlccZg8ZadDxsHi+eRP8AgelXDH9c/nXqhODXlNvIbjxbptyCTG/jC5RM+iaXcof/AB5Wpger0Gk3CmySKiMzsFVRkseAB6mgDy39ofxvN4T8EXNvpL/8Tm+idYiCAYYhgPL+G4AepYeleBeHZ1kvrfVbeO7n1bUkUW09vfqHjkRkRk8tR93bgKVGc55Pb17+3fDHifx28mtOmoSvbltPsoAZJlj3bF4X7u5SznJAw4zjFaXwZ8FyJcTeItTlkmHmOunxOAqIn3QyqvAAVQoPU4LdxgA6X4U+BYfB+jNJNEjaveHzLmXO4rk5EYPoPbqa72kAwKa8iojM7BFUEszHAAHc0AKSMdfevKfHnxn0XQZbu00ox393bLunuGfbbW/pucZLsTwETJJ4yMEjzj4z/GJNTtdU0vw3qMEFpFBvWQkk3o37SFI7dSF4yASTjAPj/wAPfCWteOtTih0xbrUoU8uS4ErGO2jcBiDI+P4SxG0AsQSARQB1Wqa54z+Iw1me8vb2S1s4ZJo4o4fIt49gDfvFbA+YHA5ZhxkEVxGnaBca/Mj2c2pXRkkWJIoY90jxbeSQmcDIIzg9BxzX11ovwh09pFufFV4+rSbi/wBhiT7NYRsRglYE4PHdic16Pp+n2mm2y2+nWtvawL0jgjCKPwAoA+VvA3w58W6b5M66TdyJFu2+baxKxJCjOx5FH8IwxXd156V2V1p3xjNu8GlpplvCGJSSe0hM4U9QTuZTznnGfevoHB9aWgD5ek+HviiG7muJNHuRaySieW2KxzRbhkkiNXJbJI6kjjoa4me+s7KK70zxp4dsYb9S0sE8lu9uijjCKoGVHJxtCHI4NfazAnoazNe0HTNfsjZ61YW19bH+CeMNj6HqPqKAPnHwZ4x1Xw1bR3mi6pPqugO+wWF65kK8dI5DyWzxtHOT908V7r4S8UaF4+0Od7Ty54j+5u7O4QFoyQPldD1BB69DXkni/wCB8nh8XOo+AHeaF/muNJuQJVlAzjbnqRnI/iHUE9K858O6tqehef4g0Zb221Kxb/SYLlSfNjUgSkrwZFHcjLA/eycMAD2HXvAT+DLptQ8LKItJ+9LDtLpDg5HmJzuQdnALqBjOMFfMfEGi3GvzG7svtUNxYTyTSzm5/eZdi5YocnBVVxKrEHjOMEj6S8BeL9P8Y6JHfWLKsu0edDuyUJHUeqnse/1BFcj478EraBdT0q2+0WkEjTNZfPmAkH54thDbQSx2A5GSV7qwMq/BX4lTa7DHoHilJbXxBEmYjcLtN1Hzg+m7A/Hr617ACMCvlHXNDvDZXieFL1ry5F2LmyjvHWGYSP8AOPssmfnwFAABwQpGCRivdPhX41/4S7RsXq+Rq9uNtxEw2k4JUsB2O4EMOzD0IJBGh8TP+RbtP+wzpP8A6cbeurrlPiZ/yLlp/wBhnSf/AE429dXQAUUUUAFFFFABRRRQAUUUUAFFFFABRRXJ+GPHmja9fz6cJvsmrW8jxSWc5w25SQdp6N0PTn1AqZTjFpN7m9PDVasJVKcW1He3T/gHWUUUVRgFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFNdgoySABySaAFJ5pMnvivH9V+IGv8AjPW7nQfhXDAYbZjHe+ILpd1vCf7sQ/jb35HtjmtKH4ceIRZHzPiX4mOoE7hKoiEQP/XMryP+BCgD0/PPFLXkOg+MfE3hHxRa+HfiWbe4tb9/L03XbeMRxyv2ilXorHt059eteuKSTzQA6iiigAooooAKKKKACiiigAooooAKwfHVi2peDtcs0GZJrKVU9d207T+eK3qjkUOGVvusMH6UAUvD2of2roGmagMEXdtFPx/tKD/WtBsAEkjHfNcj8LiU8GWtoc7rGaeyOeceXKyj9AK439oHx0dF0f8A4R7S5GOq6imJNnWKE8H/AIE3IHtn2rrwGCqY6vGhT3f4Lq/kZ1qsaUHORxWuTSfF/wCL8GnWjM3h/TSQXU/KYlI8x/q5wo9tvvX0nEiRRrHEqpGgCqqjAAHQCuC+C/ggeDfCqi6QDVr3E10e6cfLH/wEE/iTXoFd+dYynVqRw+H/AIVJWXn3fzZjhaUopzn8UtX/AJHneoXAb496Tbg8p4euXP4zxD+leiV5Velh+0BZXP8AALE6fk9A0iNMB9cQn9a9VFeKdQUUUUARzOsal3ICqNzE9APWvLtCjf8Asv4aXMwxLf6zcX7+/nWV9KP0cCuv+JNzJa+BtaeDPnyWzW8WOu+T92v6uKo+ILVLDUPh1aQjbHb6o0Sj0C6beAfyoA4Xx34v8e+HfENxbaPpg1VzP58VvtG2W05G2ID52ccbsAkE9MEVwHi34x+KfFelXOkp4SudOgcFbtGzvdMcqGYADPpgk9Oma+n9W0mw1e1FvqdpFcwhtyrIudp9QeoPuKyB4I0Q4EsN1PGOBFNeTSJ/3yWxQB85/s9+ALq5urq6eGS0iljaC+mPDGJmDNCuOjHaqnHRSx4JFfVtvGkUKRxIqRoAqqowAB0AHpWVrVzB4a8M3d1bQW8VtZQmQRk+VGijkk4HAHJOBWF4R+JPhvxFokV/Fqlpa7iytHcSiL5lOGKlsblyPvD9DxQB2hbB6V8wftL/ABNe+tp/C/hiSSW3802+oSwqSJG6GLcO2eD6kEdjnp/jp8XY9G0mTT9Cn8t7kGM3SnDspHLRDrt/6aYwei5PI84+HPgy58e6pb6ZpkVxpnhOwKS392Ymie9k2jAQEnGVJ9wG3MSWoA5/4T/C+/8Aihq8Wo6g0tvodvtjurrZsaUqMCGLscDALDAA9T1+zvD2iab4f0mDTNFtIrOxgGEiiGAPcnqSe5PJqTRNMstG0u103S7dLaxtoxHFCgwFUfz+tXwAOlACKMCloooAKKKKACiiigBu3knvXn/xH8DQa2p1GxjZb+Mh5EjwGlwMbkzwJQM4PQj5WyMY9CppUYNAHznoNrq2mCTxFoxs9Pe0tRJNDCMQXSFgFkEWBt3r95R0dOOeD6n8NfGVx4phZLqCMt5IuY7qCORIpomdlU7ZFVgTsOOoOCQe1eb+J11r4Za8DaxvL4Rt7e5u7QzLLOnnH5hbyEZKHO7Y545ANaHwQ07WrfxLJc+ZY/2C2n7FjsCzwKWk8xPnPBcGSUbVyFHXrQB13jrwPBfw3E9nZi4t5dz3NlGQj7yMGaBuiyEcMp+WQcHnmvM/AWkXnh7xhJFodw17BeQvqWnyPKT500ZCXMEm7lGdSMqR8rKvXBr6PUAjPU1zeseENPvNRXVbFV07W42LJfwRqX6YIYEYZSOoPPA5BANAGZ4y1O31jwTpd9ZkmC41bSXXcMMP+Jjb5BHYg5BHYiu5ryvXNK1nStKul1OexmsrjXtInt/syuhVzqFv5mVYnaCQGwCeS3tXqlABRRRQAUUUUAFFFFABRRRQAUUUUAFfJ/xs019K+JWovECi3Oy7jK8H5h8x/wC+g1fWFY2oeGtL1HWf7SvrZZ7j7I1nhwCvlsSSMevJH0J9a5cXh3iIKK7nv8O5xHKcTKtNXTi1b7mvyOJ+Buq67q+g+fqmrWeoWiZjA+Y3MTDs5IAPHPc89a9Pr5z1ax1T4N+Mk1DTd9x4evG2lCchl6mNvRxztbv/AN9CvevDut2HiHSYNR0qcTW0o691PdWHYj0qcJU09lP4l/VzXiHBL2ix+Hs6NTVNK1n1TS2f5/eaVFFFdh82FFFFABRRRQAUUUUAFFFFABRRRQAjdK8h+IurX3jPxT/wrrw1cPBCYxLruoR9beA/8sVP99+h9j9a7b4k+LIPBvhS61SRTLc5EFpbr96eduEQfjyfYGsz4Q+EJPCnhpn1NhN4g1OQ3upz5yXmbnbn0XOB+J70AdR4c0TTfDei2+maNaxWljbrhEQY/EnufUmrVrqFldyPHa3ltPInLLHIrFfqAa+U/jn8QtT8S/ERfCOl3BttBtJvJuOW23Tqfn3hCGKg8BcjkZ9KbL8JtU8PeF38SaPJqlrf2Kme2a3IRyAcltjYYKAG+U8kbT3IoA+l/HPhiy8YeF77RdRX91cJ8kmMtFIOVdfcHBrlfgf4k1HUtHv/AA/4mZv+El8PTfY7st1lT/lnL77lHXvjPeum+Huut4m8EaHrMhXzby0jlk24wHx8w/PNcD8SJz4E+J2geM44z/ZmpgaNq+Oi5IMUp+hBH0GO9AHsdFNQ5B5yPWnUAFFFFABRRRQAUUUUAFFFFABRxRWd4g1mx8P6Rcanqs6wWkC7mY9T6ADuT0AqoQlOSjFXbE2krs881DxdZ+Av+E1N6d8iXyXFnbk8zNPErYHoN6yZPoD34rkfgn4TvfFPiCfx54pzMzSl7RXHEkg434/urjCj1H+zzj6PY6r8bfHTajqayW3hqxbaEBOFXr5anu7cFj2H/ARX0raW0Nnaw21rEkNvCgjjjQYVVAwAB6V9LiZRyXDPCwf7+a99/wAq/lXm+v8Awxwwvip+0fwrbzfckB5paKK+YO88o1ZX/wCEr1PUVJUWviLTIt3s0SxH/wBKMfjXq4ry/wAS208Ph7xtOYZQx1q3uEJU/MqLaHI9QCp6ehr1CgAooooAz9Z0y21a2S3vUd4lljmAViPmRgy9PcCsPxj/AMjD4E/7DMv/AKb7yusrlPGfPiLwJ/2GZP8A03XlAHV0UUUAQ3UMdxA8M8ayQyKUdGGQwIwQR3FeHar8BDBNIvhLxNqmladJIZPsKzuEjY90IOB+IJ9693rirbx7BL48vNAlszDZQLIi6m0o8t7iNI5JIsY42pIDuz/C4420AcD4Z+BdvpWpfb55be51F2y1/eu15Mp4+ZAwVA3ozK2PSvZNH0u20fT4rKwj2Qx8/McszHksx6licknuTXFWnxO0q58SSRiWRNDFlbyx3UtjcRNJNNOYk2blG+MkphlBHOd2OknjH4iQ6LcodORb2G3e9ivoxFJvWSC188IpA75XLYYYPsaAO+wfWlGe9cjonxB0bVnsbeJNUW+uYopWtxpd2fJEhIUyN5QCKSrYdtoIUkHHNXfEPi3TvD+o+Tqs8MFslhLfySHzGkVI5I0JCKhBGZRn5g2cYUjJUA6EjPelrJ8PeItN8QJdHS5ZWa1kEU8U9vJbyRsVDDckiqwyrAg4wQeKxj8RvDQsWvftF+bMSLCk40u6KTOzFVWJvLxKSRj5N1AHX0GuS0j4h+G9Xu1tbC6vHnYS7VfTrmPe0X+sRS0YBkXug+YelU7zx/aXF1ptvohkaZ9UgsbyG+sp7aWJJI5HDBJFRhnZwcEdaAO42+5pRXFeH/GMtz8LdH8U6mtpFPd21vLKoMiRK0jKuBhXYDLccH3IGSH3XxI8PRvqENvPcz3doLpfL+xXCrLLbhvNiSTy9rMNp4Uk4GQCKAOxx7mlPSuFsPih4el0awvr972ye5tUupInsLk/Z0bHzu3ljbHnIErYRtpIPBp3iX4k6TpOka3d2UN/qEmlFkmWOyuBCXWRY2QTiMoWDNggEkYPocAHbBcU4AYrjpPiFottLP8AbZJ4Ile3iiT7HdG5eSYOVRoDCGUnyzgDJPcDjLpfiP4WisoLs6hM0EsckpMdlO7QojlHaVVQmIKwIJkCgEH0NAHX0YpFYMoZSCpGQRyCKWgDlPiYP+KctP8AsM6T/wCnG3rq65T4mf8AIt2n/YZ0n/0429dXQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBS1nS7PWdNnsNTgSe0nXa6N/MehHUHtXgF3ba98GfEhubLffeHLpgDu+64/utj7sgGcHv8AmB9GVW1KwtdTsZrPUII7i1mXa8cgyGH+e9c9fD+1tKLtJbM9nKs2eB5qNWPPRn8UX+a7Nf10tn+FfEmm+KNKS/0icSRHh0PDxt/dYdj/AJFbNfPfiXwbr/w01Z9f8GTSz6YOZYiN5jTrtkX+JP8Aa6j2616V8O/iTpXjCFICy2erAfPau33/AFMZ/iHt1H61FHE3fs6qtL8/Q6MwyVRpfXMBL2lF/fHykv1O6ooorrPngooooAKKKKACiiigApG6GlqC/u4rGxuLu5bbBbxtLIfRVBJP5CgDyy6tj4y+OapM3maT4Qt1l8vHytezDKk+pVMH2OK7Lx/4v07wR4fk1TUhJL82yG3iA3zP12jP0JJ6ADNcx+z7FJc+B5vEF4mLzxDfT6lKe+1nKoPoFUYrgf2jZPtfxG8JWN1cRLZxwSTGNvmCkuAZGA6BQA2eOA3XkUAeQeGBfR/EyPWdTtryzstTv9ziPy2kheaYGM4cZ2hynb0I6ivfP2k5dYtfBel21iiSCRxbzTsT8rMAm4EnjgsCT2c/UcXqvxas30xNA8LeHINStUdZTc3BMXnujI/mKgHyDOCCzDgduK1bP4mp4ybT9D8XaC+n3UN4l1b+W4niuniyTCQ6sc84I69QDkYIA3QrjxR8JNL0W5vHupvCDywwTW90qbrdXIG9cEsrBmzt5BGehxXsHxZ8Px+J/hxr+luqs8ls0kRPZ0+ZT+YFeM/HVfFmoeFLjVtYtIoPDdtOEOnB3jkjyVCy8cOFxxnHLH2r6PtpUubeOWP5opUDKT3Ujj9KAOQ+CmvyeJfhd4e1K4Ytctb+TMT1LxkoSfc7c/jXb149+zwjaS3jfwyT8mk63L5QPXy5OV/DjP417DQAUUUUAFFFFABRRRQAUUVk+KPEOmeGNJl1HWblYLdOg6s7dlUdyf8APFXTpyqSUIK7eyE2oq7LGt6tZaHpdxqOqXCW9pAu53b+Q9SegA5NfON1d658cfGAtLXzLHw3ZtvORkRr03N2aRucDtz7kq8niP45eJfLjD2Hhm0kye6xD1P9+Qjt0Gew5P0L4X8Pab4Y0eLTdGtxDbR8nuzserMe5P8Anivp0qeQQu7SxLXqoJ/+3f1tvwe9jHppBfj/AMA5zWPDMehaDoCeGbJmOjXsUqQx43yI37uUk92KOxPriu4ByaCM0YGa+XnOU5Ocnds70klZC0UUVIxpU5yKdRRQAUUUUAFcr4y/5GLwJ/2GpP8A03XldVWfreiaVr1qlrrmmWOpWyOJFivIEmRXAIDBWBGcEjPuaANCiuV/4Vx4H/6E3w3/AOCuD/4mj/hXHgf/AKE3w3/4K4P/AImgDqq4M/CnwuY4nNof7RW7ku5dTCRi7uDIzmRJJQuSjCRlK8fLgDGAa0v+FceB/wDoTfDf/grg/wDiaP8AhXHgf/oTfDf/AIK4P/iaAMcfCvTntJYLvWtcuybW3tIJZpId9skEoliKFYgCVcA5cNnoc1Yt/hnpapL9r1HVb6Wa4urmaW4kjDSPcQCCTOxFAG0cAAYPtxWh/wAK48D/APQm+G//AAVwf/E0f8K48D/9Cb4b/wDBXB/8TQBmn4a2c15odzfa1ql5Jo/li3aWGzWTCNuUGVIFkA6AhWUMBg5yc6virwVp3ia7e4v5ruN2sJdPIhdQPLkkikJ5U/NmFcHpgnjphn/CuPA//Qm+G/8AwVwf/E0f8K48D/8AQm+G/wDwVwf/ABNAGtpmiW2naxrGpQPM0+qSxyzK5BVSkaxjbgZAwo6k81ytj8LtJttVfUWvr+W5e6huyRHbQKzxOXG5YYUDEk8swLY43CtT/hXHgf8A6E3w3/4K4P8A4mj/AIVx4H/6E3w3/wCCuD/4mgCrc/DrSri2aFrvUkBuL+53RzKjB7zf5mCFyMeY23uMDJNZ/hn4SaF4euRPZ3N60n2q3uz+7t4VLwrIqZWKJF5ErZOMnA5652v+FceB/wDoTfDf/grg/wDiaP8AhXHgf/oTfDf/AIK4P/iaAHx+CtOj8CWfhNZrs6daxwxJIXXzSImVlyduM5QZ49elQL4A0kPAWmvGEV7fXwUuuGe7EgkU4X7o81tuORgZJ7yf8K48D/8AQm+G/wDwVwf/ABNH/CuPA/8A0Jvhv/wVwf8AxNAHOXfwb0O8+wPe397d3FnapZRzXdpY3DGBCSkZEluyjbk/MAGOeSeMXr/4WaRf6jq95dXt+ZNSgkgcQx20GxXZWzmOFWkK7RtMpfHPqc6v/CuPA/8A0Jvhv/wVwf8AxNH/AArjwP8A9Cb4b/8ABXB/8TQBEngSzOpx6jealqV5fLcW9y00piUyPAsipkJGowRK2cAdB05zi6p8HPDmoTJPJJOLhXuGMsttaXORNO87LtnhkUAPI2CADg4JNb//AArjwP8A9Cb4b/8ABXB/8TR/wrjwP/0Jvhv/AMFcH/xNAHTwxrDEkUahURQqgAAAD2HAp9cr/wAK48D/APQm+G//AAVwf/E0f8K48D/9Cb4b/wDBXB/8TQAnxM/5Fy0/7DOk/wDpxt66uuatPAPg6zuobq08J+H7e5gdZIpYtOhR43ByGVguQQQCCK6WgAooooAKKKKACiiigAooooAKKKKACiiigAooooADzwa8k+IPwgttTlbU/Crrp2pg+YYQdsUjdcrj7jfTj6da9borKrRhWjyzR3YDMcRl9X2uHlZ9ez8mup4N4a+KeteFb4aL8QLK4Yx8C52/vVHQE9pF/wBoc/71e1aLrGna5YreaTeQ3du38cbZwfQjqD7HmofEXh7SvEdibTWbOK5i6qWGGQ+qsOQfpXjOr/C3xJ4Rv21TwDqU0qLz5BYLLj0I+7IPY4+hrl/f4f8Avx/Ff5nutZZnGqaw9Z/+C5P/ANt/L1Pe6K8T8NfGpra5Gn+NtNls7lDteeKMjaf9uM8j8M/SvXNF1rTdctBc6RewXcJ6tE4O0+hHUH2NdNLEU6vwv/M8fH5PjMvf7+GnRrVP5rT9TQooorY8wKKKKACvO/j7rZ0L4SeIrlfvywfZV+shCfyJr0SvJP2moluPhgbViN1xqNpEqn+ImUcflmgDuPCttF4f8B6VblAsVhp0QZVGPuRjP8jXyv4hhtvEHwr8UeOb57e78Q32pJbt5o3mziByI1IzjcpUcdsD+9XsP7TWp6hB4S03RNLS4aTVJmjdLdyskiooOxSAepZTjHO3HeuPsvAvg/wxpt7Z6vqkWnXlwqqYpLkTPchhv+YBNyAAqFYLwVJ5xyAQ/BrwpFrulJEtq0MC5jN3BcYV3AyzhUABAO3hvRRyMV6HqfgOLVPiLorw747HQGF3IBAUadyrFB5nCn5j0XGBuHGRXIeCfhr4i0Wa21vw741sp9Ej3M0jWxmlMSsSVG04c4UemSPwrpILPxN4whutcvPEj6Pp0LFoore52RRgFGBkwo3DaWznGcjp1oA4b4yyfEfxHoEsWo6XBo2jfaAttZKwlkn2qxG+QE4JA4GBk4HNe2/CbxTp/i7wPp95pivEIEFrPbSHMkEiAAo36HPcGvNPGPj7+yPD82kapfJrtx57Tfb7W0l3WsLN+7diAEWRTu6sMYXg80n7K6XEkvjK/jj26Vc3UQidCTFJMoYSshPLA/Kd2B1oA3/DSf2V+0t4rtt2U1fSbe+2+hQiP+h/OvYF6V5LcBU/aes2Aw0vhqRc+uJgR/WvWx0oAKKKKACiiigAoqtqF9a6bZyXeoXMVtbRDLyyuFVR7k14b41+M15q15/Ynw5tJri5lOwXnlFnb/rmh6f7zfkOtehgMsxGPlaitFu3ol6sxrV4UV7z+XU9D+I/xI0jwTalbhhdao65iso2+b2Ln+FffqewNeR+HvCfib4vaymveLZ5bTQ1P7lFG3cufuwqeg9XPX37dP8ADv4MCO6GteO5P7Q1KRvN+yu/mIGPOZWP329un1r2tAFAVVCqowAB0r1p47DZTF0sA+eq96nbyiv1/PpzqlUxD5q2ke3+ZU0bS7LRdNgsNLto7a0hG1I0HA9/cnuT1q7RRXzcpObcpO7Z2pJKyCiiipGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAYviTwtoviW38rWtPhuSBhZCNsif7rjkfnivJtY+DGpaTdm/8ABGtSxTJysUrmOQewkXg/Qge5r3OisKuGp1dZLXv1PVwGd43ALloz93+V6x+5/oeAw/Ejxx4OkW38YaM11ADjzpE8tj9JFBRvyJ967jQPjF4U1UKtzcy6bOf4bpML/wB9LkY+uK9EkRJUZJUV0YYKsMgj3FcRr/wr8JayWd9NFnM3/LSzbysf8B+7+lY+yxFP4JXXn/mel9fynG/71QdOXem9P/AXovkdhY31pqEAmsLqC6hPR4ZA6n8RVmuH+Hfw8s/BF3qU1peS3Quwir5qANGq5JGR1zkdh0ruK6qbk43mrM8LGU6FOs44afPDo2rdO3lsFeRftEoJdO8GW7ZCS+JLNG+mTXrteR/H4kXPw9A4B8TW2R2+61Wcpc/aA8Ny654MjvrNpUvdHuFvUMShn2DiTAPUhTu/4DivKfhBqFlrGs6z4l8Svbtcky3Krs4ddgJijyMLjG4nOQAOgzX05fXEFpZ3FzdyLHbwozys3RUAySfwr4o0PxLDYeDvE+mmKW2i1CK4fTbqeN8vD52CFbO3OwyAgD+H8wD3jwD4/wBe8feJ444tGs4vCoEqPLKXUzkLtZQMEHO8NsbHA61ci8aQeCvF7eEb+2dtLf5rS5kcbsn53DDABXBcrjk7SOTXIfAfxZp3h7wZDDEI5IpJnlmDviUOSfukIAwwp4J4yOcdMP4j3cXiDx/4Z0W5SE6td6tFNeQxmTiM/IschLFchSxGOMcjg0AenfFLWtDufA2pQaabSQzyO8r7HWONguWlkCKWbghunPB5FRfst3M1x8JbRZQBFFdTx24DZ/d7sjr7k15T8ZfAOv8Ag3QbuW08QNd6NL+78t5GiuCmRuVsfK5Coo3NycAAV9HfDm20i18C6GnhyLytKa0SSBC2SAw3Ese7ZJz75oA4m5dX/ahslx80fhuRvzmFeuDpXkOjbdQ/ab1+dBn+zdCgtWPozvv/AJGvXx0oAKjlmihMYlkRDI2xAxxubk4HqcA/lWP4x8U6Z4S0eTUdYnCRjiONeXlbsqjuf0HevlTXPijr2reNLXX1MUb2ZYWdqctFCGUrnHGW5ySepA7DFe5lOQ4jM1KcNIq+r6vol+r6HJiMXChZPVn2Dd3MFnbvcXc8UEEYy8krhVUepJ4FeR+NPjpo2mlrXw1C2r3pO0SYKQqfr1b8OD61y1n8MvHPjueO98b6w9rak71hdhIwH+zGuEXP5+1eteC/hx4b8I7ZNNshLegc3dziSX8D0X/gIFb/AFbLMv1xE/bT/ljpH5y6/L7iOevW+Bcq7vf7jyCx8DeOviddx6h4zvZdO0wHdHFIm0gf7EPAHpubn617b4O8GaL4Qs/I0SzWN2GJbh/mll/3m/oMD2FdHRXDjs4r4yPstIU1tGOi/wCCbUsNCm+bd92HOaKKK8o6AooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvHP2m99r4R0LWFAKaTrdrduc4wASM/mcfjXsdc/498OReLPBur6HKwQXtu0aOf4H6q34MAaAMz4s2lzq3ww8Q2+mljNNZMyhOrrjcyj/AHlBH415b8H/ABLpUWjxWGsotzp7W5S33wGQIpwmwDaD8wDBjjkryTkY734F+JJtc8ERWOp5XWtEc6bfxN94PH8oJ+oA59Qa8f8AjL8KZvDMOpa3ockf9jTyRoYFZYXtvMm+YbivzIWbqWBHAOQBQBTXwXpuq/ECTT/hX4nnjkjaWSaJ2kaG0+UKQsyHlTgDbn+EAniuh8D+GLD4beKf7R1q9udVujbl4bqS28mKNtzec43EsecKWx1kGMA5pn7P+qtpKWVnb2MjSSKTcooTcVZUYScckEYwWx0br26CXQ9L8a32r6Fc6i8PiHR76Y2epspJljZ95ikDHEiDKgrwDt470DOL+PPiOC6S9gubi3i1SRSscOxi9um4HkkcNhUP8OMjqc17t8H9Pu9L+GHhmz1BDHdx2aeYh6qT82D74NeI/CfwRJ4t8UanDrmsrqOjeGb9IUiigCx3cqLgNznAAUA9Sw74r6J8Wa1D4c8M6prF0QIrK3ec+5A4H4nA/GgR538FlOq+NviT4kdSVuNW/s+GT+8luu3j9K9dAwK8++Aujy6N8LdHF0pW8vVe/nz13zMX5+ilR+Feg0AYXiHwloXiKaOXW9NhvZI1KIZM/KDycc8Vz8vwh8CygBtAjGP7txMv8nrvaK66WPxVGKjTqySXZtfqZyo05O8op/Io6LpdroumQafp6yJaQDbEjytIVX03MScDtzwOKvUUVzSk5tyk7tlpJKyCiiipGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVTVtQtdI0q91LUJfJsrOF7ieTaW2RopZjgAk4APABNW65X4sf8ks8Zf8AYFvf/RD0AYH/AAu/wB/0GLr/AMFV5/8AGq0fD3xV8HeIdatdJ0nVJpb+6LCGN7C4iDlUZyNzxhR8qseT2r5p8MeGU1PRtV1m/vGtNN00xq5jhE0kju2FVVLKPqSR+NejTWNpp37UeiW2n2sFrbJI5WKCMIgzp8xOAOOtbzpRjszpnRjG9mfRFI3Q4paKwOY8T+Jlre/DvxtF8RdDtpJtJuQtt4htIlzuQcLOAO47n29Ca9PuodK8ZeEpIt8d5pGqWxAdCCro44Ye46+xFbF1BHc28kE8aSwyKUdHGVZTwQR3FeQf2Nr/AMJryWXwtZT674Jmcyy6UjbrnTyeWaDP3077Ov8AOgDyltH8S/D29nsLvQIp4lYxjUILCWdb+NiG3O0bAhsog2HAAz266Xg74U678RdQuNb8Vm+8N2awx20EESskk+A2WKSZKjDkfVjjjivfvB/jvw34uizoerQTTjh7Zz5c0Z7ho2wwxXTTzRQQtJPIkUaj5nc7QPqTQBz3gXwfo/gjQU0jQLcxW4Yu7ucvK54LMe54+nYYrh/isZPHHibTfh7p5Jtdyahrky9IrdTlIj/tOwHHoM+taXib4i/aruTQPh5HHrniNvlaSM7rSxB/5aTSDjjso5OK6D4eeEI/CWmTia6fUNYvZDcahqMo+e5lPf2UdAvQCgDqIUWONUjXaigKo9AOlPoooA5r4h3d7Z+G0bTLyWxuZtQsLT7REiM8aTXkMTlQ6sudrtjKmuP8a6k/hC70i21Pxn42lk1O7is4Wt9OsGjV5CQN0htQg6H5d27HIUiur+Jf/IuWf/Ya0n/0429Yfxh8LeIPFi+H4NCi0rydN1S31V5Ly8kiZ2i3fuwqxPwQ33s8f3TQBo6fHqukePtN0258Ralq1leaZeXDR3sVquySKW1VSphhjPSZ8gkjp6V2tchcmZviX4ZNykcc50PUTIkbl1VvOsMgMQCRnvgZ9BXX0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVi+N9Kn17wXr+kWbxJc6hp9xaRNKSEDyRsoLEAnGSM4BraooA+cNE+FPxK0WG7h0698MJBdqqzxSXEkqSBTkZV7YjIPQ4zW/wCFvh145HxS0nxX4svdEuPszyNM1tO5kcG3kiUBfJRf4x3HA717hRVupJ7mjqye4UHgUV4gut7fiv4igu9RtpZbfVIFtLO48V3NnKV+zwMEislBjmBYtgEgMxINQZntwOexoIzivCrP4vaxJYTXP2rw5eMdMivZIraGVf7Ld7iKJluT5rFvLWRmcbUPyHgDmpLn4r6tBpN5dJq/hW4gttWmsvt0MahZ4kt4ZA0MMl2nmHdKwO2UnAXCkmgDt/Gnwq8J+L7wXup6b5WpAg/bbOQwTH6lfvfiDWUvwQ8JzmL+2Jda1lY/uJqGpSyKB2GARxXReJtXmgt/CMseW+36lbxOT5sPytE7E7QwPb7r7h6gkA1gfDHxpr+v3eipro0to9W0T+1oxZW8kRgIkRShLSPvB8zOQFxjHPWgDufD2haZ4e05LDQ9PtrCzTkRQIFBPqfU+55rTA5rwPU9d1Xwv4g8Y+JI4NKuriTX00cXktmA9lb/AGWGQbpZLiNfKztGwtGC7Ft3ISt7RPiRqmo3GjQ6nqXhjQRc2on+0XLLcR3z/aJIvLt2juNgYLGjEB5CDKBg4JIB6/RXhWl/FvxFff2uWt9AtHt7aaXyb26t4Hs3SVUCyg3RdgQx5ZIRu2jOGyPTPht4hl8T+GE1GeeGeQzPGXhtxCh2nHy7ZplYf7SyMp7UAb2q6bY6vYS2Oq2VtfWUuPMt7mJZY3wQRlWBBwQD9QKwP+FceB/+hN8N/wDgrg/+JrqqKAMXRPCfhzQbt7rQ9A0jTbl0MbS2dlHC5QkEqWVQcZAOPYVtUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBztr4N0i2e9kj/ALSNxdxeTJcSandSTLHndtSRpC8Yyc4Qir+gaHp+gWcltpcUiJLK08ryzPNJLIcZZ5HLMxwAMkngAdq06KACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Eggs are passed in the stool of the definitive host (usually an herbivorous mammal)",
"    <strong>",
"     (1)",
"    </strong>",
"    , and under favorable conditions (moisture, warmth, shade), larvae hatch within several days. The released rhabditiform larvae grow in the soil or on vegetation",
"    <strong>",
"     (2)",
"    </strong>",
"    , and after 5 to 10 days (and two molts), they become filariform (third-stage) larvae that are infective",
"    <strong>",
"     (3)",
"    </strong>",
"    . Infection of the human host occurs upon ingestion of these filariform larvae",
"    <strong>",
"     (4)",
"    </strong>",
"    . The larvae reach the small intestine, where they reside and mature into adults. Adult worms inhabit the digestive tract of their definitive hosts and may occur as incidental infections in humans",
"    <strong>",
"     (5)",
"    </strong>",
"    .",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Trichostrongylosis. Available at:",
"     <a href=\"file://www.dpd.cdc.gov/dpdx/html/Frames/S-Z/Trichostrongylosis/body_Trichostrongylosis_page1.htm\" target=\"_blank\">",
"      file://www.dpd.cdc.gov/dpdx/html/Frames/S-Z/Trichostrongylosis/body_Trichostrongylosis_page1.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_1_15381=[""].join("\n");
var outline_f15_1_15381=null;
var title_f15_1_15382="Epi injection hemoclipping";
var content_f15_1_15382=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F82331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F82331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bleeding duodenal ulcer treated with combination hemoclipping and epinephrine injection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 437px; height: 580px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic view of an actively bleeding dudenal ulcer (left panels). The right panels show the bleeding has been arrested following treatment with epinephrine injection and placement of hemoclips.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dennis M Jensen, MD, and Gustavo A Machicado, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_1_15382=[""].join("\n");
var outline_f15_1_15382=null;
var title_f15_1_15383="Lurasidone: Drug information";
var content_f15_1_15383=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lurasidone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?16/30/16869?source=see_link\">",
"    see \"Lurasidone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F11407065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10946844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Latuda&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F15251999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Latuda&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F10946847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antipsychotic Agent, Atypical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F11407099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Schizophrenia:",
"     </b>",
"     Oral: Initial: 40 mg once daily; titration is not required; maximum recommended dose: 160 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Concomitant CYP3A4 inhibitors/inducers:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      CYP3A4 inhibitors:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Concomitant administration with a",
"     <b>",
"      strong",
"     </b>",
"     CYP3A4 inhibitor (eg, ketoconazole) is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Concomitant administration with a",
"     <b>",
"      moderate",
"     </b>",
"     CYP3A4 inhibitor (eg, diltiazem):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     U.S. labeling: Initial dose: 20 mg once daily; do not exceed 80 mg daily of lurasidone",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Canadian labeling: Do not exceed 40 mg daily of lurasidone",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      CYP3A4 inducers:",
"     </i>",
"     Concomitant administration with a",
"     <b>",
"      strong",
"     </b>",
"     CYP3A4 inducer (eg, rifampin) is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F11407100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F11407097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;50 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: Initial: 20 mg daily; maximum: 80 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;50 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: Maximum: 40 mg daily",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F11407096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Mild impairment (Child-Pugh class A): No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Moderate impairment (Child-Pugh class B): Initial: 20 mg daily; maximum: 80 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Severe impairment (Child-Pugh class C): Initial: 20 mg daily; maximum: 40 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Mild impairment (Child-Pugh class A): No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Moderate and severe impairment (Child-Pugh class B and C): Maximum: 40 mg daily",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F11412864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Latuda&reg;: 20 mg, 40 mg, 80 mg, 120 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F11407068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F11407101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with food (&ge;350 calories).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10946848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of schizophrenia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13210511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Latuda&reg; may be confused with Lantus&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F11407076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Somnolence (dose-related: 8% to 27%), akathisia (dose-related: 6% to 22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Fasting glucose increased (10% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Extrapyramidal symptoms (24% to 26%), parkinsonism (6% to 17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Insomnia (10%), agitation (5%), anxiety (5%), dizziness (4%), dystonia (&le;7%), restlessness (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Prolactin increased (&ge;5 x ULN: females: 8%; males: 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (10%), vomiting (8%), weight gain (&ge;7% increase in baseline body weight: 6%), dyspepsia (6%), salivary hypersecretion (2%), abdominal pain, appetite decreased, diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Back pain (3%), CPK increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Creatinine increased (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal dreams, amenorrhea, anemia, angina, angioedema, AV block, bradycardia, breast enlargement, breast pain, cerebrovascular accident, dysarthria, gastritis, dysphagia, dysmenorrhea, dysuria, erectile dysfunction, galactorrhea, hypertension, leukopenia, neuroleptic malignant syndrome, orthostatic hypotension, panic attack, renal failure, rhabdomyolysis, seizure, sleep disorder, suicidal behavior, syncope, tardive dyskinesia, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F11407072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to lurasidone or any component of the formulation; concomitant use with strong CYP3A4 inhibitors (eg, ketoconazole) and inducers (eg, rifampin)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F11407073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Altered cardiac conduction: Antipsychotics may alter cardiac conduction; life-threatening arrhythmias have occurred with therapeutic doses of antipsychotics. Relative to other antipsychotics, lurasidone has minimal effects on the QT",
"     <sub>",
"      c",
"     </sub>",
"     interval and therefore, risk for arrhythmias is low. However, Canadian labeling recommends avoiding use of lurasidone in patients with a history of cardiac arrhythmias, situations that may increase the risk of torsade de pointes and/or sudden death due to QT prolongation including bradycardia, congenital QT prolongation, electrolyte disturbances (ie, hypokalemia or hypomagnesemia), or in combination with other QT",
"     <sub>",
"      c",
"     </sub>",
"     -prolonging agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Blood dyscrasias: Leukopenia, neutropenia, and agranulocytosis (sometimes fatal) have been reported in clinical trials and postmarketing reports with antipsychotic use; presence of risk factors (eg, pre-existing low WBC or history of drug-induced leuko-/neutropenia) should prompt periodic blood count assessment. Discontinue therapy at first signs of blood dyscrasias or if absolute neutrophil count &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cerebrovascular effects: An increased incidence of cerebrovascular effects (eg, transient ischemic attack, stroke), including fatalities, has been reported in placebo-controlled trials of antipsychotics for the unapproved use in elderly patients with dementia-related psychosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Dyslipidemia: Increases in total cholesterol and triglyceride concentrations have been observed with atypical antipsychotic use; during clinical trials of lurasidone, there were no significant changes in total cholesterol or triglycerides observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Esophageal dysmotility/aspiration: Antipsychotic use has been associated with esophageal dysmotility and aspiration; use with caution in patients at risk of pneumonia (eg, Alzheimer's disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Extrapyramidal symptoms (EPS): May cause extrapyramidal symptoms, including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia (potentially irreversible). Risk of tardive dyskinesia may be increased in elderly patients, particularly elderly women. Risk of dystonia (and probably other EPS) may be greater with increased doses, use of conventional antipsychotics, males, and younger patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hyperglycemia: Atypical antipsychotics have been associated with development of hyperglycemia; in some cases, may be extreme and associated with ketoacidosis, hyperosmolar coma, or death. Use with caution in patients with diabetes or other disorders of glucose regulation; monitor for worsening of glucose control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hyperprolactinemia: Use is associated with increased prolactin levels; clinical significance of hyperprolactinemia in patients with breast cancer or other prolactin-dependent tumors is unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Neuroleptic malignant syndrome (NMS): Use may be associated with neuroleptic malignant syndrome; monitor for mental status changes, fever, muscle rigidity, and/or autonomic instability (risk may be increased in patients with Parkinson's disease or Lewy body dementia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension; use with caution in patients at risk of this effect (eg, concurrent medication use which may predispose to hypotension/bradycardia or presence of hypovolemia) or in those who would not tolerate transient hypotensive episodes. Use caution with history of cerebrovascular or cardiovascular disease (MI, heart failure, or ischemic disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Sedation: Low to moderately sedating, use with caution in disorders where CNS depression is a feature; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Suicidal ideation: The possibility of a suicide attempt is inherent in psychotic illness or bipolar disorder; use with caution in high-risk patients during initiation of therapy. Prescriptions should be written for the smallest quantity consistent with good patient care.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Temperature regulation: Impaired core body temperature regulation may occur; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Weight gain: Significant weight gain has been observed with antipsychotic therapy; incidence varies with product. Monitor waist circumference and BMI.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with severe cardiac disease, hemodynamic instability, prior myocardial infarction or ischemic heart disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Dementia:",
"     <b>",
"      [U.S. Boxed Warning]: Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to placebo.",
"     </b>",
"     Most deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature.",
"     <b>",
"      Lurasidone is not approved for the treatment of dementia-related psychosis.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic disease or impairment; dosage reduction is recommended in moderate-to-severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Parkinson's disease: Use with caution in patients with Parkinson's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution in patients with renal disease; dosage reduction is recommended in moderate-to-severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Seizures: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold. Elderly patients may be at increased risk of seizures due to an increased prevalence of predisposing factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; High potential for interactions: Concurrent use with strong inhibitors/inducers of CYP3A4 is contraindicated; dosage adjustment is recommended with concurrent use of moderate CYP3A4 inhibitors (eg, diltiazem).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Elderly: Use in patients with dementia is associated with an increased risk of mortality and cerebrovascular accidents; avoid antipsychotic use for behavioral problems associated with dementia unless alternative nonpharmacologic therapies have failed and patient may harm self or others. In addition, use may cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F11426684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F11429650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotics. Severe extrapyramidal symptoms have occurred in some patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antipsychotics may diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-Parkinson's Agents (Dopamine Agonist): Antipsychotics (Atypical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist).  Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson's disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Lurasidone. Management: U.S. labeling: start at 20 mg/day and limit to max of 80 mg/day with moderate CYP3A4 inhibitor.  Canadian labeling: limit to max of 40 mg/day with moderate CYP3A4 inhibitor; avoid concomitant use of grapefruit products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: Lurasidone may enhance the QTc-prolonging effect of Disopyramide.  Management: Consider alternatives to disopyramide in patients with acute lurasidone overdose.  If disopyramide treatment cannot be avoided, monitor for excessive QTc interval prolongation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOPamine: May enhance the hypotensive effect of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     EPINEPHrine (Systemic, Oral Inhalation): May enhance the hypotensive effect of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium formulations: May enhance the neurotoxic effect of Antipsychotics. Lithium formulations may decrease the serum concentration of Antipsychotics. Specifically noted with chlorpromazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antipsychotics may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Procainamide: Lurasidone may enhance the QTc-prolonging effect of Procainamide.  Management: Consider alternatives to procainamide in patients with acute lurasidone overdose.  If procainamide treatment cannot be avoided, monitor for excessive QTc interval prolongation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinagolide: Antipsychotics may diminish the therapeutic effect of Quinagolide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Lurasidone may enhance the QTc-prolonging effect of QuiNIDine.  Management: Consider alternatives to quinidine in patients with acute lurasidone overdose.  If quinidine treatment cannot be avoided, monitor for excessive QTc interval prolongation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: Antipsychotics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F11407080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Administration with food (&ge;350 calories) increased C",
"     <sub>",
"      max",
"     </sub>",
"     and AUC of lurasidone ~3 times and 2 times, respectively, compared to administration under fasting conditions. Lurasidone exposure was not affected by the fat content of the meal.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F11407069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11407070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No teratogenic or adverse developmental effects were observed in animal reproduction studies. Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization. Healthcare providers are encouraged to enroll women 18-45 years of age exposed to lurasidone during pregnancy in the Atypical Antipsychotics Pregnancy Registry (866-961-2388 or file://www.womensmentalhealth.org/pregnancyregistry).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F11407071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16328053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if lurasidone is excreted in breast milk. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F11407085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken with food (&ge;350 calories).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Latuda Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (30): $554.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (30): $603.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg (30): $603.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (30): $965.88",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F11407103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs; fasting lipid profile and fasting blood glucose/Hgb A",
"     <sub>",
"      1c",
"     </sub>",
"     (baseline and periodically); CBC frequently during first few months of therapy in patients with pre-existing low WBC or a history of drug-induced leukopenia/neutropenia; BMI, personal/family history of obesity, waist circumference; blood pressure; mental status, abnormal involuntary movement scale (AIMS), extrapyramidal symptoms; orthostatic blood pressure changes for 3-5 days after starting or increasing dose. Weight should be assessed prior to treatment and regularly throughout therapy. Consider titrating to a different antipsychotic agent for a weight gain &ge;5% of the initial weight.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F11407083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lurasidone is a benzoisothiazol-derivative atypical antipsychotic with mixed serotonin-dopamine antagonist activity. It exhibits high affinity for D",
"     <sub>",
"      2",
"     </sub>",
"     , 5-HT",
"     <sub>",
"      2A",
"     </sub>",
"     , and 5-HT",
"     <sub>",
"      7",
"     </sub>",
"     receptors; moderate affinity for alpha",
"     <sub>",
"      2C",
"     </sub>",
"     -adrenergic receptors; and is a partial agonist for 5-HT",
"     <sub>",
"      1A",
"     </sub>",
"     receptors. Lurasidone has no significant affinity for muscarinic M",
"     <sub>",
"      1",
"     </sub>",
"     and histamine H",
"     <sub>",
"      1",
"     </sub>",
"     receptors. The addition of serotonin antagonism to dopamine antagonism (classic neuroleptic mechanism) is thought to improve negative symptoms of psychoses and reduce the incidence of extrapyramidal side effects as compared to typical antipsychotics.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F11407086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 6173 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Primarily via CYP3A4; two active metabolites (ID-14283 and ID-14326) and two major nonactive metabolites (ID-20219 and ID-20220) produced",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: 9% to 19%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 18 hours; Main active metabolite, ID-14283 (exo-hydroxy metabolite), exhibits a half-life of 7.5-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: 1-3 hours; steady state concentrations achieved within 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (~9%); feces (~80%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/1/15383/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Challenges and Solutions in Developing New Medications for Schizophrenia,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 2010, 71(10):1391-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/1/15383/abstract-text/21062617/pubmed\" id=\"21062617\" target=\"_blank\">",
"        21062617",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Citrome  L, &ldquo;Lurasidone for Schizophrenia: A Brief Review of a New Second-Generation Antipsychotic,&rdquo;",
"      <i>",
"       Clin Schizophr Relat Psychose",
"      </i>",
"      s, 2011, 4(4):251-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/1/15383/abstract-text/21177242/pubmed\" id=\"21177242\" target=\"_blank\">",
"        21177242",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moore TA, &ldquo;Schizophrenia Treatment Guidelines in the United States,&rdquo;",
"      <i>",
"       Clin Schizophr Relat Psychoses",
"      </i>",
"      , 2011, 5(1):40-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/1/15383/abstract-text/21459738/pubmed\" id=\"21459738\" target=\"_blank\">",
"        21459738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16085 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-77.94.48.4-CE85A84A2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_1_15383=[""].join("\n");
var outline_f15_1_15383=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11407065\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10946844\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15251999\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10946847\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11407099\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11407100\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11407097\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11407096\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11412864\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11407068\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11407101\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10946848\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13210511\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11407076\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11407072\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11407073\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11426684\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11429650\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11407080\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11407069\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11407070\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11407071\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16328053\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11407085\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322872\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11407103\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11407083\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11407086\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16085\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16085|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/30/16869?source=related_link\">",
"      Lurasidone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_1_15384="Anal fissure: Medical and surgical management";
var content_f15_1_15384=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anal fissure: Medical and surgical management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/1/15384/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/1/15384/contributors\">",
"     Elizabeth Breen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/1/15384/contributors\">",
"     Ronald Bleday, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/1/15384/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/1/15384/contributors\">",
"     Martin Weiser, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/1/15384/contributors\">",
"     Lawrence S Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/1/15384/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/1/15384/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/1/15384/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H72480775\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An anal fissure is one of the most common benign anorectal conditions, which may result from high anal pressure. The goals of therapy are to break the cycle of sphincter spasm and tearing of the anal mucosa, and to promote healing of the fissure. Medical therapy is successful in the majority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], with surgery being reserved for refractory cases (",
"    <a class=\"graphic graphic_algorithm graphicRef82392 \" href=\"UTD.htm?14/23/14705\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This topic is also discussed in a guideline issued by the American Gastroenterological Association. The American Gastroenterological Association (AGA) guideline for the diagnosis and care of patients with anal fissure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/3\">",
"     3",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     file://www.gastro.org/practice/medical-position-statements",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, and prevention are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/24/34181?source=see_link\">",
"     \"Anal fissure: Clinical manifestations, diagnosis, prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72479757\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72479764\">",
"    <span class=\"h2\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical therapy has traditionally consisted of three components: relaxation of the internal sphincter, institution and maintenance of atraumatic passage of stool, and pain relief. In many cases, these goals can be accomplished with fiber therapy to keep the stools soft and formed, and warm sitz baths following bowel movements to relax the sphincter [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/4\">",
"     4",
"    </a>",
"    ]. Topical anesthetic creams to soothe the inflamed anoderm are often prescribed, but have not been shown to be more effective than fiber and sitz baths alone [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30616?source=see_link&amp;anchor=H30890946#H30890946\">",
"     \"Management of chronic constipation in adults\", section on 'Dietary changes and bulk forming laxatives'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72479771\">",
"    <span class=\"h3\">",
"     Topical and injection therapies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72479779\">",
"    <span class=\"h4\">",
"     Topical nitroglycerin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The observation that the posterior commissure of the internal anal sphincter is less perfused than the other sections led to the concept that ischemia could be contributing to the persistence of anal fissures [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    increases local blood flow and reduces pressure in the internal anal sphincter, which may further facilitate healing. It is applied as a 0.2 to 0.4 percent ointment and is typically given for eight weeks. In 2011, the US Food and Drug Administration approved a 0.4 percent nitroglycerin ointment (Rectiv, ProStrakan Group). Prior to that, the commercially available nitroglycerin ointments in the United States were 2 percent, a concentration that may not be well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/8\">",
"     8",
"    </a>",
"    ]. A 0.2 percent concentration can be custom-made by a pharmacist.",
"   </p>",
"   <p>",
"    Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    has been evaluated in multiple series and in controlled trials that have generally shown a beneficial effect compared with placebo, although discordant data have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/9-16\">",
"     9-16",
"    </a>",
"    ]. A meta-analysis of 75 randomized trials of medical therapy for anal fissures found that topical nitroglycerine was better than placebo in the healing of anal fissures (49 verus 36 percent), but that fissures recurred in 50 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major side effect of topical nitroglycerine is headache. In one study, it occurred 10 to 15 minutes after application and lasted no more than 30 minutes in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/18\">",
"     18",
"    </a>",
"    ]. Headaches occurred most commonly after two weeks of therapy, and decreased thereafter. As with other forms of nitrate therapy, patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    (Viagra) are at increased risk for hypotension. Nitrates should not be prescribed within 24 hours of taking this medication (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30282?source=see_link\">",
"     \"Treatment of male sexual dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?43/31/44529?source=see_link\">",
"     \"Patient information: Anal fissure (Beyond the Basics)\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72479786\">",
"    <span class=\"h4\">",
"     Topical diltiazem",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pilot study included 15 patients treated with topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    gel (2 percent; not commercially available in the United States) applied three times daily for eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/19\">",
"     19",
"    </a>",
"    ]. Healing was achieved in 10 of 15 patients (67 percent) without headache or other significant side effects.",
"   </p>",
"   <p>",
"    Similar results with topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    were observed in a separate study of 71 patients; healing was observed in 75 percent after two to three months of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/20\">",
"     20",
"    </a>",
"    ]. Twenty-seven of the 41 responding patients (66 percent) remained symptom free during a median of 32 weeks of follow-up. Six of seven patients with recurrent symptoms were successfully treated with a second course. No side effects were reported. In another report, topical diltiazem was associated with healing in 19 of 39 patients who had failed to heal with topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72479793\">",
"    <span class=\"h4\">",
"     Topical bethanechol",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pilot study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    also included 15 patients treated with topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/56/25476?source=see_link\">",
"     bethanechol",
"    </a>",
"    gel (0.1 percent; also not commercially available in the United States) applied three times daily for eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/19\">",
"     19",
"    </a>",
"    ]. Topical bethanechol was effective in healing anal fissures in 9 of 15 patients (60 percent), again without headache or other significant side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72479800\">",
"    <span class=\"h4\">",
"     Botulinum toxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Botulinum toxin is a potent inhibitor of the release of acetylcholine from nerve endings and has been used successfully for decades to treat certain spastic disorders of skeletal muscle such as blepharospasm and torticollis, and more recently, for achalasia. Injection of botulinum toxin into the anal sphincter can improve healing in patients with chronic anal fissure. It is typically given as injections around the anal canal (10 to 100 units total).",
"   </p>",
"   <p>",
"    In one study, 30 consecutive patients with chronic anal fissure were randomized to intrasphincteric",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"     botulinum toxin type A",
"    </a>",
"    or saline injection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/22\">",
"     22",
"    </a>",
"    ]. Injection was accomplished by palpation of the internal anal sphincter and administration of a total volume of 0.4 mL (in two equal doses for a total of 20 units of botulinum toxin) via a 27-gauge needle close to the fissure on each side. No sedation or local anesthesia was used. After two months, significantly more patients who had received botulinum toxin had healed (73 versus 13 percent). Four patients who had received botulinum toxin required a second injection (25 units), and all subsequently healed. No relapses occurred during an average follow-up of 16 months. One patient developed temporary flatus incontinence. Temporary fecal incontinence after therapy has been reported in other series [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As suggested in the above study [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/22\">",
"     22",
"    </a>",
"    ], repeated therapy with botulinum toxin may be beneficial for patients who relapse or do not respond to initial treatment. This was underscored in a series that included 50 patients, 20 of whom had relapsed following initial treatment, and 30 of whom had failed initial treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/24\">",
"     24",
"    </a>",
"    ]. The 20 patients who relapsed were retreated with the same dose as initial treatment (5 units), while the 30 in whom treatment had failed were retreated with a higher dose (10 units). Nineteen of the 20 patients (95 percent) treated with 5 units were pain-free within one week, and healing was observed in 70 percent by three months. In the group treated with 10 units, 22 of 30 (73 percent) became pain-free by one week, and 19 (63 percent) showed healing three months after injection. Transient mild incontinence was observed in two patients (7 percent). Initial treatment failures may have been due to a relatively low dose of botulinum toxin compared with other reports [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/22\">",
"     22",
"    </a>",
"    ]. However, pathologic causes of recurrent or unhealing fissures (such as inflammatory bowel disease) should be considered in these patients.",
"   </p>",
"   <p>",
"    The long-term outcome of patients treated with botulinum toxin has not been well described, but recurrence appears to be common. One report with the longest follow-up included 57 patients who had completely healed six months after injection and were followed for 42 months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/25\">",
"     25",
"    </a>",
"    ]. A recurrent fissure was observed in 22 patients (42 percent). Compared with patients who achieved long-term healing, those with recurrence were significantly more likely to have had anterior fissures (45 versus 6 percent), had a longer duration of disease, needed reinjection (59 versus 26 percent), required a higher total dose to achieve healing, and had not achieved as great a percentage decrease of maximum anal squeeze pressure after injection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72479807\">",
"    <span class=\"h4\">",
"     Topical nitroglycerin plus botulinum toxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A possible additive effect of topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    plus botulinum toxin injection was evaluated in a controlled trial involving 30 patients who did not respond to topical nitroglycerin [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/26\">",
"     26",
"    </a>",
"    ]. Patients were randomly assigned to botulinum toxin injection with or without topical nitroglycerin. The healing rate at six weeks was significantly higher in those who received combination therapy (66 versus 20 percent). No significant differences were seen at 8 and 12 weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72479814\">",
"    <span class=\"h3\">",
"     Oral therapies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72479821\">",
"    <span class=\"h4\">",
"     Oral nifedipine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability of the calcium channel blocker",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    to reduce resting internal anal sphincter pressure prompted its use for the treatment of patients with chronic anal fissures. In an open label trial, 15 patients were treated with a slow-release nifedipine (Adalat, Bayer pharmaceuticals, 20 mg twice daily) for eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/27\">",
"     27",
"    </a>",
"    ]. Treatment was associated with an initial reduction in maximum anal resting pressure and pain scores. Complete healing was observed in nine patients (60 percent) after eight weeks, while three additional patients were asymptomatic. Ten patients experienced flushing, one developed mild ankle edema, and four had mild headaches. This study has been criticized because of the short duration of follow-up, frequent side effects, relatively poor efficacy of nifedipine compared with other approaches, and lack of a control group [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72479828\">",
"    <span class=\"h4\">",
"     Oral diltiazem",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of topical versus oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    was evaluated in a controlled trial involving 50 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/29\">",
"     29",
"    </a>",
"    ]. Complete fissure healing by eight weeks was observed in nine patients (38 percent) receiving oral diltiazem compared with 15 patients (65 percent) receiving topical treatment. Side effects were more common in those receiving oral therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72479835\">",
"    <span class=\"h3\">",
"     Comparisons of therapies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72479842\">",
"    <span class=\"h4\">",
"     Topical nifedipine versus topical nitroglycerin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    was compared with topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    in a randomized controlled trial involving 52 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/30\">",
"     30",
"    </a>",
"    ]. The healing rate was higher with nifedipine (89 versus 58 percent) and treatment side effects were less frequent (5 versus 40 percent). Reductions in pain scores were significantly lower in both groups. Recurrence developed in a similar proportion of patients (42 and 31 percent, respectively) after a mean of 183 and 124 weeks, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72479849\">",
"    <span class=\"h4\">",
"     Topical nitroglycerin versus botulinum toxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least three randomized controlled trials have compared topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    with botulinum toxin A [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. Two of them were performed by the same group [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/31,33\">",
"     31,33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest trial (involving 100 patients) found significantly higher rates of healing at two months in patients randomized to botulinum toxin A (92 versus 70 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A similarly higher rate of healing with botulinum toxin A at two months (96 versus 60 percent) was observed in a second trial involving 50 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Side effects (mainly headache) were more frequent in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    group. However, mild (mainly transient) incontinence to flatus was observed more frequently in the botulinum toxin group. Patients with side effects (or an incomplete response) to one treatment often had success when crossed to the other.",
"   </p>",
"   <p>",
"    A meta-analysis also found that topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    and botulinum toxin had similar healing rates [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/17\">",
"     17",
"    </a>",
"    ]. A reasonable conclusion is that both treatments are acceptable options for first-line therapy; one or the other option can be used in patients who do not respond, or who are intolerant to treatment. Botulinum toxin appears to be somewhat more effective (at least with short-term follow-up) but has a higher frequency of mild incontinence. Because botulinum toxin is more invasive and is associated with a greater risk of mild incontinence, we generally reserve it for patients who have not responded to topical nitroglycerin (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/24/34181?source=see_link\">",
"     \"Anal fissure: Clinical manifestations, diagnosis, prevention\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72479856\">",
"    <span class=\"h4\">",
"     Topical diltiazem versus botulinum toxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    and botulinum toxin appear to be similarly effective. Short-term healing rates were better for patients treated with botulinum toxin injections compared with topical diltiazem, but healing rates at three months and pain reduction were found to be equivalent. In a randomized trial including 143 patients with anal fissures treated with botulinum toxin and a placebo cream or topical diltiazem and a placebo (saline) injection, there was no significant difference in healing (43 percent for both groups) or pain reduction (82 versus 78 percent) at three months follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72479863\">",
"    <span class=\"h2\">",
"     Surgical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery should be reserved for patients in whom anal fissures fail to heal despite adequate medical therapy. The goal of surgical therapy is to relax the internal anal sphincter, which is most often accomplished by a lateral internal sphincterotomy. This procedure involves division of the internal anal sphincter from its distal-most end for a distance equal to that of the fissure, or up to the dentate line. The sphincter can be divided in a closed or open fashion, depending upon the preference of the surgeon. The sphincterotomy heals best if it is performed in the right or left lateral position, and",
"    <strong>",
"     not",
"    </strong>",
"    in the posterior or anterior midline. The fissure itself does not require surgical therapy (eg, fissurectomy) unless it has an atypical appearance and a biopsy is warranted.",
"   </p>",
"   <p>",
"    Lateral sphincterotomy is successful in approximately 95 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/35-37\">",
"     35-37",
"    </a>",
"    ] and has a significantly higher healing rate than medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/17\">",
"     17",
"    </a>",
"    ]. In one series of 350 patients who underwent open or closed lateral internal anal sphincterotomy for acute or chronic anal fissure, only 21 patients (6 percent), failed to heal or developed a recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/36\">",
"     36",
"    </a>",
"    ]. Five of these patients were eventually diagnosed with Crohn's disease. Postoperative infections developed in eight patients (2 percent), four of which were associated with fistulas. Incontinence for flatus or stool, which was usually transient, developed in 17 percent. The results were similar for the open and closed methods.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72479870\">",
"    <span class=\"h3\">",
"     Lateral sphincterotomy versus topical nitroglycerin",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least two controlled trials have compared the efficacy of lateral sphincterotomy versus topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. One trial involved 65 patients who were randomly assigned to one or the other modality [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/38\">",
"     38",
"    </a>",
"    ]. Healing at eight weeks was observed significantly more often in those randomized to surgery (97 versus 61 percent). Twelve patients who received topical nitroglycerin eventually underwent lateral sphincterotomy. Poor tolerance and compliance were risk factors for failure to heal with topical nitroglycerin.",
"   </p>",
"   <p>",
"    A second study included 54 patients who were followed for up to two years after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/39\">",
"     39",
"    </a>",
"    ]. In the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    group, 18 patients (67 percent) healed by five weeks and 24 (89 percent) by ten weeks. Minor side effects were experienced by eight patients (30 percent). In the surgical group, 26 (96 percent) healed by five weeks and 100 percent by ten weeks. Minor fecal incontinence was experienced by 44 percent, which remained in 15 percent after 24 months follow-up. The percentage of patients healed at the five-week point was significantly higher in the surgical group. The author concluded that nitroglycerin should be considered as the first choice with surgery reserved for patients in whom treatment is unsuccessful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72479877\">",
"    <span class=\"h3\">",
"     Lateral sphincterotomy versus botulinum toxin injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least one controlled trial has directly compared lateral sphincterotomy with botulinum toxin injection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/40\">",
"     40",
"    </a>",
"    ]. The authors concluded that the proportion of patients with healing after botulinum toxin A injection was high overall (albeit lower than sphincterotomy at one year), but the rate of healing was slower than with lateral sphincterotomy. However, botulinum toxin injection was associated with fewer complications and faster recovery.",
"   </p>",
"   <p>",
"    The study included 111 patients with chronic anal fissures who were randomly assigned to treatment with botulinum toxin or to lateral sphincterotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/40\">",
"     40",
"    </a>",
"    ]. Patients were assessed at regular intervals for one year. Complete healing was observed in 64 percent of patients in the botulinum group at two months. Ten nonresponding patients underwent a second injection yielding an overall healing rate of 87 percent at six months. The healing rate was significantly higher by two months in the sphincterotomy group (98 versus 64 percent), but was similar to the botulinum group at six months (96 versus 87 percent). After one year, there were seven recurrences in the botulinum group resulting in an overall success rate of 75 percent; there were no recurrences after six months in the sphincterotomy group (two patients had recurrences prior to six months). Complication rates were significantly higher in the sphincterotomy group (including eight cases of fecal incontinence versus none in the botulinum group). Full return to normal activities was also more rapid in the botulinum group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72479884\">",
"    <span class=\"h3\">",
"     Lateral sphincterotomy versus oral nifedipine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A controlled trial randomly assigned 132 patients with a chronic anal fissure to a lateral sphincterotomy, a tailored sphincterotomy, or oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/41\">",
"     41",
"    </a>",
"    ]. The surgical approaches were associated with significantly better fissure healing rates at 16 weeks and less recurrence. Compliance with nifedipine was poor due to side effects and slow healing. There was no difference in continence between the three treatment groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72479891\">",
"    <span class=\"h3\">",
"     Risk of incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, a concern with surgery for anal fissures is the risk of fecal incontinence. Fecal incontinence can be characterized as either minor (defined as inadvertent escape of flatus or partial soiling of undergarments with liquid stool) or major (involuntary excretion of feces). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22458?source=see_link\">",
"     \"Fecal incontinence in adults\"",
"    </a>",
"    .) Most series of sphincterotomy for anal fissures have described only minor incontinence. The risk has varied among reports from as low as 0 to as high as 24 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/42\">",
"     42",
"    </a>",
"    ]. In most reports the risk has been less than 10 percent.",
"   </p>",
"   <p>",
"    However, it is possible that the rates reported in many studies may be underestimates, a point that was illustrated in a survey study involving 298 patients who underwent sphincterotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/43\">",
"     43",
"    </a>",
"    ]. Significantly more patients reported minor incontinence than was recorded in the medical record. Temporary incontinence was reported by 31 percent of patients while 30 percent described persistent incontinence to gas. No patients described major incontinence. Fecal incontinence was more likely in women who had two or more previous vaginal deliveries.",
"   </p>",
"   <p>",
"    Another survey study included 487 patients who had undergone lateral internal sphincterotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/37\">",
"     37",
"    </a>",
"    ]. Fissures had healed by a median of three weeks after surgery in 96 percent of patients and were recurrent in only 8 percent. Some degree of fecal incontinence was reported in 45 percent of patients at some time in the postoperative period and was more likely in women (53 versus 33 percent). Incontinence to flatus, mild soiling, and gross incontinence occurred in 31, 39, and 23 percent of patients respectively. However, by the time of the survey (an average of five years after the procedure), only six percent reported incontinence to flatus, while eight percent had minor fecal soiling, and one percent experienced loss of solid stool. Only three percent of patients reported that incontinence had ever affected their quality of life.",
"   </p>",
"   <p>",
"    Considered together, these data suggest that 30 to 45 percent of patients will experience minor incontinence following lateral sphincterotomy, which persists in 6 to 30 percent of patients after long-term follow-up. This can be compared to a background rate of fecal incontinence in the general population of approximately 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/44\">",
"     44",
"    </a>",
"    ]. The risk is increased in women, particularly those who have had previous vaginal deliveries. The minor incontinence generally does not have a major impact on quality of life. Major incontinence is rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72479898\">",
"    <span class=\"h2\">",
"     Dilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A Lord's or four finger dilatation in the operating room has been used for the treatment of anal fissures [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/45\">",
"     45",
"    </a>",
"    ]. Although this treatment can improve the spasm in the internal anal sphincter, it is associated with a high incidence of sphincter tears and fecal incontinence.",
"   </p>",
"   <p>",
"    Pneumatic balloon dilation has also been performed for treatment of chronic anal fissures [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15384/abstract/46\">",
"     46",
"    </a>",
"    ]. Experience is limited and it has not been compared directly with other approaches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72479905\">",
"    <span class=\"h2\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;An optimal strategy for the management of anal fissures has not been established. Our current approach based upon the published literature and clinical experience is illustrated in the following algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef82392 \" href=\"UTD.htm?14/23/14705\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/40/25218?source=see_link\">",
"       \"Patient information: Anal fissure (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/31/44529?source=see_link\">",
"       \"Patient information: Anal fissure (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72481570\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The goals of therapy are to break the cycle of sphincter spasm and tearing of the anal mucosa, and to promote healing of the fissure. An optimal strategy for the management of anal fissures has not been established. Our current approach based upon the published literature and clinical experience is illustrated in the following algorithm (",
"      <a class=\"graphic graphic_algorithm graphicRef82392 \" href=\"UTD.htm?14/23/14705\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H72480775\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Medical therapy is successful in many patients, with surgery being reserved for refractory cases. In many cases, these goals can be accomplished with fiber therapy to keep the stools soft and formed, and warm sitz baths following bowel movements to relax the sphincter. Options for patients who fail to respond to these measures include topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      and botulinum toxin injection. (See",
"      <a class=\"local\" href=\"#H72479764\">",
"       'Medical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      increases local blood flow and reduces pressure in the internal anal sphincter, which may further facilitate healing. It is applied as a 0.2 to 0.4 percent ointment. Trials have generally shown a beneficial effect of nitroglycerin compared with placebo. The most common side effect is headache. (See",
"      <a class=\"local\" href=\"#H72479779\">",
"       'Topical nitroglycerin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Botulinum toxin is a potent inhibitor of the release of acetylcholine from nerve endings. Injection of botulinum toxin into the anal sphincter can improve healing in patients with chronic anal fissure and repeated therapy with botulinum toxin may be beneficial for patients who relapse or do not respond to initial treatment. The long-term outcome of patients treated with botulinum toxin has not been well described, but recurrence appears to be common. (See",
"      <a class=\"local\" href=\"#H72479800\">",
"       'Botulinum toxin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Studies suggest that either topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      or botulinum toxin injection is a reasonable treatment for patients who require therapy beyond fiber and sitz baths. In addition, patients can be switched to the other treatment if they do not respond or are intolerant to the initial treatment. Botulinum toxin appears to be somewhat more effective (at least with short-term follow-up) but has a higher frequency of mild incontinence. Because botulinum toxin is more invasive and is associated with a greater risk of mild incontinence, we generally reserve it for patients who have not responded to topical nitroglycerin. (See",
"      <a class=\"local\" href=\"#H72479849\">",
"       'Topical nitroglycerin versus botulinum toxin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgery should be reserved for patients in whom anal fissures fail to heal despite adequate medical therapy. The goal of surgical therapy is to relax the internal anal sphincter, which is most often accomplished by a lateral internal sphincterotomy. Lateral sphincterotomy is successful in approximately 95 percent of patients. However, 30 to 45 percent of patients will experience minor incontinence following lateral sphincterotomy, which persists in 6 to 30 percent of patients after long-term follow-up. The risk is increased in women, particularly those who have had previous vaginal deliveries. The minor incontinence generally does not have a major impact on quality of life, and major incontinence is rare. (See",
"      <a class=\"local\" href=\"#H72479863\">",
"       'Surgical therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/1\">",
"      Shub HA, Salvati EP, Rubin RJ. Conservative treatment of anal fissure: an unselected, retrospective and continuous study. Dis Colon Rectum 1978; 21:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/2\">",
"      Jensen SL. Maintenance therapy with unprocessed bran in the prevention of acute anal fissure recurrence. J R Soc Med 1987; 80:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/3\">",
"      Americal Gastroenterological Association. American Gastroenterological Association medical position statement: Diagnosis and care of patients with anal fissure. Gastroenterology 2003; 124:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/4\">",
"      Dodi G, Bogoni F, Infantino A, et al. Hot or cold in anal pain? A study of the changes in internal anal sphincter pressure profiles. Dis Colon Rectum 1986; 29:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/5\">",
"      Jensen SL. Treatment of first episodes of acute anal fissure: prospective randomised study of lignocaine ointment versus hydrocortisone ointment or warm sitz baths plus bran. Br Med J (Clin Res Ed) 1986; 292:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/6\">",
"      Schouten WR, Briel JW, Auwerda JJ. Relationship between anal pressure and anodermal blood flow. The vascular pathogenesis of anal fissures. Dis Colon Rectum 1994; 37:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/7\">",
"      Klosterhalfen B, Vogel P, Rixen H, Mittermayer C. Topography of the inferior rectal artery: a possible cause of chronic, primary anal fissure. Dis Colon Rectum 1989; 32:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/8\">",
"      Lund JN, Armitage NC, Scholefield JH. Use of glyceryl trinitrate ointment in the treatment of anal fissure. Br J Surg 1996; 83:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/9\">",
"      Gorfine SR. Topical nitroglycerin therapy for anal fissures and ulcers. N Engl J Med 1995; 333:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/10\">",
"      Lund JN, Scholefield JH. A randomised, prospective, double-blind, placebo-controlled trial of glyceryl trinitrate ointment in treatment of anal fissure. Lancet 1997; 349:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/11\">",
"      Oettl&eacute; GJ. Glyceryl trinitrate vs. sphincterotomy for treatment of chronic fissure-in-ano: a randomized, controlled trial. Dis Colon Rectum 1997; 40:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/12\">",
"      Bacher H, Mischinger HJ, Werkgartner G, et al. Local nitroglycerin for treatment of anal fissures: an alternative to lateral sphincterotomy? Dis Colon Rectum 1997; 40:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/13\">",
"      Altomare DF, Rinaldi M, Milito G, et al. Glyceryl trinitrate for chronic anal fissure--healing or headache? Results of a multicenter, randomized, placebo-controled, double-blind trial. Dis Colon Rectum 2000; 43:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/14\">",
"      Richard CS, Gregoire R, Plewes EA, et al. Internal sphincterotomy is superior to topical nitroglycerin in the treatment of chronic anal fissure: results of a randomized, controlled trial by the Canadian Colorectal Surgical Trials Group. Dis Colon Rectum 2000; 43:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/15\">",
"      Zuberi BF, Rajput MR, Abro H, Shaikh SA. A randomized trial of glyceryl trinitrate ointment and nitroglycerin patch in healing of anal fissures. Int J Colorectal Dis 2000; 15:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/16\">",
"      Kennedy ML, Sowter S, Nguyen H, Lubowski DZ. Glyceryl trinitrate ointment for the treatment of chronic anal fissure: results of a placebo-controlled trial and long-term follow-up. Dis Colon Rectum 1999; 42:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/17\">",
"      Nelson RL, Thomas K, Morgan J, Jones A. Non surgical therapy for anal fissure. Cochrane Database Syst Rev 2012; 2:CD003431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/18\">",
"      Lund JN, Scholefield JH. Glyceryl trinitrate ointment for chronic anal fissure (letter). Lancet 1997; 349:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/19\">",
"      Carapeti EA, Kamm MA, Phillips RK. Topical diltiazem and bethanechol decrease anal sphincter pressure and heal anal fissures without side effects. Dis Colon Rectum 2000; 43:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/20\">",
"      Knight JS, Birks M, Farouk R. Topical diltiazem ointment in the treatment of chronic anal fissure. Br J Surg 2001; 88:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/21\">",
"      Jonas M, Speake W, Scholefield JH. Diltiazem heals glyceryl trinitrate-resistant chronic anal fissures: a prospective study. Dis Colon Rectum 2002; 45:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/22\">",
"      Maria G, Cassetta E, Gui D, et al. A comparison of botulinum toxin and saline for the treatment of chronic anal fissure. N Engl J Med 1998; 338:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/23\">",
"      Jost WH. One hundred cases of anal fissure treated with botulin toxin: early and long-term results. Dis Colon Rectum 1997; 40:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/24\">",
"      Jost WH, Schrank B. Repeat botulin toxin injections in anal fissure: in patients with relapse and after insufficient effect of first treatment. Dig Dis Sci 1999; 44:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/25\">",
"      Minguez M, Herreros B, Espi A, et al. Long-term follow-up (42 months) of chronic anal fissure after healing with botulinum toxin. Gastroenterology 2002; 123:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/26\">",
"      Lysy J, Israelit-Yatzkan Y, Sestiery-Ittah M, et al. Topical nitrates potentiate the effect of botulinum toxin in the treatment of patients with refractory anal fissure. Gut 2001; 48:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/27\">",
"      Cook TA, Humphreys MM, McC Mortensen NJ. Oral nifedipine reduces resting anal pressure and heals chronic anal fissure. Br J Surg 1999; 86:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/28\">",
"      Beattie G, Siriwardena A. Bacterial infection and extent of necrosis are determinants of organ failure in patients with acute necrotizing pancreatitis. Br J Surg 2000; 87:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/29\">",
"      Jonas M, Neal KR, Abercrombie JF, Scholefield JH. A randomized trial of oral vs. topical diltiazem for chronic anal fissures. Dis Colon Rectum 2001; 44:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/30\">",
"      Ezri T, Susmallian S. Topical nifedipine vs. topical glyceryl trinitrate for treatment of chronic anal fissure. Dis Colon Rectum 2003; 46:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/31\">",
"      Brisinda G, Maria G, Bentivoglio AR, et al. A comparison of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure. N Engl J Med 1999; 341:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/32\">",
"      De Nardi P, Ortolano E, Radaelli G, Staudacher C. Comparison of glycerine trinitrate and botulinum toxin-a for the treatment of chronic anal fissure: long-term results. Dis Colon Rectum 2006; 49:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/33\">",
"      Brisinda G, Cadeddu F, Brandara F, et al. Randomized clinical trial comparing botulinum toxin injections with 0.2 per cent nitroglycerin ointment for chronic anal fissure. Br J Surg 2007; 94:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/34\">",
"      Samim M, Twigt B, Stoker L, Pronk A. Topical diltiazem cream versus botulinum toxin a for the treatment of chronic anal fissure: a double-blind randomized clinical trial. Ann Surg 2012; 255:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/35\">",
"      Hyman N. Incontinence after lateral internal sphincterotomy: a prospective study and quality of life assessment. Dis Colon Rectum 2004; 47:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/36\">",
"      Lewis TH, Corman ML, Prager ED, Robertson WG. Long-term results of open and closed sphincterotomy for anal fissure. Dis Colon Rectum 1988; 31:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/37\">",
"      Nyam DC, Pemberton JH. Long-term results of lateral internal sphincterotomy for chronic anal fissure with particular reference to incidence of fecal incontinence. Dis Colon Rectum 1999; 42:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/38\">",
"      Evans J, Luck A, Hewett P. Glyceryl trinitrate vs. lateral sphincterotomy for chronic anal fissure: prospective, randomized trial. Dis Colon Rectum 2001; 44:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/39\">",
"      Parellada C. Randomized, prospective trial comparing 0.2 percent isosorbide dinitrate ointment with sphincterotomy in treatment of chronic anal fissure: a two-year follow-up. Dis Colon Rectum 2004; 47:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/40\">",
"      Mente BB, Irk&ouml;r&uuml;c&uuml; O, Akin M, et al. Comparison of botulinum toxin injection and lateral internal sphincterotomy for the treatment of chronic anal fissure. Dis Colon Rectum 2003; 46:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/41\">",
"      Ho KS, Ho YH. Randomized clinical trial comparing oral nifedipine with lateral anal sphincterotomy and tailored sphincterotomy in the treatment of chronic anal fissure. Br J Surg 2005; 92:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/42\">",
"      Nelson R. Operative procedures for fissure in ano. Cochrane Database Syst Rev 2005; :CD002199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/43\">",
"      Casillas S, Hull TL, Zutshi M, et al. Incontinence after a lateral internal sphincterotomy: are we underestimating it? Dis Colon Rectum 2005; 48:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/44\">",
"      Nelson R, Norton N, Cautley E, Furner S. Community-based prevalence of anal incontinence. JAMA 1995; 274:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/45\">",
"      WATTS JM, BENNETT RC, GOLIGHER JC. STRETCHING OF ANAL SPHINCTERS IN TREATMENT OF FISSURE-IN-ANO. Br Med J 1964; 2:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15384/abstract/46\">",
"      Renzi A, Brusciano L, Pescatori M, et al. Pneumatic balloon dilatation for chronic anal fissure: a prospective, clinical, endosonographic, and manometric study. Dis Colon Rectum 2005; 48:121.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83135 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-189.41.172.26-97BC8CC2DC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_1_15384=[""].join("\n");
var outline_f15_1_15384=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H72481570\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H72480775\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H72479757\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H72479764\">",
"      Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H72479771\">",
"      - Topical and injection therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H72479779\">",
"      Topical nitroglycerin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H72479786\">",
"      Topical diltiazem",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H72479793\">",
"      Topical bethanechol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H72479800\">",
"      Botulinum toxin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H72479807\">",
"      Topical nitroglycerin plus botulinum toxin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H72479814\">",
"      - Oral therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H72479821\">",
"      Oral nifedipine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H72479828\">",
"      Oral diltiazem",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H72479835\">",
"      - Comparisons of therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H72479842\">",
"      Topical nifedipine versus topical nitroglycerin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H72479849\">",
"      Topical nitroglycerin versus botulinum toxin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H72479856\">",
"      Topical diltiazem versus botulinum toxin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H72479863\">",
"      Surgical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H72479870\">",
"      - Lateral sphincterotomy versus topical nitroglycerin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H72479877\">",
"      - Lateral sphincterotomy versus botulinum toxin injection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H72479884\">",
"      - Lateral sphincterotomy versus oral nifedipine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H72479891\">",
"      - Risk of incontinence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H72479898\">",
"      Dilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H72479905\">",
"      Recommendation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H72481570\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/83135\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/83135|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?14/23/14705\" title=\"algorithm 1\">",
"      Rx anal fissures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/24/34181?source=related_link\">",
"      Anal fissure: Clinical manifestations, diagnosis, prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22458?source=related_link\">",
"      Fecal incontinence in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30616?source=related_link\">",
"      Management of chronic constipation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/31/44529?source=related_link\">",
"      Patient information: Anal fissure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/40/25218?source=related_link\">",
"      Patient information: Anal fissure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30282?source=related_link\">",
"      Treatment of male sexual dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_1_15385="Initial treatment of mildly active rheumatoid arthritis in adults";
var content_f15_1_15385=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial treatment of mildly active rheumatoid arthritis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/1/15385/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/1/15385/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/1/15385/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/1/15385/contributors\">",
"     Stanley Cohen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/1/15385/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/1/15385/contributors\">",
"     James R O'Dell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/1/15385/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/1/15385/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/1/15385/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of rheumatoid arthritis (RA) is directed toward the control of synovitis and the prevention of joint damage. Joint damage, which may ultimately result in disability, begins early in the course of disease, and patients are less likely to completely respond to therapy the longer that active disease persists [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15385/abstract/1\">",
"     1",
"    </a>",
"    ]. Improved outcomes have resulted from the availability and use of potent and well-tolerated disease-modifying antirheumatic drugs (DMARDs) used alone and in combination to aggressively induce and maintain tight control of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15385/abstract/2-10\">",
"     2-10",
"    </a>",
"    ]. These DMARDs can control synovitis and slow, or even stop, radiographic progression [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15385/abstract/2,9,11,12\">",
"     2,9,11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link\">",
"     \"Clinical features of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41210?source=see_link\">",
"     \"Pathogenesis of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link&amp;anchor=H6422708#H6422708\">",
"     \"General principles of management of rheumatoid arthritis in adults\", section on 'Tight control'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These observations regarding the course of disease and the efficacy of current therapeutic approaches, coupled with limits in the ability to accurately identify individuals with a poor prognosis, support our view that every patient with established active RA should be treated with DMARDs at the earliest stage of disease, ideally within less than three months of symptom onset. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link&amp;anchor=H344394776#H344394776\">",
"     \"General principles of management of rheumatoid arthritis in adults\", section on 'Prognosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link&amp;anchor=H111269724#H111269724\">",
"     \"General principles of management of rheumatoid arthritis in adults\", section on 'Early use of DMARDs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The choice of therapeutic agents, including both antiinflammatories and DMARDs, is influenced by the degree of disease activity, the risk of a particular medication for a given patient, and patient preferences. The initial treatment of patients with mildly active RA will be reviewed here. The diagnosis and differential diagnosis of RA, the general principles of management, an overview of the therapy of RA, the initial treatment of moderately to severely active RA, and the treatment of disease resistant to initial therapy are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=see_link\">",
"     \"Diagnosis and differential diagnosis of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/3/31802?source=see_link\">",
"     \"Initial treatment of moderately to severely active rheumatoid arthritis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/6/42090?source=see_link\">",
"     \"Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7782239\">",
"    <span class=\"h1\">",
"     DEFINITION OF MILDLY ACTIVE RA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with mildly active rheumatoid arthritis (RA) typically meet",
"    <span class=\"nowrap\">",
"     ACR/EULAR",
"    </span>",
"    criteria for RA and have all of the following (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=see_link\">",
"     \"Diagnosis and differential diagnosis of rheumatoid arthritis\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fewer than five inflamed joints",
"     </li>",
"     <li>",
"      Mildly elevated or normal erythrocyte sedimentation rate and C-reactive protein levels",
"     </li>",
"     <li>",
"      No extraarticular disease",
"     </li>",
"     <li>",
"      No evidence of erosions or cartilage loss on plain radiographs of the hands, wrists, and feet",
"     </li>",
"     <li>",
"      Low levels of measures of disease activity such as the DAS28, CDAI, SDAI, or RAPID (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/33/7706?source=see_link\">",
"       \"Assessment of rheumatoid arthritis activity in clinical trials and clinical practice\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most of these patients will lack poor prognostic features such as rheumatoid factor or antibodies to cyclic citrullinated peptides.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H208723354\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several general principles important in the management of all patients with RA. These principles are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    .) Briefly, these include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Achievement and maintenance of tight control of disease activity, defined as remission or a state of minimal disease activity, without compromising safety",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Frequent monitoring of activity by assessing history, the physical examination, acute phase reactants, and use of measures of disease activity (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/33/7706?source=see_link\">",
"       \"Assessment of rheumatoid arthritis activity in clinical trials and clinical practice\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The prompt use of more aggressive DMARD therapy (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      in patients being treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      ) in patients with failure to induce either remission or minimal disease activity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of all patients diagnosed with RA with disease-modifying antirheumatic drug (DMARD) therapy",
"     </li>",
"     <li>",
"      Use of antiinflammatory therapies, including nonsteroidal antiinflammatory drugs and glucocorticoids, to help control symptoms until DMARDs take effect",
"     </li>",
"     <li>",
"      Evaluation and ongoing care by a rheumatologist",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H208723766\">",
"    <span class=\"h1\">",
"     NONPHARMACOLOGIC AND PREVENTIVE THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of nonpharmacologic measures and other medical interventions are important in the comprehensive management of RA, in addition to antiinflammatory and antirheumatic drug therapies. These interventions, including patient education, vaccinations, cardiovascular risk reduction, and others, are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13591?source=see_link\">",
"     \"Nonpharmacologic and preventive therapies of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;We use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    as the initial disease-modifying antirheumatic drug (DMARD) in most patients with mildly active RA, particularly those with minimal or low levels of disease activity and those who are seronegative for rheumatoid factor and anti-CCP antibodies. Additionally, we use nonsteroidal antiinflammatory drugs (NSAIDs) or glucocorticoids in many patients on a temporary basis to quickly achieve control of signs and symptoms of disease, in addition to starting the DMARD. We then taper and withdraw the antiinflammatory medications once the DMARDs have taken effect. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Use of DMARDs'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H20660736\">",
"     'Antiinflammatory agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If patients have greater disease activity, or if an adequate trial (12 to 24 weeks) of these medications proves inadequate, we then initiate therapy with another DMARD, usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , or a combination of DMARDs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/3/31802?source=see_link\">",
"     \"Initial treatment of moderately to severely active rheumatoid arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our approach is generally consistent with other major recommendations or guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15385/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. An alternative approach favored by some experts is the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    as the initial DMARD in all patients, unless there are contraindications to its use [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15385/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Use of DMARDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the initial treatment of patients with mildly active RA, particularly those with minimal or low levels of disease activity and especially those who are seronegative, we favor DMARD therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    (HCQ)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    (SSZ). We prefer HCQ in patients with relatively less severe disease because this agent is very well-tolerated, is effective, and has a very low risk of significant toxicity. SSZ is used, either by itself or combined with HCQ, in those with relatively more severe disease or adverse prognostic features since it is more effective than monotherapy with HCQ but may be less well-tolerated. Efficacy pf treatment of rheumatoid arthritis with hydroxychloroquine, as well as sulfasalazine as monotherapy and in combination, is supported by results of randomized clinical trials. (See",
"    <a class=\"local\" href=\"#H20660556\">",
"     'Patients who lack poor prognostic features'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H10\">",
"     'Patients with mild activity and poor prognostic signs'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Alternatively, some rheumatologists favor the use of MTX in this patient subset because of its proven efficacy , long term durability, and proven effectiveness as co-therapy with added synthetic and biologic DMARDs. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Patients with mild activity and poor prognostic signs'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link&amp;anchor=H344394776#H344394776\">",
"     \"General principles of management of rheumatoid arthritis in adults\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of HCQ",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    SSZ in patients with mildly active RA is consistent with the 2008 American College of Rheumatology recommendations on the use of DMARDs in RA [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15385/abstract/13\">",
"     13",
"    </a>",
"    ]. The recommendations of the European League Against Rheumatism (EULAR) also note that patients with low disease activity may not require",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , which they otherwise suggest as the initial DMARD [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15385/abstract/14\">",
"     14",
"    </a>",
"    ]. The EULAR recommendations favor limiting the use of HCQ monotherapy to patients with very mild disease and contraindications to other DMARDs. Our approach is described below for each of the agents used in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20660556\">",
"    <span class=\"h3\">",
"     Patients who lack poor prognostic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    (HCQ), be used as the initial DMARD for patients who have mildly active RA and lack poor prognostic features, such as functional limitation, extraarticular disease manifestations, positive rheumatoid factor or anti-cyclic citrullinated peptide antibodies, or bony erosions on radiographs [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15385/abstract/17\">",
"     17",
"    </a>",
"    ]. Such patients have fewer joints involved, as well as less swelling and tenderness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/9/43161?source=see_link\">",
"     \"Antimalarial drugs in the treatment of rheumatic disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link&amp;anchor=H344394776#H344394776\">",
"     \"General principles of management of rheumatoid arthritis in adults\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We also use HCQ in patients with findings limited to mild inflammatory arthritis and a positive antinuclear antibody test, in whom a distinction cannot be made between early RA, undifferentiated immune-inflammatory disease, and early systemic lupus erythematosus. We use HCQ as the initial DMARD because of its very low level of toxicity, although HCQ may be less effective than MTX, SSZ, and other DMARDS. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Patients with mild activity and poor prognostic signs'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Additional benefits of HCQ in patients with RA are the reduced risk of diabetes mellitus associated with use of the drug and its favorable effects on lipids [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15385/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. We use HCQ at doses of 200 to 400",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    up to 6.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (based upon ideal body weight); other antimalarial drugs may also be of benefit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/9/43161?source=see_link&amp;anchor=H17#H17\">",
"     \"Antimalarial drugs in the treatment of rheumatic disease\", section on 'Ocular health'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HCQ has been compared with placebo in randomized trials in patients with active RA, where it exhibits moderate efficacy in RA compared with placebo and is very well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15385/abstract/17,20-22\">",
"     17,20-22",
"    </a>",
"    ]. A 2000 systematic review and meta-analysis of four trials, which involved 592 patients randomized to receive either HCQ or placebo, showed significant benefit from HCQ compared with placebo; various outcome measures including joint counts, pain, and global assessments were assessed (standardized mean differences from placebo ranging from -0.33 to -0.52) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15385/abstract/23\">",
"     23",
"    </a>",
"    ]. There were no differences between groups in withdrawals for toxicity, but withdrawals for lack of efficacy were significantly less frequent in the HCQ group. In one study, as an example, withdrawals for lack of efficacy at six months were significantly fewer with HCQ compared with placebo (16 versus 34 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15385/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiographic deterioration was comparable at 12 months in patients randomized to either HCQ or placebo in the one study that examined this question [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15385/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HCQ is extremely well-tolerated. The adverse effects of HCQ and recommendations for drug monitoring, including baseline and follow-up ophthalmologic evaluation, are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/9/43161?source=see_link&amp;anchor=H7#H7\">",
"     \"Antimalarial drugs in the treatment of rheumatic disease\", section on 'Adverse effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/9/43161?source=see_link&amp;anchor=H16#H16\">",
"     \"Antimalarial drugs in the treatment of rheumatic disease\", section on 'Monitoring for toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The administration of HCQ commonly results in clinical improvement within two to three months, but maximum effects may require up to four to six months of therapy. In patients who do not respond adequately to HCQ within three months, we add an alternative DMARD, usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX), or combine HCQ with other DMARDs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    and MTX. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/3/31802?source=see_link&amp;anchor=H3981583#H3981583\">",
"     \"Initial treatment of moderately to severely active rheumatoid arthritis in adults\", section on 'Initial therapy with methotrexate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Patients with mild activity and poor prognostic signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some of us suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    (SSZ) (gradually titrated up to a dose of 1000 mg two or three times daily) rather than HCQ in patients with mild disease activity but relatively more symptoms and signs of active synovitis or poor prognostic features, such as functional limitation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15385/abstract/24\">",
"     24",
"    </a>",
"    ]. Some rheumatologists and one of the authors prefer to limit SSZ use to patients lacking poor prognostic features and use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    in those patients who have poor prognostic signs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link&amp;anchor=H2541292#H2541292\">",
"     \"General principles of management of rheumatoid arthritis in adults\", section on 'Other considerations in RA management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/3/31802?source=see_link&amp;anchor=H3981583#H3981583\">",
"     \"Initial treatment of moderately to severely active rheumatoid arthritis in adults\", section on 'Initial therapy with methotrexate'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link&amp;anchor=H344394776#H344394776\">",
"     \"General principles of management of rheumatoid arthritis in adults\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relative efficacy of SSZ compared with HCQ was assessed in a randomized controlled trial of 60 patients in which the median number of erosions at 48 weeks was significantly lower with SSZ (5 versus 16) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15385/abstract/25\">",
"     25",
"    </a>",
"    ]. Although SSZ works more quickly than HCQ and has greater clinical efficacy, it is not as well tolerated as HCQ [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15385/abstract/25\">",
"     25",
"    </a>",
"    ]. SSZ may be used as monotherapy but is most commonly used in the United States together with other DMARDs, typically in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and HCQ.",
"   </p>",
"   <p>",
"    In a meta-analysis of eight randomized trials, which included 552 subjects who received SSZ and 351 who received placebo, active therapy was significantly more effective than placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15385/abstract/26\">",
"     26",
"    </a>",
"    ]. SSZ, compared with placebo, significantly reduced the duration of morning stiffness (61 versus 33 percent), the number of painful joints (59 versus 33 percent), the number of swollen joints (51 versus 26 percent), and the amount of joint pain (42 versus 15 percent). Whether SSZ alone can retard the rate or prevent the development of erosive disease is less well-established than its clinical benefit. Studies from two major centers found a reduction in the development of new erosions in the first three years of disease in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15385/abstract/25,27,28\">",
"     25,27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional studies indicate that SSZ is of comparable efficacy to parenteral gold and of greater efficacy than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    . In studies using lower doses of MTX than are generally currently employed, SSZ was comparable to both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    . The supportive data regarding its efficacy and safety and a more detailed discussion of the use of SSZ in RA are presented in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/27/2490?source=see_link\">",
"     \"Sulfasalazine in the treatment of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Side effects of SSZ may limit its use in some patients. The adverse reactions described for SSZ are either idiosyncratic (eg, hypersensitivity or immune-related), such as skin reactions or hepatitis, or dose-related, such as gastrointestinal upset, headache, leukopenia, or anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15385/abstract/29\">",
"     29",
"    </a>",
"    ]. The idiosyncratic reactions require permanent drug discontinuation, while the dose-related effects may be managed by dose reduction. Approximately 20 to 25 percent of patients withdraw from clinical trials because of intolerable side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15385/abstract/30\">",
"     30",
"    </a>",
"    ]. Two-thirds of such withdrawals result from symptoms due to gastrointestinal and central nervous system toxicity, and approximately 4 to 5 percent because of rash [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15385/abstract/30\">",
"     30",
"    </a>",
"    ]. A complete blood count, serum hepatic aminotransferases, blood urea nitrogen, and creatinine should be obtained every two to four weeks during the first three months of therapy with SSZ. Once safety and tolerability have been established in the initial three months, laboratory testing should be obtained every 8 to 12 weeks; testing after six months of therapy should be performed every 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15385/abstract/13,24\">",
"     13,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/27/2490?source=see_link&amp;anchor=H4#H4\">",
"     \"Sulfasalazine in the treatment of rheumatoid arthritis\", section on 'Adverse effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients who do not respond adequately to SSZ within three months, we use MTX or a comparably effective alternative, or we combine SSZ with other DMARDs, such as HCQ and MTX. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/3/31802?source=see_link\">",
"     \"Initial treatment of moderately to severely active rheumatoid arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3978675\">",
"    <span class=\"h3\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;We generally do not use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    for the treatment of RA in patients able to take other established DMARDs, although it has been used in the past for some patients with mild RA. Minocycline exhibits modest benefit compared with placebo in trials involving patients with longstanding active RA, but greater benefit in rheumatoid factor (RF) positive patients with RA for less than a year [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15385/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. It was superior to HCQ in another study of RF-positive patients with early disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15385/abstract/35\">",
"     35",
"    </a>",
"    ]. However, minocycline has not been directly compared with SSZ, MTX, or other major DMARDs currently in common use, and there are limited data to demonstrate that minocycline prevents the development of bone erosions or otherwise reduces joint injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3978786\">",
"    <span class=\"h3\">",
"     Patients resistant to initial DMARD therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The more potent nonbiologic DMARDs, such as MTX and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    , and the biologic DMARDs, such as the tumor necrosis factor inhibitors, are preferred in patients who do not respond adequately, have more active disease, or have poor prognostic markers compared with the patients described above. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/6/42090?source=see_link\">",
"     \"Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20661238\">",
"    <span class=\"h2\">",
"     Symptomatic treatment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20660736\">",
"    <span class=\"h3\">",
"     Antiinflammatory agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;We include a nonsteroidal antiinflammatory drug (NSAID) at full therapeutic dose (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    500 mg twice daily) in the initial treatment of many patients with mildly active RA, unless contraindicated by gastrointestinal (eg, peptic ulcer, gastroesophageal reflux), renal (eg, renal insufficiency), or cardiovascular (eg, uncontrolled hypertension, heart failure) disease. NSAIDs do not prevent the development of erosive disease in patients with continued disease activity, although they can provide clinically important symptomatic relief of pain, stiffness, and swelling. In the occasional patient with mildly active RA in whom NSAIDs are insufficient, we use glucocorticoids as bridging therapy until adequate responses to DMARDs occur. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Use of DMARDs'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20660778\">",
"    <span class=\"h4\">",
"     Initial symptomatic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative efficacy and toxicity of the different NSAIDs vary for individuals. The choice of the initial agent, therefore, depends upon the patient&rsquo;s history of prior prescription or over-the-counter NSAID use, including the dose taken, and",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    tolerance of and previous response to such medications. We titrate the dose of the NSAID to the optimum tolerated level and treat for at least two weeks before making a decision to switch to another NSAID for lack of efficacy, because maximal analgesic and antiinflammatory effects are usually achieved within 10 to 14 days. The use of NSAIDS, especially in older adults, may require simultaneous gastroprotection (eg, with proton pump inhibitors). Increased risk of adverse cardiovascular effects is also a concern with many NSAIDs; thus, the duration of NSAID use should generally be limited once DMARD therapy becomes effective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26947?source=see_link\">",
"     \"NSAIDs (including aspirin): Treatment of gastroduodenal toxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=see_link\">",
"     \"Nonselective NSAIDs: Adverse cardiovascular effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=see_link\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The dose of a given medication required by different patients may vary. Effective total daily antiinflammatory doses include 500 mg twice daily of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    , 800 mg three to four times daily of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    , 200 mg once daily of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    , or a single daily dose of a longer acting agent, such as 20 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/25/9625?source=see_link\">",
"     piroxicam",
"    </a>",
"    . Alternatives to the non-salicylate NSAIDs are the non-acetylated salicylates (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5350?source=see_link\">",
"     salsalate",
"    </a>",
"    , 2000 to 3000",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    which have proven antiinflammatory activity with fewer adverse gastrointestinal effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5703?source=see_link\">",
"     \"NSAIDs: Therapeutic use and variability of response in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=see_link\">",
"     \"Overview of selective COX-2 inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We continue trials of individual NSAIDs until the patient has achieved adequate control of symptoms with minimal side effects and until effective control of disease activity with DMARD therapy is achieved (ie, decreased swollen joints and acute phase reactants). Treatment with glucocorticoids should be offered as a &ldquo;bridge therapy&rdquo; if adequate control of inflammation is not achieved within two weeks; other experts have recommended a two week trial of another NSAID before resorting to glucocorticoids. We do not combine NSAIDs with each other. Clinical experience suggests that substantially increased risk of gastrointestinal toxicity associated with high dose NSAID use outweighs the very limited benefit (if any) that may occur when using more than one agent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=see_link\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20660420\">",
"    <span class=\"h4\">",
"     Inadequate response to NSAIDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic glucocorticoids, such as oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    , are needed infrequently in patients with early, mildly active RA. We use glucocorticoids in such patients if disease is not well-controlled with a combination of NSAIDs and a DMARD. We suggest starting with 5 to 15",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of prednisone or equivalent, depending upon the severity of the inflammation and comorbidities, to ameliorate symptoms and then tapering to a lower dose as tolerated (preferably no more than 7.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of prednisone) to maintain control temporarily while DMARDs begin to take effect. In general, this will permit reduction and discontinuation of the glucocorticoids within four to six months. Alternatively,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    acetate (120 mg administered intramuscularly) is used by some rheumatologists as &ldquo;bridge therapy,&rdquo; which may be repeated at four and eight weeks if DMARDs have not controlled symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15385/abstract/36\">",
"     36",
"    </a>",
"    ]. Further information regarding the benefits and hazards of various doses of glucocorticoids, their route of administration, and long term use can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41065?source=see_link\">",
"     \"Use of glucocorticoids in the treatment of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/3/31802?source=see_link&amp;anchor=H3693989#H3693989\">",
"     \"Initial treatment of moderately to severely active rheumatoid arthritis in adults\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intraarticular injections of long-acting glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    hexacetonide) are used to reduce synovitis in particular joints that are more inflamed than others. A single active joint out of proportion to others in RA should always raise concern about infection, which may be difficult to distinguish from RA alone. Thus, if infection is a consideration, joint fluid should be obtained to exclude infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41065?source=see_link\">",
"     \"Use of glucocorticoids in the treatment of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30951?source=see_link\">",
"     \"Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=see_link&amp;anchor=H14#H14\">",
"     \"Septic arthritis in adults\", section on 'Rheumatoid arthritis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Analgesics",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the medications noted above, we use analgesic medications, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    , for additional pain relief if required. We avoid the use of opioids in patients with mildly active RA because their pain can be controlled by effective use of antiinflammatories and DMARDs that control the disease process. Patients who appear to require opioids for adequate pain relief should be evaluated for fibromyalgia or other comorbid causes of pain (eg, fracture, tumor, spinal disorders, or others).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MONITORING AND REEVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the initial treatment of patients with mildly active RA, the patient should be reevaluated every four to eight weeks, depending upon several variables. These include the extent to which symptoms are controlled by treatment, whether adjustments or changes are required in the medication regimen, and the need to monitor for possible drug toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15385/abstract/24,37,38\">",
"     24,37,38",
"    </a>",
"    ]. We advise the periodic reevaluation of disease activity using a quantitative composite measure at each assessment (eg, DAS28 or CDAI). These visits also provide an opportunity for patient education and other interventions noted above. The composite measures and their use, direct links to calculators for these measures, and the approach to monitoring of patients being treated for RA are presented in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/33/7706?source=see_link\">",
"     \"Assessment of rheumatoid arthritis activity in clinical trials and clinical practice\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients who fail to achieve remission or very low disease activity within three months of initiating therapy or who require more than 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or equivalent glucocorticoid to maintain a state of remission, we suggest use of a more potent DMARD (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ) or a combination of DMARDs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/3/31802?source=see_link\">",
"     \"Initial treatment of moderately to severely active rheumatoid arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1488163\">",
"    <span class=\"h1\">",
"     DRUG THERAPY FOR FLARES",
"    </span>",
"    &nbsp;&mdash;&nbsp;RA has natural exacerbations (also known as flares) and reductions of continuing disease activity. It is important to distinguish a disease flare, characterized by symptoms and physical and laboratory findings of increased inflammatory synovitis, from noninflammatory causes of local or generalized increased pain. The severity of the flare and background drug therapy influence the choice of therapies. Drug therapy for flares is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link\">",
"     \"Clinical features of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/21/26962?source=see_link\">",
"       \"Patient information: Disease modifying antirheumatic drugs (DMARDs) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/61/21463?source=see_link\">",
"       \"Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/44/24264?source=see_link\">",
"       \"Patient information: Rheumatoid arthritis treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/40/27266?source=see_link\">",
"       \"Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/29/39378?source=see_link\">",
"       \"Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with mildly active rheumatoid arthritis (RA) typically have fewer than five inflamed joints, no extraarticular disease, negative rheumatoid factor",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      anti-CCP antibody testing, and no evidence of erosions or cartilage loss on plain radiographs. We recommend that all patients with the diagnosis of RA, including patients with mild disease, be treated with a disease-modifying antirheumatic drug (DMARD) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Additional principles for the treatment of RA include achieving and maintaining tight control of disease activity, with the ideal goal of remission; the use of antiinflammatory agents, including glucocorticoids, only as adjunctive agents; and the participation of a rheumatologist in the evaluation and ongoing care of the patient. (See",
"      <a class=\"local\" href=\"#H7782239\">",
"       'Definition of mildly active RA'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H208723354\">",
"       'General principles'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link&amp;anchor=H111269724#H111269724\">",
"       \"General principles of management of rheumatoid arthritis in adults\", section on 'Early use of DMARDs'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patient education and other nonpharmacologic and preventive therapies are needed for all patients with RA. (See",
"      <a class=\"local\" href=\"#H208723766\">",
"       'Nonpharmacologic and preventive therapies'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13591?source=see_link\">",
"       \"Nonpharmacologic and preventive therapies of rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with mildly active RA, particularly those without poor prognostic features or with findings limited to mild inflammatory arthritis and a positive antinuclear antibody test (in whom a distinction cannot be made between early RA and early systemic lupus erythematosus), we suggest that an antimalarial drug, preferably HCQ, be used rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      as the initial DMARD (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20660556\">",
"       'Patients who lack poor prognostic features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with mildly active RA with more symptoms and signs of active synovitis, functional limitation, or positive testing for rheumatoid factor or anti-cyclic citrullinated peptide antibodies, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      (SSZ), rather than an antimalarial drug (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). An alternative approach preferred by some experts and one of the authors is to initiate treatment with MTX in such patients. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Patients with mild activity and poor prognostic signs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We use antiinflammatory drug therapy in addition to DMARDs, including nonsteroidal antiinflammatory drugs (NSAIDs), or glucocorticoids on a temporary basis to quickly achieve control of signs and symptoms of disease, and we then taper and withdraw these medications once DMARDs have taken effect. Intraarticular injections of long-acting glucocorticoids are used to reduce synovitis in particular joints that are more inflamed than others. When clinically indicated, joint fluid should be obtained to exclude infection. (See",
"      <a class=\"local\" href=\"#H20660736\">",
"       'Antiinflammatory agents'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20660778\">",
"       'Initial symptomatic therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20660420\">",
"       'Inadequate response to NSAIDs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During the initial treatment of patients with mildly active RA, the patient should be reevaluated every four to eight weeks to assess the effectiveness of therapy and to monitor for possible drug toxicity. We advise the periodic reevaluation of disease activity using a quantitative composite measure at each assessment. In patients who fail to achieve remission within three months of initiating therapy or who require more than 5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or equivalent glucocorticoid to maintain a state of remission, we suggest a more potent DMARD or combination of DMARDs (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Monitoring and reevaluation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/3/31802?source=see_link\">",
"       \"Initial treatment of moderately to severely active rheumatoid arthritis in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15385/abstract/1\">",
"      Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000; 43:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15385/abstract/2\">",
"      Schoels M, Knevel R, Aletaha D, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 2010; 69:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15385/abstract/3\">",
"      Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52:3381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15385/abstract/4\">",
"      Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007; 146:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15385/abstract/5\">",
"      de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Verpoort KN, et al. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. Arthritis Rheum 2008; 58:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15385/abstract/6\">",
"      M&ouml;tt&ouml;nen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999; 353:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15385/abstract/7\">",
"      Puolakka K, Kautiainen H, M&ouml;tt&ouml;nen T, et al. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. Arthritis Rheum 2004; 50:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15385/abstract/8\">",
"      Rantalaiho V, Korpela M, Hannonen P, et al. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial. Arthritis Rheum 2009; 60:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15385/abstract/9\">",
"      Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15385/abstract/10\">",
"      Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007; 66:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15385/abstract/11\">",
"      Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001; 358:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15385/abstract/12\">",
"      Sokka T, Kautiainen H, H&auml;kkinen A, Hannonen P. Radiographic progression is getting milder in patients with early rheumatoid arthritis. Results of 3 cohorts over 5 years. J Rheumatol 2004; 31:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15385/abstract/13\">",
"      Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15385/abstract/14\">",
"      Smolen JS, Landew&eacute; R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15385/abstract/15\">",
"      Huizinga TW, Pincus T. In the clinic. Rheumatoid arthritis. Ann Intern Med 2010; 153:ITC1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15385/abstract/16\">",
"      Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15385/abstract/17\">",
"      Davis MJ, Dawes PT, Fowler PD, et al. Should disease-modifying agents be used in mild rheumatoid arthritis? Br J Rheumatol 1991; 30:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15385/abstract/18\">",
"      Wasko MC, Hubert HB, Lingala VB, et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 2007; 298:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15385/abstract/19\">",
"      Tam LS, Gladman DD, Hallett DC, et al. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol 2000; 27:2142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15385/abstract/20\">",
"      Clark P, Casas E, Tugwell P, et al. Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial. Ann Intern Med 1993; 119:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15385/abstract/21\">",
"      A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA Study. Am J Med 1995; 98:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15385/abstract/22\">",
"      Das SK, Pareek A, Mathur DS, et al. Efficacy and safety of hydroxychloroquine sulphate in rheumatoid arthritis: a randomized, double-blind, placebo controlled clinical trial--an Indian experience. Curr Med Res Opin 2007; 23:2227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15385/abstract/23\">",
"      Suarez-Almazor ME, Belseck E, Shea B, et al. Antimalarials for treating rheumatoid arthritis. Cochrane Database Syst Rev 2000; :CD000959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15385/abstract/24\">",
"      American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002; 46:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15385/abstract/25\">",
"      van der Heijde DM, van Riel PL, Nuver-Zwart IH, et al. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989; 1:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15385/abstract/26\">",
"      Weinblatt ME, Reda D, Henderson W, et al. Sulfasalazine treatment for rheumatoid arthritis: a metaanalysis of 15 randomized trials. J Rheumatol 1999; 26:2123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15385/abstract/27\">",
"      Pullar T, Hunter JA, Capell HA. Effect of sulphasalazine on the radiological progression of rheumatoid arthritis. Ann Rheum Dis 1987; 46:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15385/abstract/28\">",
"      van der Heijde DM, van Riel PL, Nuver-Zwart IH, van de Putte LB. Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-year follow-up. Lancet 1990; 335:539.",
"     </a>",
"    </li>",
"    <li>",
"     Dougados M. Sulfasalazine. In: Therapy of Systemic Rheumatic Disorders, van de Putte LBA, Furst DE, Williams HJ, van Riel PLCM (Eds), Marcel Dekker, New York 1998. p.165.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15385/abstract/30\">",
"      Box SA, Pullar T. Sulphasalazine in the treatment of rheumatoid arthritis. Br J Rheumatol 1997; 36:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15385/abstract/31\">",
"      O'Dell JR, Haire CE, Palmer W, et al. Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1997; 40:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15385/abstract/32\">",
"      Kloppenburg M, Breedveld FC, Terwiel JP, et al. Minocycline in active rheumatoid arthritis. A double-blind, placebo-controlled trial. Arthritis Rheum 1994; 37:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15385/abstract/33\">",
"      Tilley BC, Alarc&oacute;n GS, Heyse SP, et al. Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. Ann Intern Med 1995; 122:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15385/abstract/34\">",
"      O'Dell JR, Paulsen G, Haire CE, et al. Treatment of early seropositive rheumatoid arthritis with minocycline: four-year followup of a double-blind, placebo-controlled trial. Arthritis Rheum 1999; 42:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15385/abstract/35\">",
"      O'Dell JR, Blakely KW, Mallek JA, et al. Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine. Arthritis Rheum 2001; 44:2235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15385/abstract/36\">",
"      Corkill MM, Kirkham BW, Chikanza IC, et al. Intramuscular depot methylprednisolone induction of chrysotherapy in rheumatoid arthritis: a 24-week randomized controlled trial. Br J Rheumatol 1990; 29:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15385/abstract/37\">",
"      Jain R, Lipsky PE. Treatment of rheumatoid arthritis. Med Clin North Am 1997; 81:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15385/abstract/38\">",
"      Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996; 39:723.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7477 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-E8883B2495-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_1_15385=[""].join("\n");
var outline_f15_1_15385=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7782239\">",
"      DEFINITION OF MILDLY ACTIVE RA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H208723354\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H208723766\">",
"      NONPHARMACOLOGIC AND PREVENTIVE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Use of DMARDs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20660556\">",
"      - Patients who lack poor prognostic features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Patients with mild activity and poor prognostic signs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3978675\">",
"      - Other therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3978786\">",
"      - Patients resistant to initial DMARD therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20661238\">",
"      Symptomatic treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20660736\">",
"      - Antiinflammatory agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20660778\">",
"      Initial symptomatic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20660420\">",
"      Inadequate response to NSAIDs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Analgesics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MONITORING AND REEVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1488163\">",
"      DRUG THERAPY FOR FLARES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/9/43161?source=related_link\">",
"      Antimalarial drugs in the treatment of rheumatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/33/7706?source=related_link\">",
"      Assessment of rheumatoid arthritis activity in clinical trials and clinical practice",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=related_link\">",
"      COX-2 selective inhibitors: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=related_link\">",
"      Clinical features of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=related_link\">",
"      Diagnosis and differential diagnosis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=related_link\">",
"      General principles of management of rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/3/31802?source=related_link\">",
"      Initial treatment of moderately to severely active rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30951?source=related_link\">",
"      Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=related_link\">",
"      NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26947?source=related_link\">",
"      NSAIDs (including aspirin): Treatment of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5703?source=related_link\">",
"      NSAIDs: Therapeutic use and variability of response in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13591?source=related_link\">",
"      Nonpharmacologic and preventive therapies of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=related_link\">",
"      Nonselective NSAIDs: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=related_link\">",
"      Overview of selective COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41210?source=related_link\">",
"      Pathogenesis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/29/39378?source=related_link\">",
"      Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/21/26962?source=related_link\">",
"      Patient information: Disease modifying antirheumatic drugs (DMARDs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/40/27266?source=related_link\">",
"      Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/61/21463?source=related_link\">",
"      Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/44/24264?source=related_link\">",
"      Patient information: Rheumatoid arthritis treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=related_link\">",
"      Septic arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/27/2490?source=related_link\">",
"      Sulfasalazine in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/6/42090?source=related_link\">",
"      Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41065?source=related_link\">",
"      Use of glucocorticoids in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_1_15386="Candida vulvovaginitis";
var content_f15_1_15386=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Candida vulvovaginitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/1/15386/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/1/15386/contributors\">",
"     Jack D Sobel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/1/15386/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/1/15386/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/1/15386/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/1/15386/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/1/15386/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/1/15386/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vulvovaginal candidiasis refers to a disorder characterized by signs and symptoms of vulvovaginal inflammation in the presence of Candida species. It is the second most common cause of vaginitis symptoms (after bacterial vaginosis) and accounts for approximately one-third of vaginitis cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/1\">",
"     1",
"    </a>",
"    ]. In contrast to oropharyngeal candidiasis, it is generally not considered an opportunistic infection, and, unlike trichomonas vaginitis, it is not considered a sexually transmitted disease (STD).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candida species can be identified in the lower genital tract in 10 to 20 percent of healthy women in the reproductive age group, 6 to 7 percent of menopausal women, and 3 to 6 percent of prepubertal girls [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. However, identification of vulvovaginal Candida is not necessarily indicative of candidal disease, as the diagnosis of vulvovaginitis requires the presence of vulvovaginal inflammation. &nbsp;",
"   </p>",
"   <p>",
"    The prevalence of vulvovaginal candidiasis is difficult to determine because the clinical diagnosis is often based on symptoms and not confirmed by microscopic examination or culture (as many as one-half of clinically diagnosed women may have another condition [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/4\">",
"     4",
"    </a>",
"    ]). In addition, the widespread use of over-the-counter antimycotic drugs makes epidemiologic studies difficult to perform and culture without clinical correlation is likely to overestimate the prevalence of disease.",
"   </p>",
"   <p>",
"    In surveys, the prevalence of vulvovaginal candidiasis is highest among women in their reproductive years: 55 percent of female university students report having had at least one physician-diagnosed episode by age 25 years, as many as 75 percent of premenopausal women report having had at least one lifetime episode and 45 percent report having had two or more lifetime episodes, while 5 to 8 percent of women report having had four or more episodes within one year [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. The prevalence increases with age up to menopause and is higher in African-American women than in other ethnic groups. The disorder is uncommon in postmenopausal women, unless they are taking estrogen therapy. It is also uncommon in prepubertal girls, in whom it is frequently overdiagnosed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candida albicans is responsible for 80 to 92 percent of episodes of vulvovaginal candidiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/9\">",
"     9",
"    </a>",
"    ] and C. glabrata accounts for almost all of the remainder [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/10\">",
"     10",
"    </a>",
"    ]. Some, but not all, investigators have reported an increasing frequency of non-albicans species, particularly C. glabrata [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/11,12\">",
"     11,12",
"    </a>",
"    ], possibly due to widespread use of over-the-counter drugs, long-term use of suppressive azoles, and the use of short courses of antifungal drugs.",
"   </p>",
"   <p>",
"    All Candida species produce similar vulvovaginal symptoms, although the severity of symptoms is milder with C. glabrata and C. parapsilosis.",
"   </p>",
"   <p>",
"    In contrast to bacterial vaginosis, vulvovaginal candidiasis is not associated with a reduction in vaginal lactobacilli [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/13-16\">",
"     13-16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3829351\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candida organisms probably access the vagina via migration from the rectum across the perianal area [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/17\">",
"     17",
"    </a>",
"    ]; cultures of the gastrointestinal tract and vagina often show identical Candida species. Less commonly, the source of infection is sexual or relapse from a vaginal reservoir.",
"   </p>",
"   <p>",
"    Symptomatic disease is associated with an overgrowth of the organism and penetration of superficial epithelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/8,18,19\">",
"     8,18,19",
"    </a>",
"    ]. The mechanism by which Candida species transform from asymptomatic colonization to an invasive form causing symptomatic vulvovaginal disease is complex, involving host inflammatory responses and yeast virulence factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/19/37176?source=see_link\">",
"     \"Biology of Candida infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3829358\">",
"    <span class=\"h2\">",
"     Recurrent vulvovaginal candidiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent vulvovaginal candidiasis is defined as four or more episodes of symptomatic infection within one year [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/8\">",
"     8",
"    </a>",
"    ]. Longitudinal DNA-typing studies suggest that, in most women, recurrent disease is due to relapse from a persistent vaginal reservoir of organisms or endogenous reinfection with the identical strain of susceptible C. albicans [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Rarely, infection is due to a different Candida species.",
"   </p>",
"   <p>",
"    Recurrent vulvovaginal candidiasis has been associated with decreased in vivo concentration of mannose binding lectin (MBL) and increased concentration of interleukin-4. Two specific gene polymorphisms, variants in the MBL and interleukin-4 alleles, can account for this finding in some women. The prevalence of a variant MLB gene is higher in women with recurrent vulvovaginal candidiasis than in controls without candidiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Since the direct interaction of MBL with C. albicans is an important component of the host's ability to resist candidiasis, impairment of this interaction in MBL-deficient individuals, such as those with certain MBL polymorphisms, appears to predispose these women to recurrent vulvovaginal candidal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/22,24-27\">",
"     22,24-27",
"    </a>",
"    ]. These women mount a strong inflammatory response when exposed to small amounts of Candida, whereas normal women may not mount any inflammatory response and remain asymptomatic. Interleukin-4 blocks the anti-Candida response mediated by macrophages, thus elevated IL-4 levels result in inhibition of local defense mechanisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sporadic attacks of vulvovaginal candidiasis usually occur without an identifiable precipitating factor. Nevertheless, a number of factors predispose to symptomatic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Diabetes mellitus",
"      </strong>",
"      &mdash; Women with diabetes mellitus who have poor glycemic control are more prone to vulvovaginal candidiasis than euglycemic women [",
"      <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]. In particular, women with Type 2 diabetes appear prone to non-albicans Candida species [",
"      <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Antibiotic use",
"      </strong>",
"      &mdash; Use of broad spectrum antibiotics significantly increases the risk of developing vulvovaginal candidiasis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/33\">",
"       33",
"      </a>",
"      ]. As many as one-quarter to one-third of women develop the disorder during or after taking these antibiotics because inhibition of normal bacterial flora favors growth of potential fungal pathogens, such as Candida. Administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32004?source=see_link\">",
"       lactobacillus",
"      </a>",
"      (oral or vaginal) during and for four days after antibiotic therapy does not prevent postantibiotic vulvovaginitis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Increased estrogen levels",
"      </strong>",
"      &mdash; Vulvovaginal candidiasis appears to occur more often in the setting of increased estrogen levels, such as oral contraceptive use (especially when estrogen dose is high), pregnancy, and estrogen therapy.",
"     </li>",
"     <li>",
"      <strong>",
"       Immunosuppression",
"      </strong>",
"      &mdash; Candidal infections are more common in immunosuppressed patients, such as those taking glucocorticoids or other immunosuppressive drugs, or with human immunodeficiency virus (HIV) infection [",
"      <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Contraceptive devices",
"      </strong>",
"      &mdash; Vaginal sponges, diaphragms, and intrauterine devices have been associated with vulvovaginal candidiasis, but not consistently. Spermicides are not associated with Candida infection.",
"     </li>",
"     <li>",
"      <strong>",
"       Behavioral factors",
"      </strong>",
"      &mdash; Vulvovaginal candidiasis is not traditionally considered a sexually transmitted disease (STD) since it occurs in celibate women and since Candida species are considered part of the normal vaginal flora. This does not mean that sexual transmission of Candida does not occur or that vulvovaginal candidiasis is not associated with sexual activity. For example, an increased frequency of vulvovaginal candidiasis has been reported at the time most women begin regular sexual activity [",
"      <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/5,6,28\">",
"       5,6,28",
"      </a>",
"      ]. In addition, partners of infected women are four times more likely to be colonized than partners of uninfected women, and colonization is often the same strain in both partners. However, the number of episodes of vulvovaginal candidiasis a woman has does not appear to be related to her lifetime number of sexual partners or the frequency of coitus [",
"      <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/28,36,37\">",
"       28,36,37",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The type of sex may be a factor. Infection may be linked to orogenital and, less commonly, anogenital sex. Evidence of a link between vulvovaginal candidiasis and hygienic habits (eg, douching, use of",
"      <span class=\"nowrap\">",
"       tampons/menstrual",
"      </span>",
"      pads) or wearing tight or synthetic clothing is weak and conflicting [",
"      <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/28,38-45\">",
"       28,38-45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3829549\">",
"    <span class=\"h2\">",
"     Recurrent vulvovaginal candidiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk factors described above are apparent in only a minority of women with recurrent disease (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Risk factors'",
"    </a>",
"    above). In the remainder, factors that predispose to recurrent infection likely involve abnormalities in local vaginal mucosal immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/46\">",
"     46",
"    </a>",
"    ] and genetic susceptibility (see",
"    <a class=\"local\" href=\"#H3829358\">",
"     'Recurrent vulvovaginal candidiasis'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    The role of sexual transmission in recurrent infection remains unresolved, but does not appear to be a major factor as the bulk of evidence from randomized trials does",
"    <strong>",
"     not",
"    </strong>",
"    support treatment of sexual partners [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/47-50\">",
"     47-50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vulvar pruritus is the dominant feature of vulvovaginal candidiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/10,18,51-53\">",
"     10,18,51-53",
"    </a>",
"    ]. Vulvar burning, soreness, and irritation are also common, and can be accompanied by dysuria (typically perceived to be external or vulvar rather than urethral) or dyspareunia. Symptoms are often worse during the week prior to menses [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/53\">",
"     53",
"    </a>",
"    ]. The intensity of signs and symptoms varies from mild to severe, except among women with C. glabrata or C. parapsilosis infection, who tend to have mild or minimal clinical findings [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Physical examination of the external genitalia, vagina, and cervix often reveals erythema of the vulva and vaginal mucosa and vulvar edema. Vulvar excoriation and fissures are present in about one-quarter of patients. There can be little or no discharge; when present, it is classically white, thick, adherent, and clumpy (curd-like or cottage cheese-like) with no or minimal odor. However, the discharge may be thin and loose, watery, homogeneous, and indistinguishable from that in other types of vaginitis. The cervix usually appears normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general diagnostic approach to women with vaginal complaints is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36633?source=see_link\">",
"     \"Approach to women with symptoms of vaginitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of vulvovaginal candidiasis is based on the presence of Candida on wet mount, Gram&rsquo;s stain, or culture of vaginal discharge in a woman with characteristic clinical findings (eg, vulvovaginal pruritus, burning, erythema, edema,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    curd like discharge attached to the vaginal sidewall) and no other pathogens to account for her symptoms. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Clinical features'",
"    </a>",
"    above.) Because none of the clinical manifestations of vulvovaginal candidiasis is pathognomonic, suspected clinical diagnosis should always be confirmed by laboratory methods. Importantly, although vulvar pruritus is a cardinal symptom of the disorder, less than 50 percent of women with genital pruritus have vulvovaginitis candidiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Office diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vaginal pH in women with Candida infection is typically normal (4 to 4.5), which distinguishes candidiasis from trichomoniasis or bacterial vaginosis (",
"    <a class=\"graphic graphic_table graphicRef68759 \" href=\"UTD.htm?38/29/39388\">",
"     table 1",
"    </a>",
"    ). Candida species can be seen on a wet mount of the discharge; adding 10 percent potassium hydroxide destroys the cellular elements and facilitates recognition of budding yeast, pseudohyphae, and hyphae (",
"    <a class=\"graphic graphic_picture graphicRef59030 \" href=\"UTD.htm?9/37/9809\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef61326 \" href=\"UTD.htm?11/46/12005\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef53369 \" href=\"UTD.htm?12/25/12689\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef80723 \" href=\"UTD.htm?5/13/5329\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef76924 \" href=\"UTD.htm?42/21/43358\">",
"     picture 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef61641 \" href=\"UTD.htm?27/21/27987\">",
"     picture 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/56\">",
"     56",
"    </a>",
"    ]. Use of Swartz-Lamkins fungal stain (potassium hydroxide, a surfactant, and blue dye) may facilitate diagnosis by staining the Candida organisms blue so they are easier to identify [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/57\">",
"     57",
"    </a>",
"    ]. However, microscopy is negative in up to 50 percent of patients with culture confirmed vulvovaginal candidiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Microscopy is also important for looking for clue cells or motile trichomonads, which indicate bacterial vaginosis and trichomoniasis, respectively, as alternative diagnoses, co-infection, or mixed vaginitis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3828914\">",
"    <span class=\"h3\">",
"     Role of culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend not culturing all patients because culture is not necessary for diagnosis if microscopy shows yeast, and it is costly, delays the time to diagnosis by several days, and may be positive due to colonization rather than infection.",
"   </p>",
"   <p>",
"    We obtain a culture in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with clinical features of vulvovaginal candidiasis, normal vaginal pH, and no pathogens (yeast, clue cells, trichomonads) visible on microscopy. A positive culture in these patients confirms the diagnosis and reveals the species of Candida, thus avoiding empiric, un-indicated or incorrect therapy.",
"     </li>",
"     <li>",
"      Women with persistent or recurrent symptoms because many of these women have non-albicans infection resistant to azoles (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis of recurrent vulvovaginal candidiasis'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To perform a culture, a vaginal sample is obtained from the lateral wall using a cotton tipped swab and inoculated onto Sabouraud agar, Nickerson's medium, or Microstix-candida medium; these media perform equally well [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/10\">",
"     10",
"    </a>",
"    ]. Culture for Candida does not require quantification of in vitro colony count. Speciation of Candida is not essential for primary diagnostic testing as most isolates are Candida albicans; however, species identification is essential in refractory and recurrent disease. Laboratory techniques for identification of multiple Candida species are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/19/37176?source=see_link&amp;anchor=H8#H8\">",
"     \"Biology of Candida infections\", section on 'Detection in the microbiology laboratory'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3828943\">",
"    <span class=\"h3\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no reliable point of care tests for Candida available in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/59-64\">",
"     59-64",
"    </a>",
"    ]. A DNA probe test performed in a centralized laboratory offers results comparable to culture with results available in several hours, but no speciation (AFFIRM).",
"   </p>",
"   <p>",
"    Polymerase chain reaction (PCR) methods have high sensitivity and specificity and a shorter turn-around time than culture [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/65-68\">",
"     65-68",
"    </a>",
"    ], but are costly and offer no proven benefit over culture in symptomatic women [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pap smear is positive in 25 percent of patients with culture positive, symptomatic vulvovaginal candidiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/10\">",
"     10",
"    </a>",
"    ]. It is insensitive because the cells are derived from the cervix, which is not affected by Candida vaginitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Self diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Self-diagnosis of vulvovaginal candidiasis is frequently inaccurate and should be discouraged [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. In a study that administered a questionnaire to 600 women to assess their knowledge of the symptoms and signs of vulvovaginal candidiasis (and other infections) after reading classic case scenarios, only 11 percent of women without a previous diagnosis of vulvovaginal candidiasis correctly diagnosed this infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/69\">",
"     69",
"    </a>",
"    ]. Women who had had a prior episode were more often correct (35 percent), but were likely to use over-the-counter drugs inappropriately to treat other, potentially more serious, gynecologic disorders.",
"   </p>",
"   <p>",
"    In another report, the actual diagnoses in 95 women who self-diagnosed vulvovaginal candidiasis were: vulvovaginal candidiasis (34 percent), bacterial vaginosis (19 percent), mixed vaginitis (21 percent), normal flora (14 percent), trichomonas vaginitis (2 percent), and other (11 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/70\">",
"     70",
"    </a>",
"    ]. Women with a previous episode of vulvovaginal candidiasis and those who read the package insert for their over-the-counter medication were not more accurate in making a diagnosis than other women.",
"   </p>",
"   <p>",
"    Some consequences of misdiagnosis and inappropriate therapy include a delay in correct diagnosis and treatment, wasted monetary expenditure, and precipitation of vulvar dermatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Diagnosis of recurrent vulvovaginal candidiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent vulvovaginal candidiasis is defined as four or more episodes of symptomatic infection within one year [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/8\">",
"     8",
"    </a>",
"    ]. Vaginal cultures should always be obtained to confirm the diagnosis and identify less common Candida species, if present. As discussed above, recurrent disease is usually due to relapse from a persistent vaginal reservoir of organisms or endogenous reinfection with identical strains of susceptible C. albicans [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/20\">",
"     20",
"    </a>",
"    ]; however, rarely, a new strain of Candida is responsible for the infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Testing for HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vulvovaginal candidiasis occurs more frequently and has greater persistence, but not greater severity, in human immunodeficiency virus (HIV)-infected women with very low CD4 counts and high viral load; however, this population is likely to manifest other acquired immune deficiency syndrome (AIDS)-related sentinel conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/35\">",
"     35",
"    </a>",
"    ]. HIV testing of women only for the indication of recurrent vulvovaginal candidiasis is not justified, given that recurrent Candida vaginitis is a common condition in women without HIV infection and the majority of cases occur in uninfected women. The microbiology of vulvovaginal candidiasis in HIV-infected women is similar to that in HIV-negative women [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women with risk factors for acquisition of HIV should be counseled and offered screening. These risk factors are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=see_link\">",
"     \"Screening for sexually transmitted infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86369992\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other conditions to be considered in the differential diagnosis of vulvovaginitis with normal vaginal pH include hypersensitivity reactions, allergic or chemical reactions, and contact dermatitis. These conditions are discussed in detail elsewhere. Recognizing local adverse reactions to topical agents is important; otherwise, additional topical agents, including high potency corticosteroids, are often prescribed empirically and further aggravate symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5336?source=see_link\">",
"     \"Dermatitis of the vulva\"",
"    </a>",
"    .) Mechanical irritation due to insufficient lubrication during coitus can also result in vaginal discomfort.",
"   </p>",
"   <p>",
"    If vaginal pH exceeds 4.5 or excess white cells are present, mixed infection with bacterial vaginosis or trichomoniasis may be present. Mixed infection (two pathogens that are symptomatic) is estimated to occur in &lt;5 percent of patients; coinfection (two pathogens but both are not symptomatic) is more common: 20 to 30 percent of women with bacterial vaginosis are co-infected with Candida species [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30602?source=see_link\">",
"     \"Bacterial vaginosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/53/1881?source=see_link\">",
"     \"Trichomonas vaginalis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is indicated for relief of symptoms. Ten to 20 percent of reproductive age women who harbor Candida species are asymptomatic; these women do not require therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment regimen is based on whether the woman has an uncomplicated infection (90 percent of patients) or complicated infection (10 percent of patients). Criteria are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef62038 \" href=\"UTD.htm?11/31/11771\">",
"     table 2",
"    </a>",
"    ). Uncomplicated infections usually respond to treatment within a couple of days. Complicated infections require a longer course of therapy and may take two weeks to fully resolve.",
"   </p>",
"   <p>",
"    Treatment of sexual partners is unnecessary. There is no medical contraindication to sexual intercourse during treatment, but it may be uncomfortable until inflammation improves.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Uncomplicated infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Criteria for uncomplicated infection include all of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sporadic, infrequent episodes (&le;3",
"      <span class=\"nowrap\">",
"       episodes/year)",
"      </span>",
"     </li>",
"     <li>",
"      Mild to moderate",
"      <span class=\"nowrap\">",
"       signs/symptoms",
"      </span>",
"     </li>",
"     <li>",
"      Probable infection with Candida albicans",
"     </li>",
"     <li>",
"      Healthy, nonpregnant woman",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A variety of oral and topical preparations, many available over-the-counter and in single-dose regimens, is available for the treatment of uncomplicated vulvovaginal candidiasis (",
"    <a class=\"graphic graphic_table graphicRef71686 \" href=\"UTD.htm?1/13/1246\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/71\">",
"     71",
"    </a>",
"    ]. In randomized trials, oral and topical antimycotic drugs achieved comparable clinical cure rates, which are in excess of 90 percent; short-term mycologic cure is slightly lower (70 to 80 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/72-75\">",
"     72-75",
"    </a>",
"    ]. Studies that have assessed patient preference consistently reported a preference for the convenience of oral treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/73\">",
"     73",
"    </a>",
"    ]. However, topical treatments have fewer side effects (eg, possible local burning or irritation), while oral medication may cause gastrointestinal intolerance, headache, rash, and transient liver function abnormalities. In addition, oral medications take a day or two longer than topical therapy to relieve symptoms. The absence of superiority of any formulation, agent, or route of administration suggests that cost, patient preference, and contraindications are the major considerations in the decision to prescribe an anti-fungal for oral or topical administration [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest use of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    , given that most women consider oral drugs more convenient than those applied intravaginally. Fluconazole maintains therapeutic concentrations in vaginal secretions for at least 72 hours after the ingestion of a single 150 mg tablet [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/76\">",
"     76",
"    </a>",
"    ]. Side effects of single-dose fluconazole (150 mg) tend to be mild and infrequent. However, fluconazole interacts with multiple drugs; therefore, the potential for drug interactions should be addressed when prescribing this agent. Since fluconazole is now available in a generic form, a single dose regimen of fluconazole is less expensive than over-the-counter topical antifungals.",
"   </p>",
"   <p>",
"    Azole resistance has only been reported in one case of vaginitis caused by C. albicans [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/77\">",
"     77",
"    </a>",
"    ]. Thus, in vitro susceptibility tests are rarely indicated unless compliant patients with a culture-proven diagnosis have no response to adequate therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Complicated infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Characteristics of complicated infections include one or more of the following criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe",
"      <span class=\"nowrap\">",
"       signs/symptoms",
"      </span>",
"     </li>",
"     <li>",
"      Candida species other than C. albicans, particularly C. glabrata",
"     </li>",
"     <li>",
"      Pregnancy, poorly controlled diabetes, immunosuppression, debilitation",
"     </li>",
"     <li>",
"      History of recurrent",
"      <span class=\"nowrap\">",
"       (&ge;4/year)",
"      </span>",
"      culture-verified vulvovaginal candidiasis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment of complicated infection is summarized in the table and described in more detail below (",
"    <a class=\"graphic graphic_table graphicRef50932 \" href=\"UTD.htm?22/63/23548\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Severe symptoms or compromised host",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with severe inflammation or host factors suggestive of complicated infection need longer courses of oral or topical antimycotic drugs. It is unknown whether one route is more effective than the other, as comparative trials of topical versus oral treatment of complicated infection have not been performed.",
"   </p>",
"   <p>",
"    Given the convenience of oral therapy, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (150 mg orally) for two to three sequential doses 72 hours apart for treatment of complicated infections, depending on the severity of the infection (",
"    <a class=\"graphic graphic_table graphicRef50932 \" href=\"UTD.htm?22/63/23548\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/75\">",
"     75",
"    </a>",
"    ]. The efficacy of this approach was supported by a trial that randomly assigned 556 women with severe or recurrent candidiasis to therapy with a single dose of fluconazole (150 mg) or two sequential doses given three days apart [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/78\">",
"     78",
"    </a>",
"    ]. Severity of disease was based upon a scoring system involving degree of pruritus and physical signs (erythema, edema,",
"    <span class=\"nowrap\">",
"     excoriation/fissure",
"    </span>",
"    formation). The two-dose regimen resulted in significantly higher clinical",
"    <span class=\"nowrap\">",
"     cure/improvement",
"    </span>",
"    rates at evaluation on day 14 (94 versus 85 percent) and day 35 (80 versus 67 percent) in women with severe, but not recurrent, disease. However, the response to therapy was lower in the 8 percent of women infected with non-albicans Candida.",
"   </p>",
"   <p>",
"    If the patient prefers topical therapy, observational series report that complicated patients require 7 to 14 days of topical azole therapy (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/18/33056?source=see_link\">",
"     clotrimazole",
"    </a>",
"    , miconazole,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/15/26867?source=see_link\">",
"     terconazole",
"    </a>",
"    ,) rather than a one- to three-day course [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/1,75\">",
"     1,75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For severe Candida vulvar inflammation (vulvitis), low potency topical corticosteroids can be applied to the vulva for 48 hours until the antifungals exert their effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     C. glabrata",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. glabrata has low vaginal virulence and rarely causes symptoms, even when identified by culture. Every effort should be made to exclude other co-existent causes of symptoms and only then treat for C. glabrata vaginitis. Treatment failure with azoles is common (around 50 percent) in patients with C. glabrata vaginitis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/54\">",
"     54",
"    </a>",
"    ]. Moderate success (65 to 70 percent) in women infected with this organism can be achieved with intravaginal boric acid (600 mg capsule once daily at night for two weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/54\">",
"     54",
"    </a>",
"    ]. Better results (&gt;90 percent cure) have been achieved with intravaginal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    cream (5 g nightly for two weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/79\">",
"     79",
"    </a>",
"    ]. Neither boric acid capsules nor flucytosine cream is available commercially and must be made by a compounding pharmacy.",
"    <strong>",
"     Boric acid capsules can be fatal if swallowed",
"    </strong>",
"    .",
"   </p>",
"   <p>",
"    There are no good data regarding use of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    for C. glabrata vaginitis. Anecdotal reports suggest poor response and rare cures, and the potential for toxicity.",
"   </p>",
"   <p>",
"    There are also no good data on the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"     nystatin",
"    </a>",
"    , which is available as a pessary in some parts of the world. One or two pessaries of 100,000 units nystatin are inserted into the vagina nightly for 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/80\">",
"     80",
"    </a>",
"    ]. Alternatively, a suppository can be prepared by a compounding pharmacy. Potential side effects include burning, redness, and irritation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1603867152\">",
"    <span class=\"h3\">",
"     C. krusei",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candida krusei is usually resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    , but is highly susceptible to topical azole creams and suppositories, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/18/33056?source=see_link\">",
"     clotrimazole",
"    </a>",
"    , miconazole, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/15/26867?source=see_link\">",
"     terconazole",
"    </a>",
"    . We treat for 7 to 14 days. It is also likely to respond to oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    , but these oral agents have variable toxicity so topical therapy is advised for first-line therapy. In vitro susceptibility testing is indicated in compliant patients with culture-proven diagnosis of C. krusei and no response to a conventional course of one of these non-fluconazole therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of pregnant women is primarily indicated for relief of symptoms. Vaginal candidiasis is not associated with adverse pregnancy outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/81\">",
"     81",
"    </a>",
"    ]. We suggest application of a topical imidazole (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/18/33056?source=see_link\">",
"     clotrimazole",
"    </a>",
"    or miconazole) vaginally for seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/1,82\">",
"     1,82",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/15/26867?source=see_link\">",
"     Terconazole",
"    </a>",
"    , a triazole, probably has a similar safety profile, but there is less information on its use in pregnancy than for imidazoles. Vaginal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"     nystatin",
"    </a>",
"    is another option. As discussed above, a pessary is available in some parts of the world. One or two pessaries of 100,000 units nystatin are inserted into the vagina nightly for 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/80\">",
"     80",
"    </a>",
"    ]. Alternatively, a suppository can be prepared by a compounding pharmacy. Potential side effects include burning, redness, and irritation.",
"   </p>",
"   <p>",
"    Administration of oral azoles during the first trimester is contraindicated, as case reports have described a pattern of birth defects (abnormalities of cranium, face, bones, and heart) after first trimester exposure to high dose therapy (400 to 800",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. The magnitude of the teratogenic risk is unknown. Although first trimester use of a single, low dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    150 mg to treat vaginal yeast infection has not been associated with an increased risk of embryopathy, most epidemiologic studies were too small to detect an increased risk of major birth defects or rare syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/84\">",
"     84",
"    </a>",
"    ], thus it should be avoided until more data supporting its safety are available.",
"   </p>",
"   <p>",
"    Although treatment of vaginal candida colonization in healthy pregnant women is unnecessary, in Germany treatment is recommended in the third trimester because the rate of oral thrush and diaper dermatitis in mature healthy newborns is significantly reduced by maternal treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Recurrent infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of women with recurrent infections can be difficult and frustrating [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/85\">",
"     85",
"    </a>",
"    ]. Attempts should be made to eliminate or reduce risk factors for infection if present (eg, improve glycemic control, switch to lower estrogen dose oral contraceptive). Although not based upon data from randomized trials, implementing a change in one or more behavioral factors (eg, avoidance of panty liners, pantyhose, cranberry juice, sexual lubricants) to see if there is improvement may be beneficial in rare women [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/38\">",
"     38",
"    </a>",
"    ]. Management of sexual dysfunction and the marital discord that frequently accompany chronic vaginitis should also be addressed.",
"   </p>",
"   <p>",
"    Decreasing gastrointestinal Candida colonization by oral administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"     nystatin",
"    </a>",
"    does not prevent recurrent symptomatic vaginal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23279225\">",
"    <span class=\"h4\">",
"     Azoles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials comparing different therapeutic regimens have not been performed. Based on the data cited below and personal experience, we believe that the optimal therapy for recurrent vulvovaginal candidiasis in nonpregnant women consists of initial induction therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    150 mg every 72 hours for three doses, followed by maintenance fluconazole therapy once per week for six months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/86\">",
"     86",
"    </a>",
"    ]. Therapy is then discontinued, at which point some patients achieve a prolonged remission, while others relapse. A short-term relapse, with culture confirmation of the diagnosis, merits reinduction therapy with three doses of fluconazole, followed by repeat weekly maintenance fluconazole therapy, this time for one year. A minority of women persist in relapsing as soon as fluconazole maintenance is withdrawn (fluconazole dependent recurrent vulvovaginal candidiasis). Symptoms in these patients can be controlled by months or years of weekly fluconazole.",
"   </p>",
"   <p>",
"    Given the safety profile of low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    , most experts do not suggest any laboratory monitoring; however, if other oral imidazoles (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ) are used, particularly if taken daily, then monitoring liver function tests is recommended.",
"   </p>",
"   <p>",
"    Although drug interactions are reported with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    and several oral agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ), such interactions are extremely unlikely with maintenance fluconazole due to the low plasma concentrations accompanying the once weekly 150 mg dosing regimen. Accordingly, no additional testing needed.",
"   </p>",
"   <p>",
"    Alternative approaches that have been suggested include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treat each recurrent episode as an episode of uncomplicated infection (",
"      <a class=\"graphic graphic_table graphicRef71686 \" href=\"UTD.htm?1/13/1246\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/1\">",
"       1",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Treat each recurrent episode with longer duration of therapy (eg, topical azole for 7 to 14 days or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      150 mg orally on day 1, day 4, and day 7) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/1\">",
"       1",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The Infectious Diseases Society of America (IDSA) recommends 10 to 14 days of induction therapy with a topical or oral azole, followed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      150 mg once per week for six months (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/18/33056?source=see_link\">",
"       clotrimazole",
"      </a>",
"      200 mg vaginal cream twice weekly is a nonoral alternative) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173002095\">",
"    <span class=\"h5\">",
"     Evidence for suppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple observational studies of nonpregnant women with recurrent vulvovaginal candidiasis have shown that antifungal maintenance suppressive therapy taken for six months after an initial induction regimen resulted in negative cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/72,87\">",
"     72,87",
"    </a>",
"    ]. The best available option in nonpregnant women is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    150 mg orally once per week for six months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/75\">",
"     75",
"    </a>",
"    ]. However, maintenance therapy is only effective for preventing recurrent infection as long as the medication is being taken. This was illustrated in a trial of 387 women with recurrent vulvovaginal candidiasis treated with open-label fluconazole (150 mg orally at 72-hour intervals for three doses) and then randomly assigned to weekly doses of fluconazole (150 mg) or placebo for six months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/86\">",
"     86",
"    </a>",
"    ]. The maintenance therapy phase was begun two weeks after initiation of treatment in patients who were clinically cured. Study drugs were discontinued in patients diagnosed with recurrent candidal infection during follow-up visits.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The proportion of women who remained disease-free was significantly higher in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      group (91 versus 36 percent at 6 months, 73 versus 28 percent at 9 months, and 43 versus 22 percent at 12 months).",
"     </li>",
"     <li>",
"      The mean time to recurrence in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      and placebo groups was 10.2 and 4.0 months, respectively.",
"     </li>",
"     <li>",
"      Resistant isolates of C. albicans or superinfection with C. glabrata were not observed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although this regimen of maintenance",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    was convenient, safe, and as effective as other therapies, long-term cure of recurrent vulvovaginal candidiasis was not achieved in one-half of the women studied. Episodes of recurrent candidiasis resumed when maintenance therapy was discontinued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173002117\">",
"    <span class=\"h5\">",
"     Fluconazole resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women with recurrent vulvovaginal candidiasis, there is some evidence that frequent and prolonged use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    can infrequently select for fluconazole resistance in C. albicans strains previously susceptible to fluconazole, which limits the options available for treating these women. In a study of 25 women with refractory Candida vaginitis and a C. albicans isolate with fluconazole minimum inhibitory concentration (MIC) &ge;2",
"    <span class=\"nowrap\">",
"     micrograms/mL,",
"    </span>",
"    those with fluconazole MIC values of 2 and 4",
"    <span class=\"nowrap\">",
"     micrograms/mL",
"    </span>",
"    were treated successfully by increasing fluconazole dosage to 200 mg twice weekly [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/88\">",
"     88",
"    </a>",
"    ]. In the authors&rsquo; experience, a higher dose of fluconazole was not effective for women with MIC &ge;8",
"    <span class=\"nowrap\">",
"     micrograms/mL.",
"    </span>",
"    These women should be evaluated for cross-resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    , as some patients can be treated effectively with long-term maintenance daily imidazole therapy. However, use of itraconazole or ketoconazole requires intermittent hepatic function testing. Women with severe recurrent vulvovaginal candidiasis infection and high-level pan azole resistance do not have options other than topical boric acid (see",
"    <a class=\"local\" href=\"#H173002154\">",
"     'Boric acid'",
"    </a>",
"    below) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"     nystatin",
"    </a>",
"    suppositories [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In women with refractory vulvovaginal candidiasis with persistently positive C. albicans cultures, MICs to various antifungals can be tested by using the broth microdilution method conducted in accordance with Clinical and Laboratory Standards Institution (CLSI) criteria and breakpoints [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/90\">",
"     90",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/21/29018?source=see_link\">",
"     \"Antifungal susceptibility testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23279240\">",
"    <span class=\"h4\">",
"     Probiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence that women with recurrent vulvovaginal candidiasis have vaginal flora deficient in lactobacilli [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Although there is a popular belief that ingestion or vaginal administration of yogurt or other agents containing live lactobacilli decreases the rate of candidal colonization and symptomatic relapse, the few studies in this area have a number of methodologic flaws (eg, no control group, short follow-up) and small numbers of subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/91-95\">",
"     91-95",
"    </a>",
"    ]. The value of administering live lactobacilli to women with recurrent infection has been refuted in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/38,96\">",
"     38,96",
"    </a>",
"    ] and this approach should be considered unproven. In addition, the quality of commercially available probiotics varies worldwide. In the United States, the content of these products is not standardized and often of poor quality. Quality may be better in Europe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173002154\">",
"    <span class=\"h4\">",
"     Boric acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Boric acid has not been proven to be an effective treatment of recurrent vulvovaginitis and has no role in treatment of recurrent vulvovaginitis due to C. albicans, unless azole resistance is demonstrated by in vitro tests. There are no safety data on long-term use of boric acid, which causes significant local irritation and has the potential for toxicity (including death) if ingested by accident. A course of boric acid (600 mg intravaginal boric acid vaginal suppositories daily for two weeks) should be considered only in cases of proven azole-resistant infection; these cases are rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23279303\">",
"    <span class=\"h4\">",
"     Immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local vaginal hypersensitivity to C. albicans has been proposed as the cause of recurrent infection in some women [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/97\">",
"     97",
"    </a>",
"    ]. Immunotherapy of candidal vaginitis is a novel therapeutic approach under investigation, but no effective prophylactic or therapeutic vaccine has been developed for this purpose [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Treatment of partners",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although sexual transmission of Candida species can occur, most experts do not recommend treatment of sexual partners since sexual activity is not a significant cause of infection or reinfection. Although the bulk of evidence from randomized trials does",
"    <strong>",
"     not",
"    </strong>",
"    support treatment of sexual partners [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/47-50\">",
"     47-50",
"    </a>",
"    ], in woman with recurrent vulvovaginitis, this issue remains controversial.",
"   </p>",
"   <p>",
"    Treatment of symptomatic men is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/33/14872?source=see_link\">",
"     \"Balanitis and balanoposthitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Breastfeeding women",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"     Nystatin",
"    </a>",
"    does not enter breast milk and is compatible with breastfeeding.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     Fluconazole",
"    </a>",
"    is excreted in human milk, but the American Academy of Pediatrics (AAP) considers the use of fluconazole compatible with breastfeeding [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/99\">",
"     99",
"    </a>",
"    ], as no adverse effects have been reported in breastfed infants or infants treated with parenteral fluconazole [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/100\">",
"     100",
"    </a>",
"    ]. There is no information on the effect of miconazole,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/23/40306?source=see_link\">",
"     butoconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/18/33056?source=see_link\">",
"     clotrimazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/6/34914?source=see_link\">",
"     tioconazole",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/15/26867?source=see_link\">",
"     terconazole",
"    </a>",
"    on nursing infants, but systemic absorption after maternal vaginal administration is minimal, hence topical use in nursing mothers is reasonable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Postcoital hypersensitivity reaction in male partner",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a variant syndrome, male partners of women with vaginal Candida colonization develop immediate postcoital itching and burning with redness and a rash of the penis. This postcoital syndrome probably represents an acute hypersensitivity reaction to Candida organisms or antigens in the partner's vagina, even in the absence of symptomatic vulvovaginitis.",
"   </p>",
"   <p>",
"    Males with recurrent postcoital symptoms do not benefit from topical antimycotic therapy since the key to eradicating symptoms lies in eliminating Candida organisms from the lower genital tract of the female sexual partner. This often requires the female partner to follow a long-term maintenance antimycotic regimen.",
"   </p>",
"   <p>",
"    A postcoital shower and application of a topical low potency corticosteroid to the penis may provide symptomatic relief within 12 to 24 hours. Penile cultures may remain positive for Candida despite normal physical findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"     nystatin",
"    </a>",
"    does not prevent vaginal candidiasis and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32004?source=see_link\">",
"     lactobacillus",
"    </a>",
"    (oral or vaginal) does not prevent postantibiotic vulvovaginitis. In women susceptible to symptomatic yeast infections when taking antibiotic therapy, a dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (150 mg orally) at the start and end of antibiotic therapy may prevent postantibiotic vulvovaginitis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2360941\">",
"    <span class=\"h1\">",
"     COMPLEMENTARY AND ALTERNATIVE MEDICINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence from randomized trials that garlic, tea tree oil, yogurt (or other products containing live",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32004?source=see_link\">",
"     Lactobacillus",
"    </a>",
"    species), or douching is effective for treatment or prevention of vulvovaginal candidiasis due to Candida albicans [",
"    <a class=\"abstract\" href=\"UTD.htm?15/1/15386/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/1/14354?source=see_link\">",
"       \"Patient information: Vaginal yeast infection (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/54/33634?source=see_link\">",
"       \"Patient information: Vulvar itching (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/53/2899?source=see_link\">",
"       \"Patient information: Vaginal yeast infection (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Candida is considered part of the normal vaginal flora, but overgrowth of the organism and penetration of superficial epithelial cells can result in vulvovaginitis. Candida albicans accounts for 80 to 92 percent of episodes of vulvovaginal candidiasis; Candida glabrata is the next most common species. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prevalence'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Microbiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3829351\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vulvar pruritus is the dominant symptom. Vulvar burning, soreness, and irritation are common and may result in dysuria and dyspareunia. The vulva and vagina appear erythematous, and vulvar excoriation and fissures may be present. There is often little or no discharge; when present, it is classically white, thick, adherent, and clumpy (curd-like or cottage cheese-like) with no or minimal odor. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of vulvovaginal candidiasis is based on the presence of Candida on wet mount, Gram&rsquo;s stain, or culture of vaginal discharge in a woman with characteristic clinical findings. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Office diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Culture is not necessary for diagnosis if microscopy shows yeast, but should be obtained in (see",
"      <a class=\"local\" href=\"#H3828914\">",
"       'Role of culture'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Women with clinical features of vulvovaginal candidiasis, normal vaginal pH, and negative microscopy.",
"     </li>",
"     <li>",
"      Women with persistent or recurrent symptoms because many of these women have non-albicans infection resistant to azoles.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173003511\">",
"    <span class=\"h2\">",
"     Trreatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment is indicated to relieve symptoms. Asymptomatic women and sexual partners do not require treatment. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Treatment of partners'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment regimen is based on whether the woman has an uncomplicated infection (90 percent of patients) or complicated infection (10 percent of patients). Criteria are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef62038 \" href=\"UTD.htm?11/31/11771\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Uncomplicated infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral and topical antimycotic drugs achieve comparable clinical cure rates, which are in excess of 80 percent in uncomplicated infection (",
"    <a class=\"graphic graphic_table graphicRef71686 \" href=\"UTD.htm?1/13/1246\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Uncomplicated infection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest a single dose of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (150 mg) for treatment of uncomplicated infections rather than multidose and topical regimens (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Uncomplicated infection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Complicated infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with complicated infection require longer courses of therapy than women with uncomplicated infection. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Complicated infections'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women with severe symptoms, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (150 mg) in two sequential doses given three days apart rather than topical antimycotic agents (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Severe symptoms or compromised host'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For treatment of C. glabrata, we suggest intravaginal boric acid (600 mg capsule once daily at night for two weeks) rather than an azole, boric acid, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"       flucytosine",
"      </a>",
"      cream (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'C. glabrata'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For pregnant women, we suggest a topical imidazole (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/18/33056?source=see_link\">",
"       clotrimazole",
"      </a>",
"      , miconazole) vaginally for seven days rather than a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"       nystatin",
"      </a>",
"      pessary (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Oral azoles are contraindicated in pregnancy. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with recurrent vulvovaginitis (&ge;4",
"      <span class=\"nowrap\">",
"       episodes/year),",
"      </span>",
"      we suggest suppressive maintenance therapy rather than treatment of individual episodes (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We prescribe initial induction therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      150 mg every 72 hours for three doses, then maintenance fluconazole 150 mg once per week for six months. Women with recurrent infection should try to eliminate or reduce risk factors for infection. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Recurrent infection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/1\">",
"      Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/2\">",
"      Goldacre MJ, Watt B, Loudon N, et al. Vaginal microbial flora in normal young women. Br Med J 1979; 1:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/3\">",
"      Tibaldi C, Cappello N, Latino MA, et al. Vaginal and endocervical microorganisms in symptomatic and asymptomatic non-pregnant females: risk factors and rates of occurrence. Clin Microbiol Infect 2009; 15:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/4\">",
"      Berg AO, Heidrich FE, Fihn SD, et al. Establishing the cause of genitourinary symptoms in women in a family practice. Comparison of clinical examination and comprehensive microbiology. JAMA 1984; 251:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/5\">",
"      Geiger AM, Foxman B, Gillespie BW. The epidemiology of vulvovaginal candidiasis among university students. Am J Public Health 1995; 85:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/6\">",
"      Geiger AM, Foxman B. Risk factors for vulvovaginal candidiasis: a case-control study among university students. Epidemiology 1996; 7:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/7\">",
"      Hurley R, De Louvois J. Candida vaginitis. Postgrad Med J 1979; 55:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/8\">",
"      Sobel JD. Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 1985; 152:924.",
"     </a>",
"    </li>",
"    <li>",
"     Odds, FC. Candidosis of the genitalia. In: Odds, FC. Candida and candidosis: A review and bibliography, 2nd ed, Bailli&eacute;re Tindall, London 1988, p. 124.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/10\">",
"      Sobel JD. Vulvovaginal candidosis. Lancet 2007; 369:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/11\">",
"      Horowitz BJ, Giaquinta D, Ito S. Evolving pathogens in vulvovaginal candidiasis: implications for patient care. J Clin Pharmacol 1992; 32:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/12\">",
"      Vermitsky JP, Self MJ, Chadwick SG, et al. Survey of vaginal-flora Candida species isolates from women of different age groups by use of species-specific PCR detection. J Clin Microbiol 2008; 46:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/13\">",
"      Sobel JD, Chaim W. Vaginal microbiology of women with acute recurrent vulvovaginal candidiasis. J Clin Microbiol 1996; 34:2497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/14\">",
"      McClelland RS, Richardson BA, Hassan WM, et al. Prospective study of vaginal bacterial flora and other risk factors for vulvovaginal candidiasis. J Infect Dis 2009; 199:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/15\">",
"      Vitali B, Pugliese C, Biagi E, et al. Dynamics of vaginal bacterial communities in women developing bacterial vaginosis, candidiasis, or no infection, analyzed by PCR-denaturing gradient gel electrophoresis and real-time PCR. Appl Environ Microbiol 2007; 73:5731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/16\">",
"      Zhou X, Westman R, Hickey R, et al. Vaginal microbiota of women with frequent vulvovaginal candidiasis. Infect Immun 2009; 77:4130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/17\">",
"      Bertholf ME, Stafford MJ. Colonization of Candida albicans in vagina, rectum, and mouth. J Fam Pract 1983; 16:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/18\">",
"      Sobel JD, Faro S, Force RW, et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 1998; 178:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/19\">",
"      Merson-Davies LA, Odds FC, Malet R, et al. Quantification of Candida albicans morphology in vaginal smears. Eur J Obstet Gynecol Reprod Biol 1991; 42:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/20\">",
"      Vazquez JA, Sobel JD, Demitriou R, et al. Karyotyping of Candida albicans isolates obtained longitudinally in women with recurrent vulvovaginal candidiasis. J Infect Dis 1994; 170:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/21\">",
"      Lockhart SR, Reed BD, Pierson CL, Soll DR. Most frequent scenario for recurrent Candida vaginitis is strain maintenance with \"substrain shuffling\": demonstration by sequential DNA fingerprinting with probes Ca3, C1, and CARE2. J Clin Microbiol 1996; 34:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/22\">",
"      Liu F, Liao Q, Liu Z. Mannose-binding lectin and vulvovaginal candidiasis. Int J Gynaecol Obstet 2006; 92:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/23\">",
"      Donders GG, Babula O, Bellen G, et al. Mannose-binding lectin gene polymorphism and resistance to therapy in women with recurrent vulvovaginal candidiasis. BJOG 2008; 115:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/24\">",
"      Babula O, Lazdne G, Kroica J, et al. Frequency of interleukin-4 (IL-4) -589 gene polymorphism and vaginal concentrations of IL-4, nitric oxide, and mannose-binding lectin in women with recurrent vulvovaginal candidiasis. Clin Infect Dis 2005; 40:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/25\">",
"      Ip WK, Lau YL. Role of mannose-binding lectin in the innate defense against Candida albicans: enhancement of complement activation, but lack of opsonic function, in phagocytosis by human dendritic cells. J Infect Dis 2004; 190:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/26\">",
"      Lillegard JB, Sim RB, Thorkildson P, et al. Recognition of Candida albicans by mannan-binding lectin in vitro and in vivo. J Infect Dis 2006; 193:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/27\">",
"      Giraldo PC, Babula O, Gon&ccedil;alves AK, et al. Mannose-binding lectin gene polymorphism, vulvovaginal candidiasis, and bacterial vaginosis. Obstet Gynecol 2007; 109:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/28\">",
"      Foxman B. The epidemiology of vulvovaginal candidiasis: risk factors. Am J Public Health 1990; 80:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/29\">",
"      Sobel, JD. Candida vaginitis. Infect Dis Clin Pract 1994; 3:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/30\">",
"      Donders GG. Lower Genital Tract Infections in Diabetic Women. Curr Infect Dis Rep 2002; 4:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/31\">",
"      de Leon EM, Jacober SJ, Sobel JD, Foxman B. Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes. BMC Infect Dis 2002; 2:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/32\">",
"      Ray D, Goswami R, Banerjee U, et al. Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis. Diabetes Care 2007; 30:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/33\">",
"      Wilton L, Kollarova M, Heeley E, Shakir S. Relative risk of vaginal candidiasis after use of antibiotics compared with antidepressants in women: postmarketing surveillance data in England. Drug Saf 2003; 26:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/34\">",
"      Pirotta M, Gunn J, Chondros P, et al. Effect of lactobacillus in preventing post-antibiotic vulvovaginal candidiasis: a randomised controlled trial. BMJ 2004; 329:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/35\">",
"      Duerr A, Heilig CM, Meikle SF, et al. Incident and persistent vulvovaginal candidiasis among human immunodeficiency virus-infected women: Risk factors and severity. Obstet Gynecol 2003; 101:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/36\">",
"      Bradshaw CS, Morton AN, Garland SM, et al. Higher-risk behavioral practices associated with bacterial vaginosis compared with vaginal candidiasis. Obstet Gynecol 2005; 106:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/37\">",
"      Reed BD, Zazove P, Pierson CL, et al. Candida transmission and sexual behaviors as risks for a repeat episode of Candida vulvovaginitis. J Womens Health (Larchmt) 2003; 12:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/38\">",
"      Patel DA, Gillespie B, Sobel JD, et al. Risk factors for recurrent vulvovaginal candidiasis in women receiving maintenance antifungal therapy: results of a prospective cohort study. Am J Obstet Gynecol 2004; 190:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/39\">",
"      Heidrich FE, Berg AO, Bergman JJ. Clothing factors and vaginitis. J Fam Pract 1984; 19:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/40\">",
"      Elegbe IA, Elegbe I. Quantitative relationships of Candida albicans infections and dressing patterns in Nigerian women. Am J Public Health 1983; 73:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/41\">",
"      Heng LS, Yatsuya H, Morita S, Sakamoto J. Vaginal douching in Cambodian women: its prevalence and association with vaginal candidiasis. J Epidemiol 2010; 20:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/42\">",
"      Corsello S, Spinillo A, Osnengo G, et al. An epidemiological survey of vulvovaginal candidiasis in Italy. Eur J Obstet Gynecol Reprod Biol 2003; 110:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/43\">",
"      Spinillo A, Pizzoli G, Colonna L, et al. Epidemiologic characteristics of women with idiopathic recurrent vulvovaginal candidiasis. Obstet Gynecol 1993; 81:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/44\">",
"      Farage M, Bramante M, Otaka Y, Sobel J. Do panty liners promote vulvovaginal candidiasis or urinary tract infections? A review of the scientific evidence. Eur J Obstet Gynecol Reprod Biol 2007; 132:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/45\">",
"      Jankovi S, Bojovi D, Vukadinovi D, et al. Risk factors for recurrent vulvovaginal candidiasis. Vojnosanit Pregl 2010; 67:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/46\">",
"      Fidel PL Jr, Sobel JD. Immunopathogenesis of recurrent vulvovaginal candidiasis. Clin Microbiol Rev 1996; 9:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/47\">",
"      Fong IW. The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourin Med 1992; 68:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/48\">",
"      Shihadeh AS, Nawafleh AN. The value of treating the male partner in vaginal candidiasis. Saudi Med J 2000; 21:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/49\">",
"      Bisschop MP, Merkus JM, Scheygrond H, van Cutsem J. Co-treatment of the male partner in vaginal candidosis: a double-blind randomized control study. Br J Obstet Gynaecol 1986; 93:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/50\">",
"      Colli E, Landoni M, Parazzini F. Treatment of male partners and recurrence of bacterial vaginosis: a randomised trial. Genitourin Med 1997; 73:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/51\">",
"      Anderson MR, Klink K, Cohrssen A. Evaluation of vaginal complaints. JAMA 2004; 291:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/52\">",
"      Eckert LO. Clinical practice. Acute vulvovaginitis. N Engl J Med 2006; 355:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/53\">",
"      Eckert LO, Hawes SE, Stevens CE, et al. Vulvovaginal candidiasis: clinical manifestations, risk factors, management algorithm. Obstet Gynecol 1998; 92:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/54\">",
"      Sobel JD, Chaim W. Treatment of Torulopsis glabrata vaginitis: retrospective review of boric acid therapy. Clin Infect Dis 1997; 24:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/55\">",
"      Mendling W, Brasch J, German Society for Gynecology and Obstetrics, et al. Guideline vulvovaginal candidosis (2010) of the German Society for Gynecology and Obstetrics, the Working Group for Infections and Infectimmunology in Gynecology and Obstetrics, the German Society of Dermatology, the Board of German Dermatologists and the German Speaking Mycological Society. Mycoses 2012; 55 Suppl 3:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/56\">",
"      National guideline for the management of vulvovaginal candidiasis. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases). Sex Transm Infect 1999; 75 Suppl 1:S19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/57\">",
"      SWARTZ JH, LAMKINS BE. A RAPID, SIMPLE STAIN FOR FUNGI IN SKIN, NAIL SCRAPINGS, AND HAIRS. Arch Dermatol 1964; 89:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/58\">",
"      Sobel JD, Subramanian C, Foxman B, et al. Mixed Vaginitis-More Than Coinfection and With Therapeutic Implications. Curr Infect Dis Rep 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/59\">",
"      Dan M, Leshem Y, Yeshaya A. Performance of a rapid yeast test in detecting Candida spp. in the vagina. Diagn Microbiol Infect Dis 2010; 67:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/60\">",
"      Chatwani AJ, Mehta R, Hassan S, et al. Rapid testing for vaginal yeast detection: a prospective study. Am J Obstet Gynecol 2007; 196:309.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/61\">",
"      Marot-Leblond A, Nail-Billaud S, Pilon F, et al. Efficient diagnosis of vulvovaginal candidiasis by use of a new rapid immunochromatography test. J Clin Microbiol 2009; 47:3821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/62\">",
"      Hopwood V, Evans EG, Carney JA. Rapid diagnosis of vaginal candidosis by latex particle agglutination. J Clin Pathol 1985; 38:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/63\">",
"      Matsui H, Hanaki H, Takahashi K, et al. Rapid detection of vaginal Candida species by newly developed immunochromatography. Clin Vaccine Immunol 2009; 16:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/64\">",
"      Abbott J. Clinical and microscopic diagnosis of vaginal yeast infection: a prospective analysis. Ann Emerg Med 1995; 25:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/65\">",
"      Tabrizi SN, Pirotta MV, Rudland E, Garland SM. Detection of Candida species by PCR in self-collected vaginal swabs of women after taking antibiotics. Mycoses 2006; 49:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/66\">",
"      Diba K, Namaki A, Ayatolahi H, Hanifian H. Rapid identification of drug resistant Candida species causing recurrent vulvovaginal candidiasis. Med Mycol J 2012; 53:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/67\">",
"      Mahmoudi Rad M, Zafarghandi ASh, Amel Zabihi M, et al. Identification of Candida species associated with vulvovaginal candidiasis by multiplex PCR. Infect Dis Obstet Gynecol 2012; 2012:872169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/68\">",
"      Weissenbacher T, Witkin SS, Ledger WJ, et al. Relationship between clinical diagnosis of recurrent vulvovaginal candidiasis and detection of Candida species by culture and polymerase chain reaction. Arch Gynecol Obstet 2009; 279:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/69\">",
"      Ferris DG, Dekle C, Litaker MS. Women's use of over-the-counter antifungal medications for gynecologic symptoms. J Fam Pract 1996; 42:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/70\">",
"      Ferris DG, Nyirjesy P, Sobel JD, et al. Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. Obstet Gynecol 2002; 99:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/71\">",
"      Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 2000; 30:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/72\">",
"      Reef SE, Levine WC, McNeil MM, et al. Treatment options for vulvovaginal candidiasis, 1993. Clin Infect Dis 1995; 20 Suppl 1:S80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/73\">",
"      Watson MC, Grimshaw JM, Bond CM, et al. Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database Syst Rev 2001; :CD002845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/74\">",
"      Sobel JD, Brooker D, Stein GE, et al. Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. Fluconazole Vaginitis Study Group. Am J Obstet Gynecol 1995; 172:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/75\">",
"      Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/76\">",
"      Houang ET, Chappatte O, Byrne D, et al. Fluconazole levels in plasma and vaginal secretions of patients after a 150-milligram single oral dose and rate of eradication of infection in vaginal candidiasis. Antimicrob Agents Chemother 1990; 34:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/77\">",
"      Sobel JD, Vazquez JA. Symptomatic vulvovaginitis due to fluconazole-resistant Candida albicans in a female who was not infected with human immunodeficiency virus. Clin Infect Dis 1996; 22:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/78\">",
"      Sobel JD, Kapernick PS, Zervos M, et al. Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole. Am J Obstet Gynecol 2001; 185:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/79\">",
"      Sobel JD, Chaim W, Nagappan V, Leaman D. Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. Am J Obstet Gynecol 2003; 189:1297.",
"     </a>",
"    </li>",
"    <li>",
"     United Kingdom National Guideline on the Management of Vulvovaginal Candidiasis (2007). Available at www.bashh.org/documents/1798. (Accessed December 4, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/81\">",
"      Cotch MF, Hillier SL, Gibbs RS, Eschenbach DA. Epidemiology and outcomes associated with moderate to heavy Candida colonization during pregnancy. Vaginal Infections and Prematurity Study Group. Am J Obstet Gynecol 1998; 178:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/82\">",
"      Young GL, Jewell D. Topical treatment for vaginal candidiasis (thrush) in pregnancy. Cochrane Database Syst Rev 2001; :CD000225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/83\">",
"      Lopez-Rangel E, Van Allen MI. Prenatal exposure to fluconazole: an identifiable dysmorphic phenotype. Birth Defects Res A Clin Mol Teratol 2005; 73:919.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication:Use of long-term, high-dose Diflucan (fluconazole) during pregnancy may be associated with birth defects in infants file://www.fda.gov/Drugs/DrugSafety/ucm266030.htm (Accessed on September 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/85\">",
"      Sobel JD. Management of patients with recurrent vulvovaginal candidiasis. Drugs 2003; 63:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/86\">",
"      Sobel JD, Wiesenfeld HC, Martens M, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med 2004; 351:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/87\">",
"      Donders G, Bellen G, Byttebier G, et al. Individualized decreasing-dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial). Am J Obstet Gynecol 2008; 199:613.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/88\">",
"      Marchaim D, Lemanek L, Bheemreddy S, et al. Fluconazole-resistant Candida albicans vulvovaginitis. Obstet Gynecol 2012; 120:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/89\">",
"      Danby CS, Boikov D, Rautemaa-Richardson R, Sobel JD. Effect of pH on in vitro susceptibility of Candida glabrata and Candida albicans to 11 antifungal agents and implications for clinical use. Antimicrob Agents Chemother 2012; 56:1403.",
"     </a>",
"    </li>",
"    <li>",
"     CLSI. Performance standards for antimibrobial susceptibility testing. Nineteenth informational supplement. Approved standard M100&ndash;S19. Wayne (PA): Clinical and Laboratory Standards Institute; 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/91\">",
"      Hilton E, Isenberg HD, Alperstein P, et al. Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis. Ann Intern Med 1992; 116:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/92\">",
"      Shalev E, Battino S, Weiner E, et al. Ingestion of yogurt containing Lactobacillus acidophilus compared with pasteurized yogurt as prophylaxis for recurrent candidal vaginitis and bacterial vaginosis. Arch Fam Med 1996; 5:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/93\">",
"      Collins EB, Hardt P. Inhibition of Candida albicans by Lactobacillus acidophilus. J Dairy Sci 1980; 63:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/94\">",
"      Falagas ME, Betsi GI, Athanasiou S. Probiotics for prevention of recurrent vulvovaginal candidiasis: a review. J Antimicrob Chemother 2006; 58:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/95\">",
"      Martinez RC, Franceschini SA, Patta MC, et al. Improved treatment of vulvovaginal candidiasis with fluconazole plus probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14. Lett Appl Microbiol 2009; 48:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/96\">",
"      Witt A, Kaufmann U, Bitschnau M, et al. Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. BJOG 2009; 116:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/97\">",
"      Rigg D, Miller MM, Metzger WJ. Recurrent allergic vulvovaginitis: treatment with Candida albicans allergen immunotherapy. Am J Obstet Gynecol 1990; 162:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/98\">",
"      Magliani W, Conti S, Cassone A, et al. New immunotherapeutic strategies to control vaginal candidiasis. Trends Mol Med 2002; 8:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/1/15386/abstract/99\">",
"      American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001; 108:776.",
"     </a>",
"    </li>",
"    <li>",
"     Fluconazole. Drugs in Pregnancy and Lacation. 8th edition. file://wk-trusted-auth.ipublishcentral.com/services/trustedauth/reader/isbn/9780781778763 (Accessed on February 07, 2013).",
"    </li>",
"    <li>",
"     Candiasis (vulvovaginal). file://clinicalevidence.bmj.com (Accessed on December 08, 2010).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5452 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-2.133.93.82-84A455F99E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_1_15386=[""].join("\n");
var outline_f15_1_15386=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3829351\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3829358\">",
"      Recurrent vulvovaginal candidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3829549\">",
"      Recurrent vulvovaginal candidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Office diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3828914\">",
"      - Role of culture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3828943\">",
"      - Other tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Self diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Diagnosis of recurrent vulvovaginal candidiasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Testing for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86369992\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Uncomplicated infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Complicated infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Severe symptoms or compromised host",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - C. glabrata",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1603867152\">",
"      - C. krusei",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Recurrent infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H23279225\">",
"      Azoles",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H173002095\">",
"      - Evidence for suppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H173002117\">",
"      - Fluconazole resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H23279240\">",
"      Probiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H173002154\">",
"      Boric acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H23279303\">",
"      Immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Treatment of partners",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Breastfeeding women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Postcoital hypersensitivity reaction in male partner",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2360941\">",
"      COMPLEMENTARY AND ALTERNATIVE MEDICINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H173003511\">",
"      Trreatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Uncomplicated infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Complicated infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5452\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5452|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/37/9809\" title=\"picture 1\">",
"      Candida albicans vaginitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/46/12005\" title=\"picture 2\">",
"      Budding yeast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/25/12689\" title=\"picture 3\">",
"      Budding Candida cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/13/5329\" title=\"picture 4\">",
"      Pseudohyphae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/21/43358\" title=\"picture 5\">",
"      True hyphae of Candida albicans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/21/27987\" title=\"picture 6\">",
"      Candida glabrata",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5452|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/29/39388\" title=\"table 1\">",
"      Clinical features of vaginitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/31/11771\" title=\"table 2\">",
"      Classification of candidal vaginitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/13/1246\" title=\"table 3\">",
"      Treatment of uncomplicated vaginal candidiasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/63/23548\" title=\"table 4\">",
"      Treatment of complicated vaginal candidiasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/21/29018?source=related_link\">",
"      Antifungal susceptibility testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36633?source=related_link\">",
"      Approach to women with symptoms of vaginitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30602?source=related_link\">",
"      Bacterial vaginosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/33/14872?source=related_link\">",
"      Balanitis and balanoposthitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/19/37176?source=related_link\">",
"      Biology of Candida infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5336?source=related_link\">",
"      Dermatitis of the vulva",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/53/2899?source=related_link\">",
"      Patient information: Vaginal yeast infection (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/1/14354?source=related_link\">",
"      Patient information: Vaginal yeast infection (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/54/33634?source=related_link\">",
"      Patient information: Vulvar itching (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=related_link\">",
"      Screening for sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/53/1881?source=related_link\">",
"      Trichomonas vaginalis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_1_15387="Diagnostic criteria for obsessive-compulsive disorder";
var content_f15_1_15387=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F78513&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F78513&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic criteria for obsessive-compulsive disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        1. Either obsessions or compulsions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Obsessions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Recurrent thoughts, impulses or images that cause",
"marked anxiety or distress, are experienced as intrusive, go beyond",
"excessive worry about real-life problems, and are not related to",
"another mental disorder (eg, are not limited to thoughts about food in a person",
"with anorexia nervosa).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Compulsions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Ritualistic behaviors or mental acts that are performed",
"in response to an obsession or need to be rigidly carried out. These",
"behaviors are excessive and performed to decrease anxiety or distress",
"or avoid some dreaded event, but they are not realistically connected",
"to those dreaded events.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. The obsessions or compulsions are time-consuming",
"(more than one hour per day), cause clinically significant distress, or",
"interfere with a person's daily routine and occupational or social",
"functioning.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Diagnostic and Statistical Manual of Mental Disorders, 4th Ed, Primary Care Version (DSM-IV-PC). American Psychiatric Association, Washington, DC 1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_1_15387=[""].join("\n");
var outline_f15_1_15387=null;
var title_f15_1_15388="Comparison of PFC properties";
var content_f15_1_15388=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Physical properties of air, water, saline, and three perfluorochemical fluids",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Physical property",
"       </td>",
"       <td class=\"subtitle1\">",
"        Air",
"       </td>",
"       <td class=\"subtitle1\">",
"        Water",
"       </td>",
"       <td class=\"subtitle1\">",
"        Saline",
"       </td>",
"       <td class=\"subtitle1\">",
"        Perfluoro- octylbromide (LiquiVent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Perfluoro- alkylfuran (RIMAR)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Perfluoro- decalin (APF-140)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Density (gm/mL at 25&deg;C)",
"       </td>",
"       <td>",
"        0.0013",
"       </td>",
"       <td>",
"        1.00",
"       </td>",
"       <td>",
"        1.00",
"       </td>",
"       <td>",
"        1.93",
"       </td>",
"       <td>",
"        1.78",
"       </td>",
"       <td>",
"        1.95",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Viscosity (centipoise at 25&deg;C)",
"       </td>",
"       <td>",
"        0.02",
"       </td>",
"       <td>",
"        0.67",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"       <td>",
"        2.12",
"       </td>",
"       <td>",
"        1.46",
"       </td>",
"       <td>",
"        5.65",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Surface tension (dynes/cm at 25&deg;C)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        60.0",
"       </td>",
"       <td>",
"        72.0",
"       </td>",
"       <td>",
"        18.0",
"       </td>",
"       <td>",
"        15.0",
"       </td>",
"       <td>",
"        15.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vapor pressure (torr at 37&deg;C)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        50.0",
"       </td>",
"       <td>",
"        47.0",
"       </td>",
"       <td>",
"        11.0",
"       </td>",
"       <td>",
"        63.0",
"       </td>",
"       <td>",
"        14.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        O2 solubility at 25&deg;C (mL gas/100 mL liquid)",
"       </td>",
"       <td>",
"        21.0",
"       </td>",
"       <td>",
"        3.0",
"       </td>",
"       <td>",
"        3.0",
"       </td>",
"       <td>",
"        53.0",
"       </td>",
"       <td>",
"        52.0",
"       </td>",
"       <td>",
"        49.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CO2 solubility at 37&deg;C (mL gas/100 mL liquid)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        55.0",
"       </td>",
"       <td>",
"        57.0",
"       </td>",
"       <td>",
"        210.0",
"       </td>",
"       <td>",
"        160.0",
"       </td>",
"       <td>",
"        140.0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_1_15388=[""].join("\n");
var outline_f15_1_15388=null;
var title_f15_1_15389="Medications and toxins fatal in small doses";
var content_f15_1_15389=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76803&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76803&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medications and toxins potentially fatal to toddler in one or two doses",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Estimated minimum fatal dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Major effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benzocaine (eg, Orajel&reg;)",
"       </td>",
"       <td>",
"        &lt;20 mg/kg",
"       </td>",
"       <td>",
"        Methemoglobinemia, seizures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beta blockers",
"       </td>",
"       <td>",
"        Unclear",
"       </td>",
"       <td>",
"        Seizures, hypoglycemia, bradycardia, hypotension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium antagonists",
"       </td>",
"       <td>",
"        &lt;40 mg/kg",
"       </td>",
"       <td>",
"        Bradycardia, hypotension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Camphor",
"       </td>",
"       <td>",
"        Approximately 50 mg/kg",
"       </td>",
"       <td>",
"        Seizures, CNS depression, respiratory depression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chloroquine",
"       </td>",
"       <td>",
"        &lt;30 mg/kg",
"       </td>",
"       <td>",
"        Seizures, arrhythmias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clonidine",
"       </td>",
"       <td>",
"        Unclear",
"       </td>",
"       <td>",
"        Bradycardia, hypotension, CNS depression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diphenyoxylate (eg, Lomotil&reg;)",
"       </td>",
"       <td>",
"        1.2 mg/kg",
"       </td>",
"       <td>",
"        CNS depression, respiratory depression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Imidazoline-derived sympathomimetics (eg, Visine&reg;, Afrin&reg;)",
"       </td>",
"       <td>",
"        Unclear",
"       </td>",
"       <td>",
"        Lethargy, miosis, hypotension, bradycardia, respiratory depression, shock",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lindane",
"       </td>",
"       <td>",
"        Approximately 6 mg/kg",
"       </td>",
"       <td>",
"        Seizures, CNS depression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methadone",
"       </td>",
"       <td>",
"        Approximately 5 mg/kg",
"       </td>",
"       <td>",
"        CNS depression, respiratory depression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methyl salicylate",
"       </td>",
"       <td>",
"        Approximately 200 mg/kg",
"       </td>",
"       <td>",
"        Seizures, acidosis, cardiovascular collapse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Opioids (eg, methadone, long-acting morphine)",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        Miosis, CNS depression, respiratory depression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenothiazines",
"       </td>",
"       <td>",
"        Approximately 20 mg/kg",
"       </td>",
"       <td>",
"        Seizures, arrhythmias, CNS depression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenylpropanolamine",
"       </td>",
"       <td>",
"        Unclear",
"       </td>",
"       <td>",
"        Arrhythmia, intracranial bleed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Quinidine",
"       </td>",
"       <td>",
"        Approximately 50 mg/kg",
"       </td>",
"       <td>",
"        Seizures, arrhythmia, CNS depression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Quinine",
"       </td>",
"       <td>",
"        Approximately 80 mg/kg",
"       </td>",
"       <td>",
"        Seizures, arrhythmias, retinal injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sulfonylureas",
"       </td>",
"       <td>",
"        &lt;1 mg/kg",
"       </td>",
"       <td>",
"        Hypoglycemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Theophylline",
"       </td>",
"       <td>",
"        Approximately 50 mg/kg",
"       </td>",
"       <td>",
"        Seizures, arrhythmias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tricyclic antidepressants&nbsp;",
"       </td>",
"       <td>",
"        Approximately 15 mg/kg",
"       </td>",
"       <td>",
"        Seizures, arrhythmias, hypotension&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toxic alcohols (eg, methanol, ethylene glycol)",
"       </td>",
"       <td>",
"        0.3 mL/kg",
"       </td>",
"       <td>",
"        CNS depression",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from:",
"     <br>",
"      <ol>",
"       <li>",
"        Osterhoudt KC. The toxic toddler: drugs that can kill in small doses. Contemp Pediatr 2000; 17:73.",
"       </li>",
"       <li>",
"        Liebelt EL, Shannon MW. Small doses, big problems: a selected review of highly toxic common medications. Pediatr Emerg Care 1993; 9:292.",
"       </li>",
"       <li>",
"        Koren G. Medications which can kill a toddler with one tablet or teaspoonful. J Toxicol Clin Toxicol 1993; 31:407.",
"       </li>",
"       <li>",
"        Henry K, Harris CR. Deadly ingestions. Pediatr Clin North Am 2006; 53:293.",
"       </li>",
"       <li>",
"        Michael JB, Sztajnkrycer MD. Deadly pediatric poisons: nine common agents that kill at low doses. Emerg Med Clin North Am 2004; 22:1019.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_1_15389=[""].join("\n");
var outline_f15_1_15389=null;
var title_f15_1_15390="Photosensitive disorders";
var content_f15_1_15390=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F57800&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F57800&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Photosensitive disorders: Clinical features",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sex",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age of onset",
"       </td>",
"       <td class=\"subtitle1\">",
"        Timeline of eruption",
"       </td>",
"       <td class=\"subtitle1\">",
"        Location",
"       </td>",
"       <td class=\"subtitle1\">",
"        Common lesion morphology and symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Family history",
"       </td>",
"       <td class=\"subtitle1\">",
"        Action spectrum",
"       </td>",
"       <td class=\"subtitle1\">",
"        Phototesting",
"       </td>",
"       <td class=\"subtitle1\">",
"        Laboratory findings",
"       </td>",
"       <td class=\"subtitle1\">",
"        Duration/ resolution",
"       </td>",
"       <td class=\"subtitle1\">",
"        Key features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Polymorphous light eruption",
"        </strong>",
"       </td>",
"       <td>",
"        F&gt;M",
"       </td>",
"       <td>",
"        First three decades",
"       </td>",
"       <td>",
"        Hours after sun exposure, lasts days to weeks; most conspicuous in spring; improves during summer",
"       </td>",
"       <td>",
"        Sun-exposed areas",
"       </td>",
"       <td>",
"        Pruritic papules, papulovesicles, plaques",
"       </td>",
"       <td>",
"        May be present",
"       </td>",
"       <td>",
"        UVA, UVB, visible",
"       </td>",
"       <td>",
"        Normal MED; provocative phototesting may induce lesions",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Recurrent over the course of years, may improve over time",
"       </td>",
"       <td>",
"        Most common photo-dermatosis; \"hardening\" phenomenon may occur",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Juvenile spring eruption",
"        </strong>",
"       </td>",
"       <td>",
"        M&gt;F",
"       </td>",
"       <td>",
"        Primarily childhood; also may be seen in young adults",
"       </td>",
"       <td>",
"        As with PMLE",
"       </td>",
"       <td>",
"        Classically, helices of ears",
"       </td>",
"       <td>",
"        Erythematous papules, bullae",
"       </td>",
"       <td>",
"        May be present",
"       </td>",
"       <td>",
"        UVA?",
"       </td>",
"       <td>",
"        As with PMLE",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Recurrent over years, may improve with age",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Actinic prurigo",
"        </strong>",
"       </td>",
"       <td>",
"        F&gt;M, M&gt;F reported in adult onset in Asia",
"       </td>",
"       <td>",
"        Childhood",
"       </td>",
"       <td>",
"        Persistent during summer; may also be present year-round",
"       </td>",
"       <td>",
"        Sun-exposed areas, may also affect unexposed areas",
"       </td>",
"       <td>",
"        Pruritic papulonodules, crusts, excoriations, lichenification, cheiltis",
"       </td>",
"       <td>",
"        Yes, in up to 50 percent",
"       </td>",
"       <td>",
"        UVA&gt;UVB",
"       </td>",
"       <td>",
"        60 percent with reduced MED, 60-70 percent with positive provocative phototests",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Improves in adolescence, but also may persist",
"       </td>",
"       <td>",
"        More common in Native Americans. May have ocular findings. HLA-DRB1*0407.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Hydroa vacciniforme",
"        </strong>",
"       </td>",
"       <td>",
"        Slight M&gt;F",
"       </td>",
"       <td>",
"        Childhood",
"       </td>",
"       <td>",
"        Hours after sun exposure",
"       </td>",
"       <td>",
"        Face, dorsal hands",
"       </td>",
"       <td>",
"        Erythematous macules, papules, vesicles, crusts",
"       </td>",
"       <td>",
"        Rarely positive",
"       </td>",
"       <td>",
"        Likely UVA",
"       </td>",
"       <td>",
"        May show reduced MED to UVA in some cases",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Usually resolves by adolescence/young adulthood, but may persist",
"       </td>",
"       <td>",
"        Lympho-proliferative disease association with severe cases",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Chronic actinic dermatitis",
"        </strong>",
"       </td>",
"       <td>",
"        M&gt;F",
"       </td>",
"       <td>",
"        Elderly, but may be seen in younger patients",
"       </td>",
"       <td>",
"        Persistent-worsens in summer, may have findings year-round",
"       </td>",
"       <td>",
"        Sun-exposed areas",
"       </td>",
"       <td>",
"        Eczematous patches, lichenification, may see palmoplantar involvement",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        UVA, UVB, visible light",
"       </td>",
"       <td>",
"        Decreased MEDs to UVA, UVB, or visible light",
"       </td>",
"       <td>",
"        May see S&eacute;zary cells in severe cases",
"       </td>",
"       <td>",
"        Persists for years, may resolve",
"       </td>",
"       <td>",
"        Often coexistent contact dermatitis",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Solar urticaria",
"        </strong>",
"       </td>",
"       <td>",
"        F&gt;M",
"       </td>",
"       <td>",
"        Young or mid-adulthood",
"       </td>",
"       <td>",
"        Appears within minutes, individual lesions resolve within 24 hours",
"       </td>",
"       <td>",
"        Sun-exposed areas",
"       </td>",
"       <td>",
"        Urticarial plaques (hives), occasional systemic symptoms",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        UVA, UVB, visible light",
"       </td>",
"       <td>",
"        Normal MEDs, urticaria are induced within minutes of phototesting",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Persists for years, may resolve",
"       </td>",
"       <td>",
"        \"Hardening\" phenomenon may occur",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Phototoxicity",
"        </strong>",
"       </td>",
"       <td>",
"        M = F",
"       </td>",
"       <td>",
"        Any age",
"       </td>",
"       <td>",
"        Appears within hours of sun exposure, can occur after first dose of drug",
"       </td>",
"       <td>",
"        Sun-exposed areas",
"       </td>",
"       <td>",
"        Exacerbated sunburn appearance",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        UVA",
"       </td>",
"       <td>",
"        In systemic phototoxicity, MED for UVA decreased, UVB and visible light MEDs normal",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Resolves when drug discontinued and cleared from body",
"       </td>",
"       <td>",
"        Can occur in anyone",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Photoallergy",
"        </strong>",
"       </td>",
"       <td>",
"        M = F",
"       </td>",
"       <td>",
"        Any age",
"       </td>",
"       <td>",
"        Appears 1-2 days after exposure to sun and inciting agent in sensitized individual",
"       </td>",
"       <td>",
"        Sun-exposed areas",
"       </td>",
"       <td>",
"        Pruritic, eczematous lesions",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        UVA",
"       </td>",
"       <td>",
"        In systemic photoallergy, MED for UVA decreased, UVB and visible light MEDs normal",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Resolves with discontinuation of inciting agent",
"       </td>",
"       <td>",
"        Usually due to topical agents",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Erythropoietic protoporphyria",
"        </strong>",
"       </td>",
"       <td>",
"        M = F, vs slight M&gt;F",
"       </td>",
"       <td>",
"        Onset in early childhood",
"       </td>",
"       <td>",
"        Symptoms begin within minutes of sun exposure, improves in winter",
"       </td>",
"       <td>",
"        Nose, cheeks, hands",
"       </td>",
"       <td>",
"        Burning and stinging, pain, pruritus. Erythema, edema, pupura. Heals with atrophic, wax-like scars; wrinkled knuckles.",
"       </td>",
"       <td>",
"        Common, autosomal dominant",
"       </td>",
"       <td>",
"        Soret band (400-410 nm)",
"       </td>",
"       <td>",
"        Often normal, some patients may note stinging sensation or lesions",
"       </td>",
"       <td>",
"        Elevated erythrocyte protoporphyrin level",
"       </td>",
"       <td>",
"        Chronic",
"       </td>",
"       <td>",
"        May develop liver disease",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Porphyria cutanea tarda",
"        </strong>",
"       </td>",
"       <td>",
"        M = F",
"       </td>",
"       <td>",
"        Middle age, may occur earlier",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Sun-exposed areas",
"       </td>",
"       <td>",
"        Skin fragility, bullae, crusts, scarring. Hypertrichosis, hyperpigmentation, sclerodermoid changes.",
"       </td>",
"       <td>",
"        Sporadic in Type I, autosomal dominant in Type II",
"       </td>",
"       <td>",
"        Soret band (400-410 nm)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Elevated porphyrins in urine and stool",
"       </td>",
"       <td>",
"        Chronic, symptoms improve with sun protection removal of triggers, phlebotomy, antimalarials",
"       </td>",
"       <td>",
"        Often associated with hepatitis C",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_1_15390=[""].join("\n");
var outline_f15_1_15390=null;
var title_f15_1_15391="VWF multimer analysis";
var content_f15_1_15391=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F71943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F71943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    VWF multimer analysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 408px; height: 413px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Agarose gel electrophoresis (1.0 percent) of plasma followed by fixation and exposure to a monospecific radiolabeled antibody to VWF. The highest molecular weight multimers of VWF are at the top of the gel (arrow). Lane 1 - severe vWD (type 3) plasma, lane 2 - normal pooled plasma, lane 3 - type 2A plasma, lane 4 - type 2B plasma, lane 5 - vWF extracted from platelets.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Rick, ME, Diagnosis and management of von Willebrand's syndrome, Med Clin North Am 1994; 78:609.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_1_15391=[""].join("\n");
var outline_f15_1_15391=null;
